%PDF-1.3
%‚„œ”
1 0 obj
<<
/Type/ExtGState
/OPM 1
>>
endobj
2 0 obj
<<
/Type/ExtGState
/OP true
>>
endobj
3 0 obj
<<
/Type/ExtGState
/OP false
>>
endobj
4 0 obj
<<
/Length 10235
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
2 w 
0 0 0 1 K
242.029 705.426 m
339.999 705.426 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
18 0 0 18 255.1306 708.0727 Tm
0 0 0 1 k
0.075 Tc
[(AR)90(TICLES)]TJ
ET
-41 704.329 290.859 16.046 re
f
0 0 0 0 k
51.528 38.116 492 378.74 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
27.357 0 0 27.357 51.1987 396.6756 Tm
0 0 0 1 k
(T)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 67.903 409.6756 Tm
0 0 0 1 k
[(he current obesity epidemic af)20(f)1(e)1(c)1(t)1(s)]TJ
0 -1.23809 TD
-0.024 Tc
0.009 Tw
(more than 30% of adults and 17% of)Tj
-1.55952 -1.23809 TD
-0.015 Tc
0.053 Tw
(children and adolescents across the US,)Tj
0 -1.2381 TD
-0.04 Tc
0.019 Tw
(representing a major public health threat.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 207.48 373.9756 Tm
0 0 0 1 k
-0.039 Tc
(1,2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 51.528 357.6756 Tm
0 0 0 1 k
-0.015 Tc
(Additionally)Tj
4.80974 0 TD
-0.0151 Tc
(,)Tj
0.62587 0 Td
(1)Tj
0.87587 0 Td
-0.015 Tc
0.156 Tw
(in 20 Americans has a)Tj
-6.31149 -1.2381 TD
0.048 Tw
(body mass index (BMI) greater than 40)Tj
T*
-0.018 Tc
0 Tw
(kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 72.3446 334.9756 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 77.7025 331.6756 Tm
0 0 0 1 k
-0.018 Tc
0.003 Tw
(and is thus classified as extremely)Tj
-2.49281 -1.23809 TD
-0.028 Tc
0 Tw
(obese.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 76.2866 321.9756 Tm
0 0 0 1 k
-0.027 Tc
(3,4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 85.7482 318.6756 Tm
0 0 0 1 k
-0.028 Tc
0.013 Tw
(Although some data suggest that)Tj
-3.25907 -1.23809 TD
-0.027 Tc
0.012 Tw
(the population prevalence of obesity may)Tj
T*
-0.015 Tc
0.064 Tw
(be slowing,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 98.8812 295.9756 Tm
0 0 0 1 k
(1)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 104.9357 292.6756 Tm
0 0 0 1 k
-0.015 Tc
0.064 Tw
(obesity remains one of the)Tj
-5.08645 -1.23809 TD
-0.027 Tc
0.012 Tw
(major causes of preventable death world)Tj
15.18831 0.00001 TD
0 Tc
(-)Tj
-15.18831 -1.2381 TD
-0.018 Tc
0.003 Tw
(wide. Although the prevalence is similar)Tj
T*
-0.026 Tc
0.011 Tw
(for men and women, adults older than 60)Tj
0 -1.23809 TD
-0.015 Tc
0.028 Tw
(years of age are more likely to be obese)Tj
0 -1.2381 TD
-0.038 Tc
0.023 Tw
(than are younger adults, and non-Hispanic)Tj
T*
-0.015 Tc
0.171 Tw
(whites have the lowest rate of obesity)Tj
0 -1.23809 TD
-0.04 Tc
0.007 Tw
(compared with other races and ethnicities.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 211.4999 204.9755 Tm
0 0 0 1 k
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 62.028 188.6756 Tm
0 0 0 1 k
0.236 Tw
(Despite the obesity epidemic, few)Tj
-1 -1.2381 TD
0.224 Tw
[(long-ter)-25(m phar)-25(macologic options are)]TJ
0 -1.23809 TD
-0.005 Tc
0.005 Tw
(available for weight loss. Orlistat is the)Tj
0 -1.2381 TD
-0.023 Tc
0.023 Tw
(only product available in the US without)Tj
ET
0 0 0 0 k
50.5 548 493.028 93.222 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
16.8 0 0 16 50.5 608.251 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(Phentermine/T)165(opiramate f)9(or the T)125(r)20(eatment of Obesity)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
10.5 0 0 10 50.5 572.251 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(Steven M Smith, Melissa Meyer)55(, Katy E T)37(rinkley)]TJ
ET
0 0 0 0 k
50.5 656 493.028 21 re
f
0.5 w 
0 0 0 1 K
50.5 660.886 m
543.528 660.886 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
13 0 0 13 50.5 668.1355 Tm
0 0 0 1 k
0.011 Tw
[(Ne)16(w Drug Appr)28(o)39(vals)]TJ
ET
0.5 w 
0 0 0 1 K
51.5 128.26 m
214.5 128.26 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 51.5 116.0095 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
(Author information provided at end of text.)Tj
0 -1.8235 TD
-0.015 Tc
0.059 Tw
[<A9>-322(1967-2013 Harvey Whitney Books Co. All)]TJ
0 -1.1176 TD
-0.026 Tc
0.01 Tw
(rights reserved. No part of this document may)Tj
0 -1.1177 TD
-0.034 Tc
0.019 Tw
(be reproduced or transmitted in any form or by)Tj
0 -1.1176 TD
-0.021 Tc
0.006 Tw
(any means without prior written permission of)Tj
T*
-0.029 Tc
0.014 Tw
(Harvey Whitney Books Co. For reprints of any)Tj
0 -1.1177 TD
-0.038 Tc
0.023 Tw
(article appearing in )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F5 1 Tf
8.5 0 0 8.5 119.4668 53.0095 Tm
0 0 0 1 k
-0.038 Tc
0.023 Tw
(The Annals)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 159.4241 53.0095 Tm
0 0 0 1 k
-0.038 Tc
(,)Tj
0.50287 0 Td
0.023 Tw
(please contact)Tj
-13.1998 -1.1176 TD
-0.04 Tc
0 Tw
(415sales@hwbooks.com)Tj
ET
0 0 0 0.15 k
230.5 43.497 313 373.687 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7 0 0 7 242.5 391.6273 Tm
0 0 0 1 k
(OBJECTIVE)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10 0 0 10 282.1705 391.6273 Tm
0 0 0 1 k
(:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 287.9026 391.6273 Tm
0 0 0 1 k
0.005 Tw
[(T)111(o review the pharmacology)74(, ef)17(ficacy)74(, and safety of phentermine/)]TJ
-5.34148 -1.29412 TD
-0.025 Tc
0.011 Tw
(topiramate (PHEN/TPM) in the management of obese patients.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7 0 0 7 242.5 366.6273 Tm
0 0 0 1 k
-0.043 Tc
[(D)-7(A)74(T)74(A)-364(SOURCES)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10 0 0 10 294.8111 366.6273 Tm
0 0 0 1 k
(:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 300.005 366.6273 Tm
0 0 0 1 k
-0.03 Tc
0.007 Tw
(MEDLINE (1966-July 2012) was searched using the terms weight)Tj
-6.76529 -1.29412 TD
-0.005 Tc
0.101 Tw
[(loss, obesity)74(, phentermine and topiramate, phentermine, topiramate, Qnexa,)]TJ
T*
-0.018 Tc
0 Tw
(Qsymia, )Tj
3.81449 0.00001 TD
-0.028 Tc
0.013 Tw
[(and VI-0521. Additionally)74(, the new drug application and prescribing infor-)]TJ
-3.81449 -1.29412 TD
-0.04 Tc
0.011 Tw
(mation for PHEN/TPM were retrieved. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7 0 0 7 242.5 319.6273 Tm
0 0 0 1 k
-0.021 Tc
[(STUDY)-397(SELECTION)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10 0 0 10 307.0043 319.6273 Tm
0 0 0 1 k
(/)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7 0 0 7 309.6362 319.6273 Tm
0 0 0 1 k
-0.021 Tc
[(DA)74(T)74(A)-397(EXTRACTION)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10 0 0 10 374.2583 319.6273 Tm
0 0 0 1 k
(:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 379.8011 319.6273 Tm
0 0 0 1 k
-0.015 Tc
0.015 Tw
[(All studies considering the pharmacology)74(,)]TJ
-16.15307 -1.29412 TD
-0.005 Tc
0.005 Tw
[(ef)18(ficacy)73(, and safety of PHEN/TPM were reviewed with a focus on ef)18(ficacy and)]TJ
T*
-0.025 Tc
0.011 Tw
(safety data from Phase 3 trials. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7 0 0 7 242.5 283.6273 Tm
0 0 0 1 k
-0.036 Tc
[(DA)74(T)74(A)-361(SYNTHESIS)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10 0 0 10 299.849 283.6273 Tm
0 0 0 1 k
(:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 305.074 283.6273 Tm
0 0 0 1 k
-0.04 Tc
[(I)-15(n)-253(3 Phase 3 trials \(EQUIP)129(, CONQUER, and SEQUEL\), treatment)]TJ
-7.36165 -1.29412 TD
-0.015 Tc
0.139 Tw
(with PHEN/TPM consistently demonstrated statistically significant weight loss)Tj
0 -1.29411 TD
-0.034 Tc
0.019 Tw
(compared with placebo. After 56 weeks of treatment, percent weight loss achieved)Tj
0 -1.29412 TD
-0.015 Tc
0.108 Tw
(with PHEN/TPM was 10.6%, 8.4%, and 5.1% with 15/92 mg, 7.5/46 mg, and)Tj
T*
0.002 Tw
(3.75/23 mg, respectively (p < 0.0001). The 52-week extension study (SEQUEL))Tj
0 -1.29411 TD
-0.04 Tc
0.025 Tw
(showed maintained weight loss over 2 years with 9.3% and 10.5% weight loss from)Tj
0 -1.29412 TD
0.004 Tw
(baseline for 7.5/46 mg and 15/92 mg PHEN/TPM (p < 0.0001). A significantly higher)Tj
0 -1.29411 TD
-0.015 Tc
0.043 Tw
(proportion of patients achieved greater than 5%, 10%, or 15% weight loss with)Tj
0 -1.29412 TD
-0.031 Tc
0.016 Tw
(PHEN/TPM compared with placebo. Significant reductions in waist circumference,)Tj
T*
-0.037 Tc
0.022 Tw
(fasting triglycerides, and fasting glucoses were also attributable to PHEN/TPM. The)Tj
T*
-0.038 Tc
0.023 Tw
(drug was generally well tolerated in clinical trials. Adverse reactions occurring in 5%)Tj
T*
-0.015 Tc
0 Tw
(or more of study subjects included paresthesia, dizziness, dysgeusia, insomnia,)Tj
T*
-0.04 Tc
0.011 Tw
(constipation, and dry mouth.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7 0 0 7 242.5 137.6273 Tm
0 0 0 1 k
-0.015 Tc
(CONCLUSIONS)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10 0 0 10 293.0866 137.6273 Tm
0 0 0 1 k
(:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 298.6732 137.6273 Tm
0 0 0 1 k
-0.01 Tc
0.01 Tw
(PHEN/TPM is a new)Tj
8.91274 0.00001 TD
-0.0104 Tc
(,)Tj
0.54549 0 Td
-0.025 Tc
[(o)-15(n)-15(c)-15(e-daily)74(, controlled-release, combination)]TJ
-16.06684 -1.29412 TD
-0.031 Tc
0.016 Tw
(weight-loss product approved as an adjunct to diet and exercise for chronic weight)Tj
T*
-0.015 Tc
0.01 Tw
(management of obese or overweight patients with weight-related comorbidities.)Tj
T*
-0.039 Tc
0.024 Tw
[(PHEN/TPM is modestly ef)18(fective and a viable option for patients interested in losing)]TJ
T*
-0.04 Tc
0.011 Tw
(weight, although long-ter)Tj
9.9692 0.00001 TD
-0.0251 Tc
(m)Tj
1.07187 0 Td
-0.025 Tc
(safety data are lacking. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F5 1 Tf
8.5 0 0 8.5 242.5 78.6273 Tm
0 0 0 1 k
-0.0251 Tc
(Ann)Tj
1.96762 0 Td
-0.025 Tc
(Pharmacother)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 314.081 78.6273 Tm
0 0 0 1 k
-0.025 Tc
(2013;47:340-9.)Tj
-8.42129 -1.76471 TD
0.011 Tw
(Published Online, 12 Mar 2013, )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F5 1 Tf
8.5 0 0 8.5 357.777 63.6273 Tm
0 0 0 1 k
-0.025 Tc
(theannals.com)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 410.2789 63.6273 Tm
0 0 0 1 k
-0.0251 Tc
(,)Tj
0.51687 0 Td
-0.025 Tc
0.011 Tw
(doi: 10.1345/aph.1R501)Tj
ET
0 0 0 0 k
50.5 15.25 392.028 13 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 50.5 21.4116 Tm
0 0 0 1 k
-0.024 Tc
(340)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 74.2499 22.9116 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 87.431 21.4116 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 220.5559 22.9116 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 233.737 21.4116 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47)]TJ
ET
0 0 0 0 k
463.528 15 79.5 13.5 re
f
BT
/F8 1 Tf
10 0 0 10 487.9862 21.6616 Tm
0 0 0 1 k
0 Tw
(theannals.com)Tj
/F9 1 Tf
1 0 0 1 -1000 1783 Tm
1 g
-0.25 Tc
( )Tj
ET
Q

endstream
endobj
5 0 obj
<<
/Length 17102
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
Q
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 50.5 726.0132 Tm
0 0 0 1 k
-0.024 Tc
0.024 Tw
[(restrictions on duration of therapy)65(, but intolerable gastroin-)]TJ
0 -1.23809 TD
-0.002 Tc
0.002 Tw
[(testinal adverse ef)20(fects and reports of severe liver injury)]TJ
0 -1.2381 TD
-0.022 Tc
0.021 Tw
(may limit its use.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 119.4421 703.3132 Tm
0 0 0 1 k
-0.02 Tc
(5,6)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 129.1804 700.0132 Tm
0 0 0 1 k
-0.022 Tc
0.021 Tw
(Other prescription weight loss medica-)Tj
-7.49337 -1.2381 TD
-0.0074 Tc
(t)Tj
0.27064 -0.00001 TD
-0.007 Tc
0.007 Tw
[(ions, including phenter)-25(mine monotherapy)65(, are Food and)]TJ
-0.27064 -1.23809 TD
-0.018 Tc
0.018 Tw
[(Drug Administration (FDA)\320labeled for short-ter)-25(m use as)]TJ
0 -1.2381 TD
-0.025 Tc
0.013 Tw
[(monotherapy for obesity)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 149.6186 664.3132 Tm
0 0 0 1 k
(7)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 648.1132 Tm
0 0 0 1 k
-0.022 Tc
0.022 Tw
[(Current phar)-25(macologic options rarely achieve the initial)]TJ
-1 -1.22857 TD
0 Tc
0.069 Tw
(treatment goal for obesity\321a 10% reduction in weight)Tj
T*
0.065 Tw
(over 6 months of therapy)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 158.7726 625.6132 Tm
0 0 0 1 k
(3)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 165.0786 622.3132 Tm
0 0 0 1 k
0.065 Tw
(and, of the available agents,)Tj
-10.91225 -1.22857 TD
-0.023 Tc
0.023 Tw
[(phenter)-25(mine can cause rebound weight gain.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 228.8878 612.7132 Tm
0 0 0 1 k
(8)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 234.3731 609.4131 Tm
0 0 0 1 k
-0.023 Tc
(Consequent-)Tj
-17.51172 -1.22857 TD
0 Tc
0.05 Tw
[(ly)65(, newer weight loss medications tar)20(get 2 areas: initial)]TJ
T*
0.113 Tw
(treatment goals and maintenance of weight loss.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 259.6781 586.9131 Tm
0 0 0 1 k
(5)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 266.4915 583.6132 Tm
0 0 0 1 k
-0.07 Tc
[(Tw)-70(o)]TJ
-20.57062 -1.22857 TD
0 Tc
0.022 Tw
(weight loss therapies recently approved by the FDA in-)Tj
T*
-0.016 Tc
0.016 Tw
[(clude lorcaserin, a selective 5)-25(-)1(H)1(T)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 186.9846 555.8332 Tm
0 0 0 1 k
-0.015 Tc
(2c)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 195.0764 557.8132 Tm
0 0 0 1 k
-0.016 Tc
0.016 Tw
(agonist, and combina-)Tj
-13.76918 -1.22857 TD
0 Tc
0.328 Tw
[(tion phenter)-25(mine/topiramate (PHEN/TPM). FDA-ap-)]TJ
T*
-0.024 Tc
0.024 Tw
[(proved on July 17, 2012, PHEN/TPM is a once-)-75(daily ther-)]TJ
T*
-0.01 Tc
0.01 Tw
(apy combining low doses of phenter)Tj
14.26871 0.00001 TD
(mine and topiramate)Tj
-14.26871 -1.22858 TD
-0.012 Tc
0.011 Tw
(to promote weight loss while ostensibly reducing the risk)Tj
0 -1.22857 TD
-0.003 Tc
0.003 Tw
[(o)1(f)1( )1(s)1(i)1(g)1(n)1(i)1(f)1(i)1(c)1(a)1(n)1(t)1( )1(a)1(d)1(v)1(e)1(r)1(s)1(e)1( )1(e)1(f)21(fects when used at higher doses.)]TJ
T*
-0.005 Tc
0.005 Tw
(PHEN/TPM is marketed in the US under the trade name)Tj
T*
-0.022 Tc
0.022 Tw
(Qsymia (VIVUS Inc.).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 141.9323 470.8133 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 147.4243 467.5132 Tm
0 0 0 1 k
-0.022 Tc
0.022 Tw
(PHEN/TPM is approved as an ad-)Tj
-9.23089 -1.22856 TD
-0.025 Tc
0.009 Tw
(junct to a reduced-calorie diet and increased physical activ)Tj
22.00057 0 TD
0 Tc
(-)Tj
-22.00057 -1.22858 TD
0.023 Tw
(ity for chronic weight management in adult \()Tj
/F20 1 Tf
18.06954 0 Td
<B3>Tj
/F2 1 Tf
0.51367 0 Td
-0.0001 Tc
(18)Tj
1.27248 0 Td
0 Tc
0 Tw
(years\))Tj
-19.85569 -1.22857 TD
-0.007 Tc
0.007 Tw
(obese patients \(BMI )Tj
/F20 1 Tf
8.24634 0 Td
0 Tc
<B3>Tj
/F2 1 Tf
0.54225 0 Td
-0.0066 Tc
(30)Tj
1.23667 0 Td
-0.007 Tc
0 Tw
(kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 177.0753 432.1133 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 180.0359 428.8133 Tm
0 0 0 1 k
-0.0067 Tc
(\))Tj
0.57623 0 Td
-0.007 Tc
0.007 Tw
(and overweight patients)Tj
-12.91298 -1.22857 TD
-0.012 Tc
0 Tw
(\(BMI )Tj
/F20 1 Tf
2.42334 0 TD
0 Tc
<B3>Tj
/F2 1 Tf
0.5368 0.00001 TD
-0.012 Tc
0.012 Tw
(27 kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 115.5335 419.2133 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 118.4613 415.9133 Tm
0 0 0 1 k
-0.0121 Tc
(\))Tj
0.57076 0 Td
-0.012 Tc
0.012 Tw
(with at least one weight-related comor)Tj
14.95719 0 TD
0 Tc
(-)Tj
-22.00046 -1.22857 TD
-0.015 Tc
0.015 Tw
[(bidity)65(, including hypertension, type 2 diabetes, or dyslipi-)]TJ
T*
-0.021 Tc
0 Tw
(demia.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 77.4955 393.4133 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 82.9981 390.1133 Tm
0 0 0 1 k
-0.02 Tc
0.02 Tw
(The purpose of this review is to describe the phar-)Tj
-3.09506 -1.22857 TD
-0.016 Tc
0.016 Tw
[(macology)65(, ef)20(ficacy)65(, and safety of PHEN/TPM and its role)]TJ
T*
-0.025 Tc
0.013 Tw
(in the management of overweight and obese patients. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 50.5 336.4133 Tm
0 0 0 1 k
-0.025 Tc
(Pharmacology)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 315.5133 Tm
0 0 0 1 k
-0.035 Tc
0.02 Tw
[(P)-15(H)-15(E)-15(N)-15(/TPM is a fixed-)-75(dose, controlled-release, combina-)]TJ
-1 -1.22857 TD
-0.027 Tc
0.012 Tw
(tion product containing immediate-release phenter)Tj
18.92568 0 TD
(mine hy)Tj
3.07488 0.00001 TD
0 Tc
(-)Tj
-22.00056 -1.22859 TD
-0.028 Tc
(drochloride and extended-release topiramate. As a centrally)Tj
0 -1.22857 TD
-0.015 Tc
0 Tw
(acting sympathomimetic amine structurally related to am-)Tj
T*
0.054 Tw
[(phetamine, phenter)-25(mine increases norepinephrine release)]TJ
T*
-0.029 Tc
0.014 Tw
(and, to a lesser extent, dopamine release.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 210.3659 254.3134 Tm
0 0 0 1 k
(7)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 215.6604 251.0133 Tm
0 0 0 1 k
-0.029 Tc
0.014 Tw
(As a result, phen)Tj
6.27109 0.00001 TD
0 Tc
(-)Tj
-22.00065 -1.22858 TD
-0.034 Tc
0.019 Tw
[(ter)-25(mine works to suppress appetite, decrease food consump-)]TJ
0 -1.22856 TD
-0.036 Tc
0.021 Tw
(tion, and increase heart rate secondary to increasing levels of)Tj
0 -1.22857 TD
0 Tw
(catecholamines.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 112.2079 215.6133 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 117.4608 212.3134 Tm
0 0 0 1 k
(T)Tj
0.50501 0.00001 TD
-0.036 Tc
0.021 Tw
(achyphylaxis and tolerance have been ob)Tj
15.11836 0.00001 TD
0 Tc
(-)Tj
-22.00059 -1.22859 TD
-0.015 Tc
0.004 Tw
[(served with phenter)-25(mine use; the latter occurs in most pa-)]TJ
0 -1.22857 TD
-0.04 Tc
0.017 Tw
(tients and usually develops within a few weeks following ini-)Tj
0 -1.22858 TD
0 Tw
(tiation.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 76.5942 176.9133 Tm
0 0 0 1 k
(7)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 160.6134 Tm
0 0 0 1 k
-0.023 Tc
0.023 Tw
(The exact mechanism for weight loss with topiramate is)Tj
-1 -1.2381 TD
0 Tc
0 Tw
(unknown.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 92.2052 150.9134 Tm
0 0 0 1 k
0.001 Tc
(5,10)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 105.9907 147.6134 Tm
0 0 0 1 k
0.063 Tw
(As a fructose monosaccharide, topiramate)Tj
-5.28483 -1.23809 TD
0.386 Tw
(modulates voltage-gated ion channels, augments )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
10.5 0 0 10.5 277.1889 134.6134 Tm
0 0 0 1 k
(g)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 281.5058 134.6134 Tm
0 0 0 1 k
(-)Tj
-22.00055 -1.2381 TD
0.052 Tw
(aminobutyric acid (GABA) neurotransmitter activity at)Tj
T*
-0.004 Tc
0.004 Tw
[(GABA-A receptors, antagonizes the AMP)90(A/kainite sub-)]TJ
T*
-0.021 Tc
0.021 Tw
(type of the glutamate receptor)Tj
11.41649 0.00001 TD
-0.0207 Tc
(,)Tj
0.47919 0 Td
-0.021 Tc
(and inhibits carbonic anhy-)Tj
-11.8957 -1.2381 TD
-0.02 Tc
0.02 Tw
(drase isoenzymes II and IV)Tj
10.37026 0.00001 TD
0 Tc
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 161.8036 85.9134 Tm
0 0 0 1 k
-0.019 Tc
(5,10)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 174.4507 82.6134 Tm
0 0 0 1 k
-0.02 Tc
0.02 Tw
(Reduced caloric intake was)Tj
-11.8048 -1.2381 TD
0 Tc
0.053 Tw
(identified as a significant factor associated with topira-)Tj
T*
-0.004 Tc
0.004 Tw
(mate-induced weight loss in humans.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 205.3528 59.9133 Tm
0 0 0 1 k
-0.058 Tc
(11)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 213.6045 56.6134 Tm
0 0 0 1 k
-0.004 Tc
(However)Tj
3.59958 0.00001 TD
-0.0036 Tc
(,)Tj
0.49625 0 Td
-0.004 Tc
(animal)Tj
-19.6296 -1.2381 TD
0 Tc
0.19 Tw
(studies suggest increased ener)Tj
12.57253 0.00001 TD
(gy expenditure and de)Tj
9.42801 0.00001 TD
(-)Tj
2.6185 64.99044 TD
0.027 Tw
[(creased ener)20(gy ef)20(ficiency as contributors to weight loss)]TJ
0 -1.23809 TD
-0.025 Tc
0.013 Tw
[(with topiramate monotherapy)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 428.0608 716.3132 Tm
0 0 0 1 k
-0.023 Tc
(12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 309 685.0132 Tm
0 0 0 1 k
-0.025 Tc
(Pharmacokinetics)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 664.0132 Tm
0 0 0 1 k
-0.025 Tc
0.024 Tw
[(Clinical phar)-25(macokinetic data for phenter)-25(mine and topi-)]TJ
-1 -1.2381 TD
-0.02 Tc
0.02 Tw
[(ramate are highlighted in T)70(able 1. Notably)65(, PHEN/TPM is)]TJ
0 -1.23809 TD
-0.002 Tc
0.002 Tw
(not extensively metabolized by cytochrome P450 isoen-)Tj
0 -1.2381 TD
-0.001 Tc
0.001 Tw
(zymes, has low plasma protein binding, and is predomi-)Tj
T*
0 Tc
0.066 Tw
(nantly cleared as unchanged drug in the urine.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 507.4397 615.3132 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 513.7584 612.0131 Tm
0 0 0 1 k
(Conse-)Tj
-19.5008 -1.23809 TD
-0.01 Tc
0.01 Tw
[(quently)65(, PHEN/TPM has minimal drug-)-75(drug interactions)]TJ
0 -1.2381 TD
-0.021 Tc
0.021 Tw
(with a few notable exceptions. Non\320potassium-sparing di-)Tj
T*
-0.012 Tc
0.012 Tw
(uretics may potentiate hypokalemia when combined with)Tj
0 -1.23809 TD
-0.003 Tc
0 Tw
(PHEN/TPM.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 363.3 563.3132 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 368.9099 560.0132 Tm
0 0 0 1 k
-0.003 Tc
0.003 Tw
[(Additionally)65(, PHEN/TPM in combination)]TJ
-5.70571 -1.2381 TD
-0.024 Tc
0.024 Tw
[(with oral contraceptives may reduce contraceptive ef)20(f)1(i)1(c)1(a)1(c)1(y)]TJ
T*
-0.025 Tc
0.013 Tw
(by decreasing ethinyl estradiol serum concentrations.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 519.0681 537.3132 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 309 506.0132 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(Clinical T)55(rials )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 485.0132 Tm
0 0 0 1 k
0.034 Tw
[(MEDLINE \(1966)-25(-July 2012\) was searched using the)]TJ
-1 -1.23809 TD
0 Tw
[(ter)-25(ms weight loss, obesity)65(, phenter)-25(mine and topiramate,)]TJ
0 -1.2381 TD
-0.003 Tc
0.003 Tw
[(phenter)-25(mine, topiramate, Qnexa, Qsymia, and VI-)-100(0521.)]TJ
0 -1.23809 TD
-0.037 Tc
0.021 Tw
[(Additionally)65(, the new drug application and prescribing infor-)]TJ
T*
-0.035 Tc
0.02 Tw
(mation for PHEN/TPM were retrieved. All studies consider)Tj
22.00061 0 TD
0 Tc
(-)Tj
-22.00061 -1.2381 TD
-0.016 Tc
0.001 Tw
(ing the phar)Tj
4.6118 0 TD
0 Tw
(macology)Tj
3.75079 0 TD
-0.0161 Tc
(,)Tj
0.46881 0 Td
-0.016 Tc
(ef)Tj
0.725 0.00001 TD
(ficacy)Tj
2.28142 0 TD
(,)Tj
0.46889 0 Td
0.001 Tw
(and safety of PHEN/TPM)Tj
-12.30672 -1.23811 TD
0 Tc
0.044 Tw
[(were reviewed with a focus on ef)20(ficacy and safety data)]TJ
0 -1.23809 TD
-0.025 Tc
0.013 Tw
(from Phase 3 trials. )Tj
1 -1.23809 TD
0 Tw
(FDA-app)Tj
3.60136 0 TD
-0.04 Tc
0.01 Tw
(roval of PHEN/TPM for the treatment of obesity)Tj
-4.60136 -1.2381 TD
-0.037 Tc
0.022 Tw
(was based primarily on 3 clinical trials)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 457.5198 371.3132 Tm
0 0 0 1 k
-0.036 Tc
[(1)-1(2)-24(-14)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 470.5548 368.0132 Tm
0 0 0 1 k
-0.0372 Tc
(:)Tj
0.47571 0 Td
-0.037 Tc
0.022 Tw
(controlled release)Tj
-15.86188 -1.23809 TD
-0.03 Tc
0.015 Tw
[(phenter)-25(mine/topiramate in severely obese adults: a random-)]TJ
T*
-0.015 Tc
0.023 Tw
(ized, controlled trial (EQUIP))Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 430.3459 345.3132 Tm
0 0 0 1 k
-0.013 Tc
(12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 436.1659 342.0132 Tm
0 0 0 1 k
-0.0152 Tc
(;)Tj
0.52039 0 Td
-0.015 Tc
0.023 Tw
[(ef)20(fects of low-)-75(dose, con-)]TJ
-12.63143 -1.2381 TD
-0.034 Tc
0.018 Tw
(trolled-release, phenter)Tj
8.45631 0 TD
(mine plus topiramate combination on)Tj
-8.45631 -1.2381 TD
-0.04 Tc
0.019 Tw
(weight and associated comorbidities in overweight and obese)Tj
0 -1.23809 TD
-0.015 Tc
0.19 Tw
(adults (CONQUER): a randomized, placebo-controlled,)Tj
0 -1.2381 TD
0.182 Tw
(phase 3 trial)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 362.0837 293.3132 Tm
0 0 0 1 k
-0.013 Tc
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 367.9037 290.0132 Tm
0 0 0 1 k
-0.0151 Tc
(;)Tj
0.67978 0 Td
-0.015 Tc
0.182 Tw
(and two-year sustained weight loss and)Tj
-6.28965 -1.23809 TD
-0.032 Tc
0.017 Tw
(metabolic benefits with controlled release phenter)Tj
18.45856 0.00001 TD
0 Tw
(mine/topi)Tj
3.54221 0.00001 TD
0 Tc
(-)Tj
-22.00077 -1.23811 TD
-0.015 Tc
0.024 Tw
(ramate in obese and overweight adults (SEQUEL): a ran-)Tj
0 -1.23809 TD
0.172 Tw
(domized, placebo-controlled, Phase 3 extension study)Tj
21.53546 0.00001 TD
0 Tc
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 537.5899 254.3131 Tm
0 0 0 1 k
-0.013 Tc
(14)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 309 238.0132 Tm
0 0 0 1 k
-0.036 Tc
0.021 Tw
(These Phase 3 randomized, double-blind, placebo-controlled)Tj
0 -1.2381 TD
-0.027 Tc
0.011 Tw
[(trials evaluated a combination of 3 fixed-)-75(dose for)-25(mulations)]TJ
0 -1.23809 TD
-0.04 Tc
0.022 Tw
(of PHEN/TPM in patients with or without various weight-re-)Tj
0 -1.2381 TD
-0.015 Tc
0.552 Tw
(lated comorbidities.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 395.0395 202.3132 Tm
0 0 0 1 k
-0.014 Tc
(5,12)Tj
1.71492 0.00001 TD
(-14)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 421.3227 199.0132 Tm
0 0 0 1 k
-0.015 Tc
0.552 Tw
(Across these trials, the 3)Tj
-10.6974 -1.2381 TD
0.102 Tw
(PHEN/TPM doses studied were 3.75/23 mg \(low-)Tj
19.99279 -0.00001 TD
0 Tw
(dose\),)Tj
-19.99279 -1.23809 TD
-0.04 Tc
0.012 Tw
(7.5/46 mg \(mid-)Tj
6.02494 0.00001 TD
[(dose\), and 15/92 mg \(high-)-75(dose\). In addition)]TJ
-6.02494 -1.2381 TD
-0.02 Tc
0.005 Tw
(to phar)Tj
2.69289 0.00001 TD
0 Tw
(macotherapy)Tj
4.87597 0.00001 TD
-0.0203 Tc
(,)Tj
0.46455 0 Td
-0.02 Tc
0.005 Tw
(all patients received standardized diet)Tj
-8.03342 -1.23811 TD
-0.026 Tc
0.011 Tw
(and lifestyle modification counseling based on the LEARN)Tj
0 -1.23809 TD
-0.024 Tc
0.009 Tw
((Lifestyle, Exercise, Attitudes, Relationship, and Nutrition))Tj
0 -1.2381 TD
-0.028 Tc
0.013 Tw
[(Program for W)80(eight Management.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 444.341 124.3131 Tm
0 0 0 1 k
-0.026 Tc
(15)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 452.472 121.0132 Tm
0 0 0 1 k
-0.028 Tc
0.013 Tw
[(However)40(, adherence to)]TJ
-13.664 -1.2381 TD
-0.04 Tc
0.025 Tw
[(LEARN was not assessed. Further)-25(more, all patients were ad-)]TJ
0 -1.23809 TD
-0.037 Tc
0.022 Tw
[(vised to increase daily physical activity)65(, reduce caloric intake)]TJ
0 -1.2381 TD
-0.035 Tc
0.02 Tw
[(by 500)-75(-kcal/day)65(, and increase water consumption.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 503.4002 85.3131 Tm
0 0 0 1 k
-0.033 Tc
(12)Tj
0.95533 0.00001 TD
(-15)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 518.9702 82.0131 Tm
0 0 0 1 k
-0.035 Tc
0.02 Tw
(If par-)Tj
-19.99716 -1.2381 TD
-0.04 Tc
0.011 Tw
(ticipants discontinued treatment for any reason, they were en-)Tj
0 -1.23809 TD
-0.017 Tc
0.002 Tw
(couraged to remain in the study and complete monthly as-)Tj
0 -1.2381 TD
-0.04 Tc
0 Tw
(sessments. )Tj
ET
0 0 0 0 k
308.5 740.1929 235 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8.4 0 0 8 366.993 744.7228 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Phenter)-25(mine/T)90(opiramate for the T)35(reatment of Obesity)]TJ
ET
0 0 0 0 k
157.5 15.444 386 13.08 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 269.1412 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 402.2662 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 415.4473 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 515.819 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 529 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(341)Tj
ET
0 0 0 0 k
50.5 16.524 79.5 11.669 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 50.5 21.3551 Tm
0 0 0 1 k
-0.025 Tc
(theannals.com)Tj
ET
Q

endstream
endobj
6 0 obj
<<
/Length 14174
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
Q
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 726.0132 Tm
0 0 0 1 k
-0.001 Tc
0.001 Tw
(The EQUIP and CONQUER studies consisted of a 2-)Tj
-1 -1.22857 TD
-0.025 Tc
0.023 Tw
[(week screening period, 4)-75(-week postrandomization titration)]TJ
T*
-0.015 Tc
0.015 Tw
(period, and a 52-week treatment period. The aptly-named)Tj
T*
-0.022 Tc
0.022 Tw
(SEQUEL study was a 52-week extension of CONQUER.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 281.9996 690.6132 Tm
0 0 0 1 k
(5)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 50.5 674.4131 Tm
0 0 0 1 k
-0.025 Tc
0.007 Tw
(In all 3 studies, the primary end points were percent weight)Tj
0 -1.22857 TD
-0.018 Tc
0.018 Tw
(loss from baseline and percentage of subjects achieving at)Tj
T*
-0.001 Tc
0.001 Tw
(least 5% weight loss from baseline to study completion;)Tj
T*
-0.025 Tc
0.013 Tw
(secondary end points varied. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8 0 0 8 61 607.7132 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
(OBESITY WITHOUT COMORBIDITIES)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 586.6132 Tm
0 0 0 1 k
-0.015 Tc
0.11 Tw
[(T)-15(h)-15(e)-15( E)-15(Q)-15(U)-15(I)-15(P)-15( s)-15(t)-15(u)-15(d)-15(y)-15( e)-15(v)-15(aluated )15(low-)-75(dose )15(and )15(high-)-75(dose)]TJ
-1 -1.24761 TD
-0.039 Tc
0.024 Tw
(PHEN/TPM compared with placebo for a total treatment du-)Tj
0 -1.24762 TD
-0.036 Tc
0.021 Tw
[(ration of 56 weeks \(4)-75(-week titration phase; 52-week mainte-)]TJ
T*
-0.02 Tc
0.004 Tw
(nance phase\).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 105.0187 550.6132 Tm
0 0 0 1 k
-0.017 Tc
(12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 113.2526 547.3132 Tm
0 0 0 1 k
-0.02 Tc
0.004 Tw
[(Study participants were 18)-25(-70 years of age)]TJ
-5.97644 -1.24762 TD
-0.04 Tc
0.025 Tw
(with a BMI of 35 kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 140.1351 537.5132 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 145.3638 534.2132 Tm
0 0 0 1 k
-0.04 Tc
0.025 Tw
(or more and controlled triglycerides,)Tj
-9.03465 -1.24762 TD
-0.029 Tc
0.014 Tw
(blood pressure, and fasting plasma glucose. Study inclusion)Tj
0 -1.24761 TD
-0.03 Tc
0.015 Tw
[(criteria and results are detailed in T)70(able 2. Exclusion criteria)]TJ
0 -1.24762 TD
-0.017 Tc
0.002 Tw
(were extensive and included the following: weight gain or)Tj
0 -1.24763 TD
-0.04 Tc
0.007 Tw
(loss greater than 5 kg within the past 3 months; history of eat)Tj
22.00056 0 TD
0 Tc
(-)Tj
-22.00056 -1.24762 TD
-0.015 Tc
0.158 Tw
(ing disorders, previous bariatric sur)Tj
14.24505 0 TD
0 Tw
(gery)Tj
1.65142 0.00001 TD
-0.0151 Tc
(,)Tj
0.62776 0 Td
-0.015 Tc
0.158 Tw
(glaucoma, and)Tj
-16.52423 -1.24763 TD
-0.035 Tc
0.02 Tw
(nephrolithiasis; thyroid dysfunction; chronic systemic gluco)Tj
22.00051 0 TD
0 Tc
(-)Tj
-22.00051 -1.24762 TD
-0.037 Tc
0.022 Tw
[(corticoid therapy; bipolar disorder or psychosis history)65(, more)]TJ
T*
-0.027 Tc
0.012 Tw
(than 1 lifetime episode of major depression, current depres-)Tj
0 -1.24761 TD
-0.018 Tc
0.003 Tw
[(sion of moderate or greater severity)65(, presence or history of)]TJ
24.61905 29.49524 TD
-0.023 Tc
0.008 Tw
(suicidal behavior or ideation with some intent to act, or an-)Tj
0 -1.24762 TD
-0.04 Tc
0.01 Tw
(tidepressant use that had not been stable for at least 3 months;)Tj
0 -1.24763 TD
-0.0323 Tc
(s)Tj
0.35672 -0.00001 TD
-0.032 Tc
0.017 Tw
(troke, myocardial infarction, life-threatening arrhythmia, or)Tj
-0.35672 -1.24761 TD
-0.04 Tc
0.023 Tw
(coronary revascularization within the past 6 months; unstable)Tj
0 -1.24762 TD
-0.037 Tc
0.022 Tw
(angina, congestive heart failure, or known or suspected clini-)Tj
T*
-0.027 Tc
0.012 Tw
(cally significant valvular heart disease; cholelithiasis within)Tj
0 -1.24761 TD
-0.023 Tc
0.008 Tw
(the past 6 months; use of any investigational medication or)Tj
0 -1.24762 TD
-0.028 Tc
0.013 Tw
(device within the past month.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 425.0645 637.613 Tm
0 0 0 1 k
-0.027 Tc
(5,12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 437.3706 634.313 Tm
0 0 0 1 k
-0.028 Tc
0.013 Tw
(Baseline characteristics for)Tj
-12.22577 -1.24762 TD
-0.04 Tc
[(patients enrolled in EQUIP are presented in T)70(able 3. )]TJ
1 -1.21905 TD
-0.012 Tc
-0.003 Tw
[(Overall, )-15(the )-15(placebo-subtract)15(e)15(d)15( p)15(e)15(r)15(c)15(e)15(n)15(t)15( w)15(e)15(i)15(g)15(h)15(t)15( l)15(o)15(s)15(s)15( w)15(a)15(s)]TJ
-1 -1.21905 TD
-0.031 Tc
0.016 Tw
[(significant in both the low-)-75(dose and high-)-75(dose PHEN/TPM)]TJ
0 -1.21904 TD
-0.036 Tc
0.021 Tw
(groups (p < 0.0001 for both comparisons with placebo). Par-)Tj
0 -1.21905 TD
-0.015 Tc
0.494 Tw
[(ticipants receiving high-)-75(dose PHEN/TPM, low-)-75(dose)]TJ
0 -1.21904 TD
0.046 Tw
(PHEN/TPM, and placebo lost 10.9%, 5.1%, and 1.6% of)Tj
0 -1.21905 TD
-0.04 Tc
0.004 Tw
[(body weight, respectively)65(. The placebo-subtracted percentage)]TJ
T*
-0.026 Tc
0.011 Tw
(of individuals with at least 5% weight loss and 10% weight)Tj
0 -1.21904 TD
-0.015 Tc
0.053 Tw
[(loss was 49.4% and 39.8% for high-)-75(dose and 27.6% and)]TJ
0 -1.21905 TD
-0.025 Tc
0.01 Tw
[(1)35(1.4% for low-)-75(dose PHEN/TPM, respectively)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 494.3932 509.3131 Tm
0 0 0 1 k
-0.023 Tc
(12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 502.5619 506.0131 Tm
0 0 0 1 k
-0.025 Tc
[(Low-)-75(dose)]TJ
-18.43446 -1.21905 TD
-0.022 Tc
0.007 Tw
(PHEN/TPM compared with placebo resulted in significant)Tj
T*
-0.015 Tc
0.001 Tw
(reductions in waist circumference, systolic blood pressure)Tj
T*
0.186 Tw
[((SBP), and total cholesterol to high-)-75(density lipoprotein)]TJ
T*
0.026 Tw
(cholesterol (HDL-C) ratio.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 417.6762 458.1131 Tm
0 0 0 1 k
-0.013 Tc
(12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 426.2323 454.8131 Tm
0 0 0 1 k
-0.015 Tc
(Further)Tj
2.86302 0 TD
0.026 Tw
(more, compared with)Tj
-14.028 -1.21905 TD
-0.027 Tc
0.012 Tw
[(low-)-75(dose, high-)-75(dose PHEN/TPM resulted in significant re-)]TJ
T*
-0.015 Tc
0.108 Tw
(ductions in waist circumference measurements, diastolic)Tj
T*
-0.029 Tc
0.014 Tw
[(blood pressure \(DBP\) \(T)70(able 2\), reduced total cholesterol to)]TJ
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 50.5 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(342)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 74.2499 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 87.431 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 220.5559 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 233.737 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
/F8 1 Tf
10 0 0 10 488.4582 21.6616 Tm
0 0 0 1 k
0 Tw
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8 0 0 8 50.5 744.7228 Tm
0 0 0 1 k
-0.013 Tw
[(SM)-250(Smith et al.)]TJ
ET
0 0 0 0.1 k
50.5 320.089 493 13.036 re
f
50.5 297.163 493 12.137 re
f
50.5 272.889 493 12.137 re
f
50.5 249.064 493 12.137 re
f
50.5 225.2399 493 11.6871 re
f
50.5 200.966 493 12.1371 re
f
50.5 177.141 493 11.238 re
f
50.5 152.867 493 11.2379 re
f
50.5 129.043 493 12.1369 re
f
50.5 102.582 493 14.773 re
f
0.5 w 
0 0 0 1 K
51 362.833 m
543 362.833 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
9 0 0 9 177.9938 368.5827 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(T)74(able 1.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9 0 0 9 211.5094 368.5827 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(Clinical Pharmacokinetics of Phentermine/T)111(opiramate)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 413.3516 371.3327 Tm
0 0 0 1 k
(9)Tj
ET
0.5 w 
0 0 0 1 K
51 348.333 m
543 348.333 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 92.0845 352.5827 Tm
0 0 0 1 k
[(Parameter)-19994(Phentermine)-19027(T)74(opiramate)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 54 336.5827 Tm
0 0 0 1 k
(Absorption)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 89.8429 339.3327 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 57.75 324.5827 Tm
0 0 0 1 k
(C)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 63.1644 322.9327 Tm
0 0 0 1 k
-0.0001 Tc
(m)Tj
0.88887 0.00001 TD
(ax)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 73.1681 324.5827 Tm
0 0 0 1 k
-0.0002 Tc
(,)Tj
0.54177 0 Td
0 Tc
21.923 Tw
[(ng/mL)-20983(49.1 1020 )]TJ
-2.59751 -1.6 TD
-0.014 Tw
(time to C)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 87.5398 310.9327 Tm
0 0 0 1 k
(max)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 97.5435 312.5827 Tm
0 0 0 1 k
-0.0001 Tc
(,)Tj
0.54182 0 Td
0 Tc
(hours)Tj
20.5113 0 TD
-0.0003 Tc
(6)Tj
24.14631 0 Td
(9)Tj
-50.50523 -1.6 TD
0 Tc
(AUC)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 73.5813 298.9327 Tm
0 0 0 1 k
(0-t)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 79.6885 300.5827 Tm
0 0 0 1 k
-0.0002 Tc
(,)Tj
0.54179 0 Td
0 Tc
21.645 Tw
[(ng\245h/mL)-19208(1990 61600 )]TJ
-3.96693 -1.6 TD
0 Tw
(Distribution)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 91.4982 291.3326 Tm
0 0 0 1 k
(b)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 57.75 276.5827 Tm
0 0 0 1 k
(V)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 62.7524 274.9327 Tm
0 0 0 1 k
(d)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 65.8066 276.5827 Tm
0 0 0 1 k
-0.0002 Tc
(,)Tj
0.54168 0 Td
0 Tc
-0.014 Tw
[(L)-24187(348 )-22215(50.8 (central); 13.1 (peripheral))]TJ
-1.61589 -1.6 TD
[(plasma protein binding, %)-14899(17.5)-22200(15-41)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 455.7121 267.3326 Tm
0 0 0 1 k
(c)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 54 252.5827 Tm
0 0 0 1 k
(Metabolism)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 92.3313 255.3326 Tm
0 0 0 1 k
(b)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 255.4419 252.5827 Tm
0 0 0 1 k
-0.014 Tw
[(Minor)55(, primarily via CYP3A4)-11744(Not extensively metabolized)]TJ
-26.85892 -1.6 TD
0 Tw
(Excretion)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 85.2543 243.3326 Tm
0 0 0 1 k
(b)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 57.75 228.5827 Tm
0 0 0 1 k
-0.014 Tw
[(clearance, L/h)-20093(8.79 )-21937(1.17 )]TJ
0 -1.6 TD
[(half-life, hours)-20095(20 )-22771(65 )]TJ
T*
[(elimination, % (renal))-16999(70-80)-21590(70)]TJ
-0.5 -1.6 TD
0 Tw
(Impairment)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 91.4963 195.3327 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 57.75 180.5827 Tm
0 0 0 1 k
(hepatic)Tj
0.5 -1.6 TD
-0.014 Tw
[(mild (Child-Pugh score 5-6))-13735(AUC )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 273.2527 168.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 279.755 168.5827 Tm
0 0 0 1 k
-0.014 Tw
[(37%)-18904(No ef)18(fect on AUC)]TJ
-29.11067 -1.6 TD
-0.005 Tc
[(moderate (Child-Pugh score 7-9))-11510(A)-5(U)-5(C)-5( )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 273.2527 156.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 279.5567 156.5827 Tm
0 0 0 1 k
-0.014 Tw
[(60%)-18930(No ef)17(fect on AUC)]TJ
-29.57423 -1.6 TD
0 Tw
(renal )Tj
0.5 -1.6 TD
-0.014 Tw
[(mild (CrCL 50-79 mL/min))-14403(AUC )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 273.2527 132.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 279.5567 132.5827 Tm
0 0 0 1 k
[(22%)-18930(AUC )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 454.35 132.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 460.654 132.5827 Tm
0 0 0 1 k
(25%)Tj
-53.25053 -1.6 TD
-0.015 Tc
-0.014 Tw
[(moderate (CrCL 30-49 mL/min))-12463(A)-15(U)-15(C)-15( )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 273.2527 120.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 279.5567 120.5827 Tm
0 0 0 1 k
[(45%)-18930(AUC )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 454.35 120.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 460.654 120.5827 Tm
0 0 0 1 k
(85%)Tj
ET
0.5 w 
0 0 0 1 K
51 102.333 m
543 102.333 l
S
BT
/F1 1 Tf
7.5 0 0 7.5 61.5 108.5827 Tm
-0.014 Tw
[(severe (CrCL <30 mL/min))-14096(AUC )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 273.2527 108.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 279.5567 108.5827 Tm
0 0 0 1 k
[(91%)-18930(AUC )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
7.5 0 0 7.5 454.35 108.5827 Tm
0 0 0 1 k
<AD>Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 460.654 108.5827 Tm
0 0 0 1 k
(126%)Tj
-54.2205 -2.4 TD
(AUC)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 69.8313 88.9327 Tm
0 0 0 1 k
(0-t)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 77.8914 90.5827 Tm
0 0 0 1 k
-0.0001 Tc
(=)Tj
0.8443 0 Td
0 Tc
-0.017 Tw
(area under the concentration time curve, zero to the last time with measurable concentration; C)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 397.8634 88.9327 Tm
0 0 0 1 k
(max)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 409.82 90.5827 Tm
0 0 0 1 k
-0.0001 Tc
(=)Tj
0.84432 0 Td
0 Tc
-0.017 Tw
(maximum concentration; CrCl = crea-)Tj
-48.287 -1.2 TD
-0.014 Tw
(tinine clearance; V)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 115.4725 79.9327 Tm
0 0 0 1 k
(d)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 120.5063 81.5827 Tm
0 0 0 1 k
-0.0001 Tc
(=)Tj
0.84787 0 Td
0 Tc
-0.014 Tw
(volume of distribution.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 54 74.3327 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 56.7795 71.5827 Tm
0 0 0 1 k
-0.014 Tw
(Data obtained following a single 15/92-mg dose of phentermine/topiramate. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 54 64.3327 Tm
0 0 0 1 k
(b)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 57.0542 61.5827 Tm
0 0 0 1 k
-0.014 Tw
(Data obtained from individual dosing of phentermine and topiramate.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 54 54.3327 Tm
0 0 0 1 k
(c)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 56.7795 51.5827 Tm
0 0 0 1 k
-0.014 Tw
(The fraction bound decreases as blood topiramate concentrations increase from 0.5 to 250 )Tj
40.21833 0.00001 TD
0 Tw
[<B5>-20(g/mL.)]TJ
ET
0.5 w 
0 0 0 1 K
50.75 43.75 492.5 337.582 re
s
Q

endstream
endobj
7 0 obj
<<
/Length 14350
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
Q
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 50.5 726.0132 Tm
0 0 0 1 k
-0.04 Tc
0.01 Tw
(HDL-C ratio, and reduced percent triglycerides, as well as in-)Tj
0 -1.21905 TD
0.013 Tw
(creased HDL-C.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 113.542 716.5132 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 700.2131 Tm
0 0 0 1 k
-0.017 Tc
0.017 Tw
(Study limitations included a high dropout rate (40.1 %))Tj
-1 -1.23809 TD
-0.025 Tc
0.025 Tw
(and overrepresentation of female white participants, reduc-)Tj
0 -1.2381 TD
0 Tc
0.036 Tw
[(ing study generalizability)65(. However)40(, the dropout rate in)]TJ
T*
-0.013 Tc
0.013 Tw
(EQUIP is generally consistent with dropout rates in other)Tj
0 -1.23809 TD
0 Tc
0.14 Tw
[(phar)-25(macotherapy trials for obesity \(~30)-75(-50%\). Of the)]TJ
T*
0.181 Tw
[(59.9% of participants who completed the study)65(, only)]TJ
0 -1.2381 TD
-0.003 Tc
0.003 Tw
(53.7% took the drug for the full treatment course. Using)Tj
0 -1.23809 TD
0 Tc
0.386 Tw
[(the intention-to-treat last-)-75(observation-carried-forward)]TJ
0 -1.2381 TD
-0.024 Tc
0.024 Tw
[(\(ITT)90(-LOCF\) analysis for missing data and failing to obtain)]TJ
T*
-0.023 Tc
0.022 Tw
(final weight measurements for 40.1% of study participants)Tj
0 -1.23809 TD
-0.004 Tc
0.004 Tw
(may introduce bias when comparing randomized groups)Tj
0 -1.2381 TD
-0.018 Tc
0.018 Tw
(since the LOCF is based on an unrealistic assumption that)Tj
T*
-0.02 Tc
0.02 Tw
(weight will not change after the last measurement.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 253.3231 547.5131 Tm
0 0 0 1 k
-0.018 Tc
(16)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 261.7133 544.2131 Tm
0 0 0 1 k
-0.02 Tc
(How-)Tj
-20.11555 -1.23809 TD
-0.006 Tc
0.006 Tw
[(ever)40(, most weight loss occurs early and is often regained)]TJ
0 -1.2381 TD
-0.01 Tc
0.01 Tw
(with time, particularly with agents that suppress appetite,)Tj
T*
0 Tc
0.013 Tw
[(such as phenter)-25(mine and possibly topiramate. The most)]TJ
0 -1.23809 TD
-0.01 Tc
0.01 Tw
(common reasons for discontinuation were loss to follow-)Tj
0 -1.2381 TD
-0.023 Tc
0.023 Tw
(up, withdrawal of consent, or adverse events. Discontinua-)Tj
0 -1.23809 TD
-0.008 Tc
0.008 Tw
(tions due to adverse events were more common in active)Tj
T*
-0.011 Tc
0.011 Tw
(treatment groups, with a higher frequency occurring with)Tj
0 -1.2381 TD
-0.025 Tc
0.013 Tw
[(high-)-75(dose PHEN/TPM \(see \322Adverse Ef)20(fects\323\). )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8 0 0 8 61 412.3132 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(OVER)18(WEIGHT OR OBESITY WITH WEIGHT)55(-RELA)73(TED)]TJ
0 -1.6125 TD
0 Tw
(COMORBIDITIES)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 378.5132 Tm
0 0 0 1 k
-0.024 Tc
0.023 Tw
[(The CONQUER study and its 52-week extension study)65(,)]TJ
-1 -1.22857 TD
-0.005 Tc
0.005 Tw
[(SEQUEL, evaluated the safety and ef)20(ficacy of mid-)-75(dose)]TJ
T*
-0.014 Tc
0.014 Tw
((7.5/46 mg) and high-)Tj
8.6064 0 TD
(dose (15/92 mg) PHEN/TPM com)Tj
13.39415 0 TD
0 Tc
(-)Tj
-22.00055 -1.22858 TD
-0.01 Tc
0.01 Tw
(pared with placebo in individuals with 2 or more weight-)Tj
0 -1.22857 TD
-0.023 Tc
0.023 Tw
(related comorbidities \(eg, hypertension, dyslipidemia, type)Tj
-0.0001 Tc
(2)'
0.81132 0 Td
0 Tc
0.061 Tw
(diabetes, prediabetes, abdominal obesity\). Unlike the)Tj
-0.81132 -1.22857 TD
-0.008 Tc
0.008 Tw
[(EQUIP study)65(, eligible patients had a BMI of 27 kg/m)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 270.7648 304.4132 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 276.341 301.1132 Tm
0 0 0 1 k
-0.008 Tc
(or)Tj
-21.50867 -1.22857 TD
-0.025 Tc
0.024 Tw
(more and 45 kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 123.7537 291.5132 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 129.2203 288.2132 Tm
0 0 0 1 k
-0.025 Tc
0.024 Tw
[(or less. However)40(, in CONQUER, there)]TJ
-7.49717 -1.22857 TD
0.002 Tw
(was no designated lower limit on BMI for participants with)Tj
T*
0.016 Tw
(type 2 diabetes at baseline.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 156.6642 265.7132 Tm
0 0 0 1 k
-0.024 Tc
[(2,1)56(1,12)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 175.817 262.4132 Tm
0 0 0 1 k
-0.025 Tc
0.016 Tw
(Study inclusion criteria and)Tj
-11.93495 -1.22857 TD
0.006 Tw
(results are detailed in T)Tj
8.71197 0.00001 TD
(able 2. Exclusion criteria were simi-)Tj
-8.71197 -1.22858 TD
-0.009 Tc
0.009 Tw
(lar to those in the EQUIP study with the exception of the)Tj
0 -1.22857 TD
0 Tc
0.033 Tw
[(following: use of phenter)-25(mine or topiramate for weight)]TJ
0 -1.22856 TD
0 Tw
(loss or any other indication within 3 months prior to the)Tj
0 -1.22857 TD
0.037 Tw
(study; type 1 diabetes or antidiabetic medications other)Tj
T*
0.195 Tw
[(than metfor)-25(min; SBP greater than 160 mm)-200(Hg; DBP)]TJ
0 -1.22858 TD
-0.001 Tc
0.001 Tw
[(greater than 100 mm)-200(Hg or antihypertensive medication)]TJ
0 -1.22857 TD
-0.025 Tc
0.009 Tw
(use that had not been stable for the preceding month; histo-)Tj
T*
-0.022 Tc
0.022 Tw
(ry of malignancy within 5 years; obesity of known genetic)Tj
T*
(or endocrine origin; use of very-low-calorie diet or partici-)Tj
T*
-0.025 Tc
0.006 Tw
(pation in a for)Tj
5.30583 0.00001 TD
(mal weight loss program in the 3 months pri)Tj
16.69472 0.00001 TD
0 Tc
(-)Tj
-22.0006 -1.2286 TD
0.181 Tw
(or to the study; smoking cessation within previous 3)Tj
T*
-0.017 Tc
0.017 Tw
(months or plans to quit during the study period; history of)Tj
T*
-0.024 Tc
0.024 Tw
(drug/alcohol abuse within the preceding year; women who)Tj
T*
-0.022 Tc
0.021 Tw
(were pregnant, breastfeeding, or planning to conceive dur-)Tj
T*
-0.012 Tc
0.012 Tw
(ing the trial period. Prior to randomization, potential sub-)Tj
T*
-0.006 Tc
0.006 Tw
(jects were excluded for plasma bicarbonate level outside)Tj
24.61905 65.03809 TD
-0.009 Tc
0.009 Tw
[(the nor)-25(mal range, aspartate aminotransferase and alanine)]TJ
0 -1.22857 TD
-0.013 Tc
0.013 Tw
(aminotransferase greater than 2.5 times the upper limit of)Tj
T*
0 Tc
0.101 Tw
[(nor)-25(mal (ULN), fasting blood glucose greater than 240)]TJ
T*
-0.025 Tc
0.025 Tw
(mg/dL, serum triglycerides greater than 400 mg/dL, creati-)Tj
T*
0 Tc
0.001 Tw
(nine clearance less than 60 mL/min, thyroid stimulating)Tj
T*
-0.005 Tc
0.005 Tw
[(hor)-25(mone 1.5 times the ULN, or clinically significant ab-)]TJ
T*
-0.018 Tc
0 Tw
[(nor)-25(malities.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 356.9311 651.9131 Tm
0 0 0 1 k
-0.015 Tc
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 365.3476 648.6132 Tm
0 0 0 1 k
-0.017 Tc
0.017 Tw
[(At the end of the CONQUER study)65(,)1( )1(p)1(a)1(r)1(t)1(i)1(c)1(i)1(-)]TJ
-5.36644 -1.22857 TD
-0.014 Tc
0.014 Tw
(pants were automatically excluded from SEQUEL if they)Tj
T*
-0.02 Tc
0.02 Tw
(had a BMI of 22 kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 399.4534 626.1132 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 404.9583 622.8132 Tm
0 0 0 1 k
-0.02 Tc
0.02 Tw
(or less, had discontinued the study)Tj
-9.13889 -1.22857 TD
0 Tc
0.021 Tw
(drug more than 4 weeks after 56 weeks of treatment, or)Tj
T*
0.041 Tw
[(had participated in another for)-25(mal weight loss program)]TJ
T*
0.001 Tw
(during the interim between CONQUER completion and)Tj
T*
-0.025 Tc
0.013 Tw
(SEQUEL initiation.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 387.8087 574.5131 Tm
0 0 0 1 k
-0.023 Tc
(14)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 558.3632 Tm
0 0 0 1 k
-0.033 Tc
0.018 Tw
[(A)-14(t)-14( )-14(t)-14(h)-14(e)-14( )-14(c)-14(o)-14(m)-14(p)-14(l)-14(e)-14(t)-14(i)-14(on of CONQUER (56 weeks of therapy),)]TJ
-1 -1.22381 TD
-0.028 Tc
0.012 Tw
(the placebo-subtracted weight loss was significantly greater)Tj
T*
-0.039 Tc
0.024 Tw
[(at both mid-)-75(dose and high-)-75(dose PHEN/TPM compared with)]TJ
T*
-0.034 Tc
0.019 Tw
(placebo (p < 0.0001 for both comparisons to placebo).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 519.8257 523.1132 Tm
0 0 0 1 k
-0.032 Tc
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 527.8867 519.8132 Tm
0 0 0 1 k
-0.034 Tc
(The)Tj
-20.84635 -1.22381 TD
-0.021 Tc
0.006 Tw
(corresponding odds ratios for achieving at least 5% weight)Tj
T*
-0.04 Tc
0.007 Tw
[(loss in the mid-)-75(dose and high-)-75(dose groups relative to placebo)]TJ
T*
-0.036 Tc
0.021 Tw
(were 6.3 \(95% CI 4.9)Tj
7.99723 0 TD
[(-)-25(8.0; p < 0.0001\) and 9.0 \(95% CI 7.3)-25(-)]TJ
-7.99723 -1.22381 TD
0 Tc
(1)Tj
0.44188 0 TD
-0.023 Tc
0.008 Tw
(1.1; p < 0.0001\), respectively)Tj
11.03304 0 TD
-0.0231 Tc
(.)Tj
0.46186 0 Td
-0.023 Tc
(For patients completing the)Tj
-11.93678 -1.22382 TD
-0.026 Tc
0.01 Tw
(SEQUEL study)Tj
5.88851 0 TD
-0.0256 Tc
(,)Tj
0.45932 0 Td
-0.026 Tc
(mean placebo-subtracted weight loss from)Tj
-6.34783 -1.22381 TD
-0.038 Tc
0.023 Tw
(baseline (week 0 of CONQUER) to 108 weeks was also sig)Tj
22.00045 0 TD
0 Tc
(-)Tj
-22.00045 -1.22381 TD
-0.027 Tc
0.012 Tw
(nificantly greater at both doses compared with placebo \(p <)Tj
T*
-0.04 Tc
0.006 Tw
(0.0001 for both comparisons with placebo\).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 475.1036 420.3132 Tm
0 0 0 1 k
-0.038 Tc
(14)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 482.8967 417.0132 Tm
0 0 0 1 k
-0.04 Tc
0.006 Tw
(In CONQUER,)Tj
-16.56159 -1.22381 TD
-0.015 Tc
0.083 Tw
(the corresponding odds ratios for achieving at least 10%)Tj
0 -1.22382 TD
0.12 Tw
[(weight loss in the mid-)-75(dose and high-)-75(dose PHEN/TPM)]TJ
0 -1.22381 TD
-0.025 Tc
0.01 Tw
[(groups compared with placebo were 7.6 \(95% CI 5.6)-25(-10.2\))]TJ
T*
-0.04 Tc
0.005 Tw
[(and 1)35(1.7 \(95% CI 8.9)-25(-15.4\), respectively)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 465.6001 368.9132 Tm
0 0 0 1 k
-0.038 Tc
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 473.3767 365.6131 Tm
0 0 0 1 k
-0.04 Tc
0.005 Tw
[(Further)-25(more, after)]TJ
-15.65492 -1.22381 TD
0.011 Tw
(108 weeks of treatment (completion of SEQUEL), high-)Tj
20.62055 0 TD
0 Tw
(dose)Tj
-20.62055 -1.22381 TD
-0.015 Tc
0.035 Tw
(PHEN/TPM resulted in a significantly greater percentage)Tj
T*
-0.03 Tc
0.015 Tw
(weight loss compared with mid-)Tj
12.11646 0 TD
(dose in severely obese sub)Tj
9.88401 0 TD
0 Tc
(-)Tj
-22.00046 -1.22382 TD
-0.04 Tc
0.009 Tw
(jects \(BMI )Tj
/F20 1 Tf
4.13165 0 TD
0 Tc
<B3>Tj
/F2 1 Tf
0.50883 0.00001 TD
-0.04 Tc
(40 kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 389.5886 317.5131 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 394.6478 314.2131 Tm
0 0 0 1 k
-0.04 Tc
0.009 Tw
(and <45 kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 448.2126 317.5131 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 450.9726 314.2131 Tm
0 0 0 1 k
-0.0401 Tc
(\))Tj
0.51183 0 Td
-0.04 Tc
0.009 Tw
(at baseline \(p = 0.0016)Tj
-14.03303 -1.22381 TD
-0.015 Tc
0.364 Tw
(for the comparison between doses\).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 467.8995 304.6631 Tm
0 0 0 1 k
-0.013 Tc
(14)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 480.0072 301.3631 Tm
0 0 0 1 k
-0.015 Tc
0.364 Tw
(Both doses of)Tj
-16.2864 -1.22381 TD
-0.019 Tc
0.004 Tw
[(PHEN/TPM also resulted in significant reductions in SBP)110(,)]TJ
T*
-0.03 Tc
0.015 Tw
(waist circumference measurement, total cholesterol, triglyc-)Tj
T*
-0.038 Tc
0.023 Tw
(erides, fasting plasma glucose, and improved insulin concen-)Tj
T*
-0.04 Tc
0.013 Tw
(trations compared with placebo. In patients without type 2 di)Tj
22.00055 0.00001 TD
0 Tc
(-)Tj
-22.00055 -1.22381 TD
-0.04 Tc
(abetes at baseline, progression to type 2 diabetes was reduced)Tj
T*
-0.015 Tc
0.022 Tw
[(by 54% and 76%, respectively)65(, in subjects receiving mid-)]TJ
T*
-0.022 Tc
0.007 Tw
(dose and high-)Tj
5.67205 0.00001 TD
(dose PHEN/TPM compared with placebo.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 537.6308 214.7131 Tm
0 0 0 1 k
-0.02 Tc
(14)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 309 198.5631 Tm
0 0 0 1 k
-0.033 Tc
0.018 Tw
(For patients with prediabetes at baseline, the risk of progres)Tj
22.00047 0.00001 TD
0 Tc
(-)Tj
-22.00047 -1.22383 TD
-0.039 Tc
0.024 Tw
(sion to diabetes was reduced with both doses of PHEN/TPM)Tj
0 -1.22381 TD
-0.015 Tc
0.022 Tw
(compared with placebo, but only the comparison of high-)Tj
T*
-0.026 Tc
0.011 Tw
(dose PHEN/TPM with placebo was statistically significant,)Tj
T*
-0.015 Tc
0.044 Tw
(with a relative risk versus placebo of 0.47 \(95% CI 0.25)Tj
22.00054 0.00001 TD
0 Tc
(-)Tj
-22.00054 -1.22382 TD
-0.04 Tc
0 Tw
(0.88\).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 330.9739 137.6129 Tm
0 0 0 1 k
-0.038 Tc
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 338.8533 134.3129 Tm
0 0 0 1 k
-0.04 Tc
0.015 Tw
[(Further)-25(more, PHEN/TPM reduced the use of antidia-)]TJ
-2.84317 -1.2238 TD
-0.036 Tc
0.021 Tw
(betic, antihypertensive, and lipid-lowering medications com-)Tj
0 -1.22381 TD
-0.019 Tc
0.004 Tw
(pared with placebo. These results remained essentially un-)Tj
T*
-0.04 Tc
0.013 Tw
(changed at 108 weeks in the SEQUEL extension study)Tj
19.91732 0.00001 TD
(.)Tj
-18.91732 -1.22858 TD
-0.006 Tc
0.005 Tw
(Study limitations included a lack of end point data for)Tj
-1 -1.22857 TD
-0.009 Tc
0.009 Tw
(31% of the study sample, restriction of the upper limit of)Tj
0 -1.22858 TD
-0.025 Tc
0.003 Tw
(BMI, a generally homogenous study population with most-)Tj
0 -1.22857 TD
0.024 Tw
(ly women (70%) and white (86%) participants, and lack of)Tj
ET
0 0 0 0 k
308.5 740.1929 235 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8.4 0 0 8 366.993 744.7228 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Phenter)-25(mine/T)90(opiramate for the T)35(reatment of Obesity)]TJ
ET
0 0 0 0 k
157.5 15.444 386 13.08 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 269.1412 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 402.2662 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 415.4473 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 515.819 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 529 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(343)Tj
ET
0 0 0 0 k
50.5 16.524 79.5 11.669 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 50.5 21.3551 Tm
0 0 0 1 k
-0.025 Tc
(theannals.com)Tj
ET
Q

endstream
endobj
8 0 obj
<<
/Length 52602
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
50.5 14 378.5 14.524 re
f
Q
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 50.5 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(344)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 74.2499 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 87.431 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 220.5559 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 233.737 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
/F8 1 Tf
10 0 0 10 488.4582 21.6616 Tm
0 0 0 1 k
0 Tw
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8 0 0 8 50.5 744.7228 Tm
0 0 0 1 k
-0.013 Tw
[(SM)-250(Smith et al.)]TJ
ET
0 0 0 0.1 k
254.4999 43.5001 190.93 690 re
f
0.5 w 
0 0 0 1 K
62.809 43.5 m
62.809 733.5 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 9 -9 0 57.0588 273.9476 Tm
0 0 0 1 k
(T)Tj
0.51186 0 TD
-0.0252 Tc
(a)Tj
0.53084 0 TD
(b)Tj
0.58584 0 TD
(l)Tj
0.25284 0 TD
(e)Tj
0.7948 0 TD
(2)Tj
0.53084 0 TD
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 9 -9 0 57.0588 307.4632 Tm
0 0 0 1 k
-0.0252 Tc
(E)Tj
0.64182 0 TD
(f)Tj
0.23518 0 TD
-0.0251 Tc
(f)Tj
0.25288 0 TD
(i)Tj
0.19688 0 TD
(c)Tj
0.47489 0 TD
(a)Tj
0.53089 0 TD
(c)Tj
0.47489 0 TD
(y)Tj
0.73888 0 TD
(o)Tj
0.53089 0 TD
(f)Tj
0.51688 0 TD
(P)Tj
0.64188 0 TD
(h)Tj
0.53089 0 TD
(e)Tj
0.53089 0 TD
(n)Tj
0.53089 0 TD
(t)Tj
0.25288 0 TD
(e)Tj
0.53089 0 TD
(r)Tj
0.30788 0 TD
(m)Tj
0.80788 0 TD
(i)Tj
0.19688 0 TD
(n)Tj
0.53089 0 TD
(e)Tj
0.53089 0 TD
(/)Tj
0.25288 0 TD
(T)Tj
0.47509 0 TD
(o)Tj
0.53088 0 TD
(p)Tj
0.53088 0 TD
(i)Tj
0.19688 0 TD
(r)Tj
0.30788 0 TD
(a)Tj
0.53088 0 TD
(m)Tj
0.80788 0 TD
(a)Tj
0.53088 0 TD
(t)Tj
0.25288 0 TD
(e)Tj
0.79488 0 TD
(i)Tj
0.19688 0 TD
(n)Tj
0.79488 0 TD
(C)Tj
0.69688 0 TD
(l)Tj
0.19688 0 TD
(i)Tj
0.19688 0 TD
(n)Tj
0.53088 0 TD
(i)Tj
0.19688 0 TD
(c)Tj
0.47488 0 TD
(a)Tj
0.53088 0 TD
(l)Tj
0.46088 0 TD
(T)Tj
0.54909 0 TD
(r)Tj
0.30788 0 TD
(i)Tj
0.19688 0 TD
(a)Tj
0.53088 0 TD
(l)Tj
0.19688 0 TD
(s)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 7.5 -7.5 0 73.0588 412.4179 Tm
0 0 0 1 k
-0.0001 Tc
(P)Tj
0.6669 0 TD
(r)Tj
0.3889 0 TD
(i)Tj
0.2779 0 TD
(m)Tj
0.8889 0 TD
(a)Tj
0.5559 0 TD
(r)Tj
0.3889 0 TD
(y)Tj
ET
0.5 w 
0 0 0 1 K
85.309 43.5 m
85.309 733.5 l
S
BT
/F6 1 Tf
0 7.5 -7.5 0 81.0588 59.911 Tm
-0.0002 Tc
(S)Tj
0.6668 0 TD
(t)Tj
0.3328 0 TD
(u)Tj
0.6108 0 TD
(d)Tj
0.6108 0 TD
(y)Tj
5.1239 0 TD
-0.0001 Tc
(D)Tj
0.72185 0 TD
(e)Tj
0.55585 0 TD
(s)Tj
0.55585 0 TD
(i)Tj
0.27785 0 TD
(g)Tj
0.61085 0 TD
(n)Tj
9.68118 0 TD
(I)Tj
0.27785 0 TD
(n)Tj
0.61085 0 TD
(c)Tj
0.55585 0 TD
(l)Tj
0.27785 0 TD
(u)Tj
0.61085 0 TD
(s)Tj
0.55585 0 TD
(i)Tj
0.27785 0 TD
(o)Tj
0.61085 0 TD
(n)Tj
0.87481 0 TD
(C)Tj
0.72185 0 TD
(r)Tj
0.38885 0 TD
(i)Tj
0.27785 0 TD
(t)Tj
0.33285 0 TD
(e)Tj
0.55585 0 TD
(r)Tj
0.38885 0 TD
(i)Tj
0.27785 0 TD
(a)Tj
9.67766 0 TD
0 Tc
(T)Tj
0.5559 0 TD
-0.0002 Tc
(r)Tj
0.38885 0 TD
(e)Tj
0.55585 0 TD
(a)Tj
0.55585 0 TD
(t)Tj
0.33285 0 TD
(m)Tj
0.88885 0 TD
(e)Tj
0.55585 0 TD
(n)Tj
0.61085 0 TD
(t)Tj
3.17938 0 TD
-0.0001 Tc
(E)Tj
0.66686 0 TD
(f)Tj
0.33286 0 TD
(f)Tj
0.33286 0 TD
(i)Tj
0.27786 0 TD
(c)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(c)Tj
0.55586 0 TD
(y)Tj
0.81982 0 TD
(O)Tj
0.77786 0 TD
(u)Tj
0.61086 0 TD
(t)Tj
0.33286 0 TD
(c)Tj
0.55586 0 TD
(o)Tj
0.61086 0 TD
(m)Tj
0.88886 0 TD
(e)Tj
12.01324 0 TD
(S)Tj
0.66687 0 TD
(e)Tj
0.55587 0 TD
(c)Tj
0.55587 0 TD
(o)Tj
0.61087 0 TD
(n)Tj
0.61087 0 TD
(d)Tj
0.61087 0 TD
(a)Tj
0.55587 0 TD
(r)Tj
0.38887 0 TD
(y)Tj
0.81984 0 TD
(E)Tj
0.66687 0 TD
(f)Tj
0.33287 0 TD
(f)Tj
0.33287 0 TD
(i)Tj
0.27787 0 TD
(c)Tj
0.55587 0 TD
(a)Tj
0.55587 0 TD
(c)Tj
0.55587 0 TD
(y)Tj
0.81984 0 TD
(O)Tj
0.77787 0 TD
(u)Tj
0.61087 0 TD
(t)Tj
0.33287 0 TD
(c)Tj
0.55587 0 TD
(o)Tj
0.61087 0 TD
(m)Tj
0.88887 0 TD
(e)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 78.3088 647.478 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 97.0588 46.5 Tm
0 0 0 1 k
-0.0001 Tc
(O)Tj
0.7779 0 TD
(B)Tj
0.6669 0 TD
(-)Tj
0.3329 0 TD
(3)Tj
0.5559 0 TD
(0)Tj
0.5559 0 TD
(2)Tj
4.3989 0 TD
(R)Tj
0.7219 0 TD
(,)Tj
0.5418 0 TD
(D)Tj
0.7219 0 TD
(B)Tj
0.66686 0 TD
(,)Tj
0.54183 0 TD
(P)Tj
0.66686 0 TD
(G)Tj
0.77786 0 TD
(,)Tj
0.54183 0 TD
(M)Tj
0.83286 0 TD
(C)Tj
1.89818 0 TD
(A)Tj
0.66688 0 TD
(g)Tj
0.55588 0 TD
(e)Tj
0.81986 0 TD
(1)Tj
0.55588 0 TD
(8)Tj
0.55588 0 TD
(-)Tj
0.33288 0 TD
(7)Tj
0.55588 0 TD
(0)Tj
0.81986 0 TD
(y)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(s)Tj
0.49988 0 TD
(;)Tj
0.54186 0 TD
(B)Tj
0.66688 0 TD
(M)Tj
0.83288 0 TD
(I)Tj
/F20 1 Tf
0.54198 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54884 0 TD
-0.0001 Tc
(3)Tj
0.55586 0 TD
(5)Tj
0.81982 0 TD
(k)Tj
0.49986 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 94.3088 265.3654 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 97.0588 326.2493 Tm
0 0 0 1 k
-0.0001 Tc
(P)Tj
0.66688 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(n)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(5)Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(4)Tj
0.55588 0 TD
(\))Tj
1.25527 0 TD
(P)Tj
0.66689 0 TD
(l)Tj
0.22189 0 TD
(a)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(e)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(o)Tj
0.55589 0 TD
(-)Tj
0.33289 0 TD
(s)Tj
0.49989 0 TD
(u)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(t)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
1.66882 0 TD
(W)Tj
0.94386 0 TD
(C)Tj
0.98583 0 TD
(\()Tj
0.33286 0 TD
(%)Tj
1.15283 0 TD
(c)Tj
0.49986 0 TD
(h)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(g)Tj
0.55586 0 TD
(e)Tj
0.55586 0 TD
(\))Tj
0.33286 0 TD
(,)Tj
0.54183 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(:)Tj
-65.3953 -1.2 TD
(E)Tj
0.6669 0 TD
(Q)Tj
0.7779 0 TD
(U)Tj
0.7219 0 TD
(I)Tj
0.2779 0 TD
(P)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 103.3088 73.5868 Tm
0 0 0 1 k
-0.0002 Tc
(1)Tj
0.5558 0 TD
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 106.0588 104.9114 Tm
0 0 0 1 k
-0.0001 Tc
(P)Tj
0.6669 0 TD
(h)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(s)Tj
0.49991 0 TD
(e)Tj
0.81992 0 TD
(3)Tj
4.31325 0 TD
0 Tc
(T)Tj
0.57397 0 TD
-0.0001 Tc
(r)Tj
0.3329 0 TD
(i)Tj
0.2219 0 TD
(g)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(y)Tj
0.4999 0 TD
(c)Tj
0.4999 0 TD
(e)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(i)Tj
0.2219 0 TD
(d)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(s)Tj
/F20 1 Tf
0.764 0 TD
0 Tc
<B2>Tj
/F1 1 Tf
0.54884 0 TD
-0.0001 Tc
(2)Tj
0.55586 0 TD
(0)Tj
0.55586 0 TD
(0)Tj
0.81982 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(d)Tj
0.55586 0 TD
(L)Tj
0.55586 0 TD
(,)Tj
0.54182 0 TD
(u)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(r)Tj
0.33286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(e)Tj
0.55586 0 TD
(d)Tj
0.81982 0 TD
(o)Tj
0.55586 0 TD
(r)Tj
0.59682 0 TD
(n)Tj
0.55586 0 TD
(o)Tj
0.81982 0 TD
(m)Tj
0.83286 0 TD
(o)Tj
0.55586 0 TD
(r)Tj
0.33286 0 TD
(e)Tj
1.66893 0 TD
(P)Tj
0.66689 0 TD
(H)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(N)Tj
0.72189 0 TD
(/)Tj
0.27789 0 TD
(T)Tj
0.61089 0 TD
(P)Tj
0.66689 0 TD
(M)Tj
1.09689 0 TD
(C)Tj
0.72189 0 TD
(R)Tj
3.14767 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(g)Tj
0.55589 0 TD
(h)Tj
0.55589 0 TD
(t)Tj
0.54189 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(s)Tj
0.76389 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.54189 0 TD
(5)Tj
0.55589 0 TD
(6)Tj
2.8774 0 TD
(3)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(7)Tj
0.55587 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(2)Tj
0.55587 0 TD
(3)Tj
0.81985 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
<D0>Tj
0.55587 0 TD
(5)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(6)Tj
0.81984 0 TD
(\()Tj
0.33287 0 TD
(p)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
(0)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(0)Tj
0.55587 0 TD
(0)Tj
0.55587 0 TD
(0)Tj
0.55587 0 TD
(6)Tj
0.55587 0 TD
(\))Tj
-69.1925 -1.2 TD
(5)Tj
0.5559 0 TD
(6)Tj
0.8199 0 TD
(w)Tj
0.7219 0 TD
(e)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(k)Tj
0.4999 0 TD
(s)Tj
3.0787 0 TD
-0.0002 Tc
(2)Tj
0.5558 0 TD
(:)Tj
0.2778 0 TD
(1)Tj
0.5558 0 TD
(:)Tj
0.2778 0 TD
(1)Tj
6.74443 0 TD
-0.0001 Tc
(t)Tj
0.27789 0 TD
(h)Tj
0.55589 0 TD
(a)Tj
0.55589 0 TD
(n)Tj
0.81988 0 TD
(1)Tj
0.81988 0 TD
(l)Tj
0.22189 0 TD
(i)Tj
0.22189 0 TD
(p)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(d)Tj
0.55589 0 TD
(-)Tj
0.33289 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(r)Tj
0.33289 0 TD
(i)Tj
0.22189 0 TD
(n)Tj
0.55589 0 TD
(g)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(c)Tj
0.49989 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
8.6961 0 TD
(3)Tj
0.55586 0 TD
(.)Tj
0.27786 0 TD
(7)Tj
0.55586 0 TD
(5)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(2)Tj
0.55586 0 TD
(3)Tj
0.81982 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
4.35291 0 TD
-0.0151 Tc
(w)Tj
0.70687 0 TD
(e)Tj
0.54087 0 TD
(e)Tj
0.54087 0 TD
(k)Tj
0.48487 0 TD
(s)Tj
0.73384 0 TD
(\()Tj
0.31787 0 TD
(%)Tj
0.87387 0 TD
(\))Tj
0.31787 0 TD
(:)Tj
5.22411 0 TD
-0.0001 Tc
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81987 0 TD
(=)Tj
0.84787 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(9)Tj
0.81987 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81987 0 TD
(<)Tj
0.84787 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81987 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76387 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.81987 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(d)Tj
0.81987 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.55588 0 TD
(\))Tj
-81.12745 -1.20001 TD
(N)Tj
0.98588 0 TD
(=)Tj
0.84788 0 TD
(1)Tj
0.55589 0 TD
(2)Tj
0.55589 0 TD
(6)Tj
0.55589 0 TD
(7)Tj
3.78677 0 TD
(a)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
0.81988 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
1.5364 0 TD
(B)Tj
0.66691 0 TD
(P)Tj
/F20 1 Tf
0.93102 0 TD
0 Tc
<B2>Tj
/F1 1 Tf
0.47485 0 TD
-0.0001 Tc
(1)Tj
0.55585 0 TD
(4)Tj
0.55585 0 TD
(0)Tj
0.55585 0 TD
(/)Tj
0.27785 0 TD
(9)Tj
0.55585 0 TD
(0)Tj
0.81981 0 TD
(m)Tj
0.833 0 TD
0 Tc
(m)Tj
1.03276 0 TD
-0.0001 Tc
(H)Tj
0.72186 0 TD
(g)Tj
0.55586 0 TD
(,)Tj
0.54182 0 TD
(u)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(r)Tj
0.33286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(e)Tj
0.55586 0 TD
(d)Tj
0.81982 0 TD
(o)Tj
0.55586 0 TD
(r)Tj
0.59682 0 TD
(n)Tj
0.55586 0 TD
(o)Tj
0.81982 0 TD
(m)Tj
0.83286 0 TD
(o)Tj
0.55586 0 TD
(r)Tj
0.33286 0 TD
(e)Tj
4.78316 0 TD
(\()Tj
0.33285 0 TD
(n)Tj
0.81981 0 TD
(=)Tj
0.84781 0 TD
(2)Tj
0.55585 0 TD
(4)Tj
0.55585 0 TD
(1)Tj
0.55585 0 TD
(\))Tj
5.6317 0 TD
(3)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(7)Tj
0.55587 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(2)Tj
0.55587 0 TD
(3)Tj
0.81984 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
(3)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(5)Tj
1.79271 0 TD
(S)Tj
0.66688 0 TD
(B)Tj
0.66688 0 TD
(P)Tj
0.93086 0 TD
(\()Tj
0.33288 0 TD
(%)Tj
1.15286 0 TD
(c)Tj
0.49988 0 TD
(h)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(g)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(\))Tj
0.33288 0 TD
(,)Tj
0.54186 0 TD
(m)Tj
0.83288 0 TD
(e)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(:)Tj
-50.53051 -1.20001 TD
(t)Tj
0.2779 0 TD
(h)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(n)Tj
0.8199 0 TD
(2)Tj
0.8199 0 TD
(a)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(t)Tj
0.2779 0 TD
(i)Tj
0.2219 0 TD
(h)Tj
0.5559 0 TD
(y)Tj
0.4999 0 TD
(p)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(t)Tj
0.2779 0 TD
(e)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(i)Tj
0.2219 0 TD
(v)Tj
0.4999 0 TD
(e)Tj
0.8199 0 TD
(m)Tj
0.8329 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
0.5559 0 TD
(i)Tj
0.2219 0 TD
(c)Tj
0.49989 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.2779 0 TD
(i)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(s)Tj
6.1931 0 TD
(P)Tj
0.66689 0 TD
(H)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(N)Tj
0.72189 0 TD
(/)Tj
0.27789 0 TD
(T)Tj
0.61089 0 TD
(P)Tj
0.66689 0 TD
(M)Tj
1.09689 0 TD
(C)Tj
0.72189 0 TD
(R)Tj
3.64767 0 TD
(1)Tj
0.55587 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(9)Tj
0.55587 0 TD
(2)Tj
0.81984 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
(9)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(3)Tj
3.12644 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(8)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(9)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-59.52185 -1.20001 TD
(F)Tj
0.6109 0 TD
(a)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(t)Tj
0.2779 0 TD
(i)Tj
0.2219 0 TD
(n)Tj
0.5559 0 TD
(g)Tj
0.8199 0 TD
(s)Tj
0.4999 0 TD
(e)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(u)Tj
0.5559 0 TD
(m)Tj
1.0969 0 TD
(g)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(u)Tj
0.5559 0 TD
(c)Tj
0.4999 0 TD
(o)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(e)Tj
0.8199 0 TD
(l)Tj
0.2219 0 TD
(e)Tj
0.5559 0 TD
(v)Tj
0.4999 0 TD
(e)Tj
0.5559 0 TD
(l)Tj
/F20 1 Tf
0.48601 0 TD
0 Tc
<B2>Tj
/F1 1 Tf
0.47486 0 TD
(1)Tj
0.48193 0 TD
-0.0001 Tc
(1)Tj
0.55585 0 TD
(0)Tj
0.81981 0 TD
(m)Tj
0.83285 0 TD
(g)Tj
0.55585 0 TD
(/)Tj
0.27785 0 TD
(d)Tj
0.55585 0 TD
(L)Tj
5.43241 0 TD
(1)Tj
0.55585 0 TD
(5)Tj
0.55585 0 TD
(/)Tj
0.27785 0 TD
(9)Tj
0.55585 0 TD
(2)Tj
0.81981 0 TD
(m)Tj
0.83285 0 TD
(g)Tj
4.70165 0 TD
(P)Tj
0.66689 0 TD
(t)Tj
0.27789 0 TD
(s)Tj
0.49989 0 TD
(.)Tj
0.54188 0 TD
(w)Tj
0.72189 0 TD
(i)Tj
0.22189 0 TD
(t)Tj
0.27789 0 TD
(h)Tj
0.81988 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.54188 0 TD
(l)Tj
0.22189 0 TD
(e)Tj
0.55589 0 TD
(a)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(t)Tj
3.26664 0 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(2)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(9)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(;)Tj
0.54188 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(7)Tj
0.55588 0 TD
(6)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.55588 0 TD
(\))Tj
-47.87079 -1.2 TD
(\()Tj
0.33285 0 TD
(n)Tj
0.81981 0 TD
(=)Tj
0.84781 0 TD
(5)Tj
0.55585 0 TD
(1)Tj
0.55585 0 TD
(2)Tj
0.55585 0 TD
(\))Tj
5.1317 0 TD
(5)Tj
0.55589 0 TD
(%)Tj
1.15289 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(g)Tj
0.55589 0 TD
(h)Tj
0.55589 0 TD
(t)Tj
0.54189 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(s)Tj
0.76389 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
1.7664 0 TD
(D)Tj
0.72188 0 TD
(B)Tj
0.66688 0 TD
(P)Tj
0.93086 0 TD
(\()Tj
0.33288 0 TD
(%)Tj
1.15286 0 TD
(c)Tj
0.49988 0 TD
(h)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(g)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(\))Tj
0.33288 0 TD
(,)Tj
0.54186 0 TD
(m)Tj
0.83288 0 TD
(e)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(:)Tj
-19.68586 -1.2 TD
(5)Tj
0.55588 0 TD
(6)Tj
0.81986 0 TD
(w)Tj
0.72188 0 TD
(e)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(k)Tj
0.49988 0 TD
(s)Tj
0.76386 0 TD
(\()Tj
0.33288 0 TD
(%)Tj
0.88888 0 TD
(\))Tj
0.33288 0 TD
(:)Tj
3.69832 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(1)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(4)Tj
0.55588 0 TD
(2)Tj
0.55588 0 TD
(6)Tj
0.55588 0 TD
(7)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-27.63722 -1.2 TD
-0.0151 Tc
(3)Tj
0.54087 0 TD
(.)Tj
0.26287 0 TD
(7)Tj
0.54087 0 TD
(5)Tj
0.54087 0 TD
(/)Tj
0.26287 0 TD
(2)Tj
0.54087 0 TD
(3)Tj
0.78985 0 TD
(m)Tj
0.81787 0 TD
(g)Tj
0.78985 0 TD
(=)Tj
0.81785 0 TD
(4)Tj
0.54087 0 TD
(4)Tj
0.54087 0 TD
(.)Tj
0.26287 0 TD
(9)Tj
1.99177 0 TD
-0.0001 Tc
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(;)Tj
0.54188 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(2)Tj
0.55588 0 TD
(6)Tj
0.55588 0 TD
(9)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.55588 0 TD
(\))Tj
-38.57107 -1.2 TD
(1)Tj
0.55586 0 TD
(5)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(9)Tj
0.55586 0 TD
(2)Tj
0.81984 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
1.08403 0 TD
(6)Tj
0.55585 0 TD
(6)Tj
0.55585 0 TD
(.)Tj
0.27785 0 TD
(7)Tj
1.83446 0 TD
(T)Tj
0.61086 0 TD
(G)Tj
1.04182 0 TD
(\()Tj
0.33286 0 TD
(%)Tj
1.15282 0 TD
(c)Tj
0.49986 0 TD
(h)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(g)Tj
0.55586 0 TD
(e)Tj
0.55586 0 TD
(\))Tj
0.33286 0 TD
(,)Tj
0.54182 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(:)Tj
-19.51865 -1.2 TD
(P)Tj
0.66691 0 TD
(l)Tj
0.22191 0 TD
(a)Tj
0.55591 0 TD
(c)Tj
0.49991 0 TD
(e)Tj
0.55591 0 TD
(b)Tj
0.55591 0 TD
(o)Tj
0.81992 0 TD
(=)Tj
0.84792 0 TD
(1)Tj
0.55591 0 TD
(7)Tj
0.55591 0 TD
(.)Tj
0.27791 0 TD
(3)Tj
4.11204 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(5)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(6)Tj
0.55588 0 TD
(3)Tj
0.55588 0 TD
(9)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-17.8403 -1.2 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(;)Tj
0.54188 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(2)Tj
0.55588 0 TD
(7)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.55588 0 TD
(\))Tj
-29.84504 -1.2 TD
0 Tc
(T)Tj
0.5 0 TD
-0.0001 Tc
(o)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(a)Tj
0.55588 0 TD
(l)Tj
0.48586 0 TD
(c)Tj
0.49988 0 TD
(h)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(e)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(o)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(/)Tj
0.27788 0 TD
(H)Tj
0.72188 0 TD
(D)Tj
0.72188 0 TD
(L)Tj
0.55588 0 TD
(-)Tj
0.33288 0 TD
(C)Tj
0.98586 0 TD
(r)Tj
0.33288 0 TD
(a)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(i)Tj
0.22188 0 TD
(o)Tj
0.81986 0 TD
(\()Tj
0.33288 0 TD
(%)Tj
1.15286 0 TD
(c)Tj
0.49988 0 TD
(h)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(g)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(\))Tj
0.33288 0 TD
(,)Tj
0.54186 0 TD
(m)Tj
0.83288 0 TD
(e)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(:)Tj
-20.65393 -1.2 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(4)Tj
0.55588 0 TD
(8)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-18.95208 -1.2 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(3)Tj
0.55588 0 TD
(5)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(;)Tj
0.54188 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.55588 0 TD
(\))Tj
-29.84504 -1.2 TD
(H)Tj
0.72187 0 TD
(D)Tj
0.72187 0 TD
(L)Tj
0.55587 0 TD
(-)Tj
0.33287 0 TD
(C)Tj
0.98584 0 TD
(\()Tj
0.33287 0 TD
(%)Tj
1.15284 0 TD
(c)Tj
0.49987 0 TD
(h)Tj
0.55587 0 TD
(a)Tj
0.55587 0 TD
(n)Tj
0.55587 0 TD
(g)Tj
0.55587 0 TD
(e)Tj
0.55587 0 TD
(\))Tj
0.33287 0 TD
(,)Tj
0.54184 0 TD
(m)Tj
0.83287 0 TD
(e)Tj
0.55587 0 TD
(a)Tj
0.55587 0 TD
(n)Tj
0.55587 0 TD
(:)Tj
-10.95839 -1.2 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(7)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-17.8403 -1.2 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(;)Tj
0.54188 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(8)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(3)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(2)Tj
0.55588 0 TD
(3)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.55588 0 TD
(\))Tj
-85.1148 -1.6 TD
(O)Tj
0.77786 0 TD
(B)Tj
0.66686 0 TD
(-)Tj
0.33286 0 TD
(3)Tj
0.55586 0 TD
(0)Tj
0.55586 0 TD
(3)Tj
4.39888 0 TD
(R)Tj
0.72187 0 TD
(,)Tj
0.54185 0 TD
(D)Tj
0.72187 0 TD
(B)Tj
0.66687 0 TD
(,)Tj
0.54185 0 TD
(P)Tj
0.66687 0 TD
(G)Tj
4.05061 0 TD
-0.0151 Tc
(A)Tj
0.65188 0 TD
(g)Tj
0.54088 0 TD
(e)Tj
0.78986 0 TD
(1)Tj
0.54088 0 TD
(8)Tj
0.54088 0 TD
(-)Tj
0.31788 0 TD
(7)Tj
0.54088 0 TD
(0)Tj
0.78986 0 TD
(y)Tj
0.48488 0 TD
(e)Tj
0.54088 0 TD
(a)Tj
0.54088 0 TD
(r)Tj
0.31788 0 TD
(s)Tj
0.48488 0 TD
(;)Tj
0.51186 0 TD
(B)Tj
0.65188 0 TD
(M)Tj
0.81788 0 TD
(I)Tj
/F20 1 Tf
0.51198 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.53383 0 TD
-0.0152 Tc
(2)Tj
0.54083 0 TD
(7)Tj
0.78993 0 TD
-0.0001 Tc
(\()Tj
0.33286 0 TD
(n)Tj
0.55586 0 TD
(o)Tj
0.81982 0 TD
(l)Tj
0.22186 0 TD
(o)Tj
0.55586 0 TD
(w)Tj
0.72186 0 TD
(e)Tj
0.55586 0 TD
(r)Tj
0.59682 0 TD
(l)Tj
0.22186 0 TD
(i)Tj
0.22186 0 TD
(m)Tj
0.83286 0 TD
(i)Tj
0.22186 0 TD
(t)Tj
0.54182 0 TD
(f)Tj
0.27786 0 TD
(o)Tj
0.55586 0 TD
(r)Tj
0.59682 0 TD
(p)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(s)Tj
0.49986 0 TD
(.)Tj
1.49417 0 TD
(P)Tj
0.66688 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(n)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(9)Tj
0.55588 0 TD
(9)Tj
0.55588 0 TD
(4)Tj
0.55588 0 TD
(\))Tj
1.25527 0 TD
(P)Tj
0.66689 0 TD
(l)Tj
0.22189 0 TD
(a)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(e)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(o)Tj
0.55589 0 TD
(-)Tj
0.33289 0 TD
(s)Tj
0.49989 0 TD
(u)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(t)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
1.66882 0 TD
0 Tc
(W)Tj
0.92602 0 TD
-0.0001 Tc
(e)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(g)Tj
0.55588 0 TD
(h)Tj
0.55588 0 TD
(t)Tj
0.54186 0 TD
(l)Tj
0.22188 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(s)Tj
0.76386 0 TD
(\()Tj
0.33288 0 TD
(k)Tj
0.49988 0 TD
(g)Tj
0.55588 0 TD
(\))Tj
0.33288 0 TD
(,)Tj
0.54186 0 TD
(m)Tj
0.83288 0 TD
(e)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(:)Tj
-65.48838 -1.2 TD
(C)Tj
0.72189 0 TD
(O)Tj
0.77789 0 TD
(N)Tj
0.72189 0 TD
(Q)Tj
0.77789 0 TD
(U)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(R)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 268.3088 88.5776 Tm
0 0 0 1 k
-0.0002 Tc
(1)Tj
0.55582 0 TD
(3)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 271.0588 104.9114 Tm
0 0 0 1 k
-0.0002 Tc
(\()Tj
0.3328 0 TD
(3)Tj
0.5558 0 TD
(-)Tj
0.3328 0 TD
(a)Tj
0.5558 0 TD
(r)Tj
0.3328 0 TD
(m)Tj
0.8328 0 TD
(\))Tj
0.3328 0 TD
(,)Tj
0.54171 0 TD
(M)Tj
0.8328 0 TD
(C)Tj
3.2617 0 TD
(w)Tj
0.72184 0 TD
(i)Tj
0.22184 0 TD
(t)Tj
0.27784 0 TD
(h)Tj
0.81979 0 TD
(T)Tj
0.61084 0 TD
(2)Tj
0.55584 0 TD
(D)Tj
0.72184 0 TD
(M)Tj
0.83284 0 TD
(\))Tj
0.33284 0 TD
(,)Tj
/F20 1 Tf
0.54195 0 TD
0 Tc
<B2>Tj
/F1 1 Tf
0.54884 0 TD
-0.0001 Tc
(4)Tj
0.55586 0 TD
(5)Tj
0.81982 0 TD
(k)Tj
0.49986 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 268.3088 237.2144 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 271.0588 241.9735 Tm
0 0 0 1 k
-0.0001 Tc
(a)Tj
0.55585 0 TD
(n)Tj
0.55585 0 TD
(d)Tj
/F20 1 Tf
0.81996 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54883 0 TD
-0.0001 Tc
(2)Tj
0.81986 0 TD
(o)Tj
0.55588 0 TD
(f)Tj
0.54186 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.55588 0 TD
(e)Tj
0.81986 0 TD
(f)Tj
0.27788 0 TD
(o)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(l)Tj
0.22188 0 TD
(o)Tj
0.55588 0 TD
(w)Tj
0.72188 0 TD
(i)Tj
0.22188 0 TD
(n)Tj
0.55588 0 TD
(g)Tj
1.85202 0 TD
(P)Tj
0.66689 0 TD
(H)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(N)Tj
0.72189 0 TD
(/)Tj
0.27789 0 TD
(T)Tj
0.61089 0 TD
(P)Tj
0.66689 0 TD
(M)Tj
1.09689 0 TD
(C)Tj
0.72189 0 TD
(R)Tj
3.14767 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(g)Tj
0.55589 0 TD
(h)Tj
0.55589 0 TD
(t)Tj
0.54189 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(s)Tj
0.76389 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.54189 0 TD
(5)Tj
0.55589 0 TD
(6)Tj
2.8774 0 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(4)Tj
0.55588 0 TD
(6)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(8)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(1)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-73.66595 -1.2 TD
(5)Tj
0.55589 0 TD
(6)Tj
0.81988 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(k)Tj
0.49989 0 TD
(s)Tj
3.57886 0 TD
(P)Tj
0.6669 0 TD
(h)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(e)Tj
0.8199 0 TD
(3)Tj
4.81331 0 TD
(a)Tj
0.5559 0 TD
(t)Tj
0.5419 0 TD
(b)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(e)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(i)Tj
0.2219 0 TD
(n)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(:)Tj
0.5419 0 TD
(h)Tj
0.5559 0 TD
(y)Tj
0.4999 0 TD
(p)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(t)Tj
0.2779 0 TD
(e)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(i)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(n)Tj
0.8199 0 TD
(w)Tj
0.7219 0 TD
(i)Tj
0.2219 0 TD
(t)Tj
0.2779 0 TD
(h)Tj
0.8199 0 TD
(S)Tj
0.6669 0 TD
(B)Tj
0.6669 0 TD
(P)Tj
0.9309 0 TD
(1)Tj
0.5559 0 TD
(4)Tj
0.5559 0 TD
(0)Tj
0.5559 0 TD
(-)Tj
0.3329 0 TD
(1)Tj
0.5559 0 TD
(6)Tj
0.5559 0 TD
(0)Tj
3.33059 0 TD
-0.0002 Tc
(7)Tj
0.55585 0 TD
(.)Tj
0.27785 0 TD
(5)Tj
0.55585 0 TD
(/)Tj
0.27785 0 TD
(4)Tj
0.55585 0 TD
(6)Tj
0.81981 0 TD
(m)Tj
0.83285 0 TD
(g)Tj
4.9238 0 TD
-0.0001 Tc
(w)Tj
0.72187 0 TD
(e)Tj
0.55587 0 TD
(e)Tj
0.55587 0 TD
(k)Tj
0.49987 0 TD
(s)Tj
0.76384 0 TD
(\()Tj
0.33287 0 TD
(%)Tj
0.88887 0 TD
(\))Tj
0.33287 0 TD
(:)Tj
5.07412 0 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-73.94396 -1.2 TD
(N)Tj
0.98588 0 TD
(=)Tj
0.84788 0 TD
(2)Tj
0.55589 0 TD
(4)Tj
0.55589 0 TD
(8)Tj
0.55589 0 TD
(7)Tj
3.28677 0 TD
-0.0002 Tc
(2)Tj
0.55585 0 TD
(:)Tj
0.27785 0 TD
(1)Tj
0.55585 0 TD
(:)Tj
0.27785 0 TD
(2)Tj
6.74443 0 TD
0 Tc
(m)Tj
0.83276 0 TD
(m)Tj
1.03276 0 TD
-0.0001 Tc
(H)Tj
0.72185 0 TD
(g)Tj
0.81981 0 TD
(\()Tj
0.33285 0 TD
(1)Tj
0.55585 0 TD
(3)Tj
0.55585 0 TD
(0)Tj
0.55585 0 TD
(-)Tj
0.33285 0 TD
(1)Tj
0.55585 0 TD
(6)Tj
0.55585 0 TD
(0)Tj
0.81981 0 TD
(m)Tj
0.83299 0 TD
0 Tc
(m)Tj
1.03276 0 TD
-0.0001 Tc
(H)Tj
0.72187 0 TD
(g)Tj
0.81984 0 TD
(w)Tj
0.72187 0 TD
(i)Tj
0.22187 0 TD
(t)Tj
0.27787 0 TD
(h)Tj
0.81984 0 TD
(D)Tj
0.72187 0 TD
(M)Tj
0.83287 0 TD
(\))Tj
0.33287 0 TD
(,)Tj
0.54184 0 TD
(o)Tj
0.55587 0 TD
(r)Tj
0.59684 0 TD
(D)Tj
0.72187 0 TD
(B)Tj
0.66687 0 TD
(P)Tj
4.00814 0 TD
(\()Tj
0.33285 0 TD
(n)Tj
0.81981 0 TD
(=)Tj
0.84781 0 TD
(4)Tj
0.55585 0 TD
(9)Tj
0.55585 0 TD
(8)Tj
0.55585 0 TD
(\))Tj
5.1317 0 TD
(7)Tj
0.55586 0 TD
(.)Tj
0.27786 0 TD
(5)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(4)Tj
0.55586 0 TD
(6)Tj
0.81983 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
0.81983 0 TD
(=)Tj
0.84783 0 TD
(6)Tj
0.55586 0 TD
(.)Tj
0.27786 0 TD
(6)Tj
2.84863 0 TD
(W)Tj
0.94386 0 TD
(C)Tj
0.98583 0 TD
(c)Tj
0.49986 0 TD
(h)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(g)Tj
0.55586 0 TD
(e)Tj
0.81983 0 TD
(\()Tj
0.33286 0 TD
(c)Tj
0.49986 0 TD
(m)Tj
0.83286 0 TD
(\))Tj
0.33286 0 TD
(,)Tj
0.54183 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(:)Tj
-58.55099 -1.2 TD
(a)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
0.81988 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
2.0364 0 TD
-0.0002 Tc
(9)Tj
0.55584 0 TD
(0)Tj
0.55584 0 TD
(-)Tj
0.33284 0 TD
(1)Tj
0.55584 0 TD
(0)Tj
0.55584 0 TD
(0)Tj
0.81979 0 TD
(m)Tj
0.83301 0 TD
0 Tc
(m)Tj
1.03276 0 TD
-0.0002 Tc
(H)Tj
0.72185 0 TD
(g)Tj
0.8198 0 TD
(\()Tj
0.33285 0 TD
(8)Tj
0.55585 0 TD
(5)Tj
0.55585 0 TD
(-)Tj
0.33285 0 TD
(1)Tj
0.55585 0 TD
(0)Tj
0.55585 0 TD
(0)Tj
0.8198 0 TD
(m)Tj
0.83301 0 TD
0 Tc
(m)Tj
1.03276 0 TD
-0.0002 Tc
(H)Tj
0.72185 0 TD
(g)Tj
0.8198 0 TD
(w)Tj
0.72185 0 TD
(i)Tj
0.22185 0 TD
(t)Tj
0.27785 0 TD
(h)Tj
0.8198 0 TD
(D)Tj
0.72185 0 TD
(M)Tj
0.83285 0 TD
(\))Tj
0.33285 0 TD
(,)Tj
0.5418 0 TD
(o)Tj
0.55585 0 TD
(r)Tj
2.67364 0 TD
-0.0001 Tc
(P)Tj
0.66689 0 TD
(H)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(N)Tj
0.72189 0 TD
(/)Tj
0.27789 0 TD
(T)Tj
0.61089 0 TD
(P)Tj
0.66689 0 TD
(M)Tj
1.09689 0 TD
(C)Tj
0.72189 0 TD
(R)Tj
3.14767 0 TD
(1)Tj
0.55586 0 TD
(5)Tj
0.55586 0 TD
(/)Tj
0.54183 0 TD
(9)Tj
0.55586 0 TD
(2)Tj
0.81983 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
0.81983 0 TD
(=)Tj
0.84783 0 TD
(8)Tj
0.55586 0 TD
(.)Tj
0.27786 0 TD
(6)Tj
3.36252 0 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(4)Tj
0.55588 0 TD
(6)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(6)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-58.46596 -1.2 TD
(t)Tj
0.27788 0 TD
(a)Tj
0.55588 0 TD
(k)Tj
0.49988 0 TD
(i)Tj
0.22188 0 TD
(n)Tj
0.55588 0 TD
(g)Tj
/F20 1 Tf
0.82 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54883 0 TD
-0.0001 Tc
(2)Tj
0.8199 0 TD
(a)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(t)Tj
0.2779 0 TD
(i)Tj
0.2219 0 TD
(h)Tj
0.5559 0 TD
(y)Tj
0.4999 0 TD
(p)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(t)Tj
0.2779 0 TD
(e)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(i)Tj
0.2219 0 TD
(v)Tj
0.4999 0 TD
(e)Tj
0.8199 0 TD
(d)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(u)Tj
0.5559 0 TD
(g)Tj
0.5559 0 TD
(s)Tj
0.7639 0 TD
(t)Tj
0.2779 0 TD
(o)Tj
0.8199 0 TD
(a)Tj
0.5559 0 TD
(c)Tj
0.4999 0 TD
(h)Tj
0.5559 0 TD
(i)Tj
0.2219 0 TD
(e)Tj
0.5559 0 TD
(v)Tj
0.4999 0 TD
(e)Tj
3.50468 0 TD
(1)Tj
0.55585 0 TD
(5)Tj
0.55585 0 TD
(/)Tj
0.27785 0 TD
(9)Tj
0.55585 0 TD
(2)Tj
0.81981 0 TD
(m)Tj
0.83285 0 TD
(g)Tj
4.70165 0 TD
(P)Tj
0.66688 0 TD
(t)Tj
0.27788 0 TD
(s)Tj
0.49988 0 TD
(.)Tj
0.54186 0 TD
(w)Tj
0.72188 0 TD
(i)Tj
0.22188 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
/F20 1 Tf
0.82 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54883 0 TD
-0.0002 Tc
(5)Tj
0.55583 0 TD
(%)Tj
5.09324 0 TD
-0.0001 Tc
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(9)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-58.18808 -1.2 TD
(c)Tj
0.49989 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(r)Tj
0.33289 0 TD
(o)Tj
0.55589 0 TD
(l)Tj
0.48588 0 TD
(B)Tj
0.66689 0 TD
(P)Tj
0.93088 0 TD
(<)Tj
0.58389 0 TD
(1)Tj
0.55589 0 TD
(4)Tj
0.55589 0 TD
(0)Tj
0.55589 0 TD
(/)Tj
0.27789 0 TD
(9)Tj
0.55589 0 TD
(0)Tj
0.81988 0 TD
(m)Tj
0.83301 0 TD
0 Tc
(m)Tj
1.03276 0 TD
-0.0002 Tc
(H)Tj
0.72183 0 TD
(g)Tj
10.74514 0 TD
-0.0001 Tc
(\()Tj
0.33285 0 TD
(n)Tj
0.81981 0 TD
(=)Tj
0.84781 0 TD
(9)Tj
0.55585 0 TD
(9)Tj
0.55585 0 TD
(5)Tj
0.55585 0 TD
(\))Tj
5.1317 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(g)Tj
0.55589 0 TD
(h)Tj
0.55589 0 TD
(t)Tj
0.5419 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(s)Tj
0.7639 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
3.47518 0 TD
(S)Tj
0.66687 0 TD
(B)Tj
0.66687 0 TD
(P)Tj
0.93084 0 TD
(c)Tj
0.49987 0 TD
(h)Tj
0.55587 0 TD
(a)Tj
0.55587 0 TD
(n)Tj
0.55587 0 TD
(g)Tj
0.55587 0 TD
(e)Tj
0.81984 0 TD
(\()Tj
0.33287 0 TD
(m)Tj
0.83287 0 TD
(m)Tj
1.09684 0 TD
(H)Tj
0.72187 0 TD
(g)Tj
0.55587 0 TD
(\))Tj
0.33287 0 TD
(,)Tj
0.54184 0 TD
(m)Tj
0.83287 0 TD
(e)Tj
0.55587 0 TD
(a)Tj
0.55587 0 TD
(n)Tj
0.55587 0 TD
(:)Tj
-53.34891 -1.2 TD
(H)Tj
0.72188 0 TD
(y)Tj
0.49988 0 TD
(p)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(t)Tj
0.27788 0 TD
(r)Tj
0.33288 0 TD
(i)Tj
0.22188 0 TD
(g)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(y)Tj
0.49988 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(i)Tj
0.22188 0 TD
(d)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(m)Tj
0.83288 0 TD
(i)Tj
0.22188 0 TD
(a)Tj
0.81987 0 TD
(w)Tj
0.72188 0 TD
(i)Tj
0.22188 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.81987 0 TD
(T)Tj
0.61088 0 TD
(G)Tj
/F20 1 Tf
1.042 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54882 0 TD
-0.0001 Tc
(2)Tj
0.55587 0 TD
(0)Tj
0.55587 0 TD
(0)Tj
0.81984 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(d)Tj
0.55587 0 TD
(L)Tj
0.81984 0 TD
(a)Tj
0.55587 0 TD
(n)Tj
0.55587 0 TD
(d)Tj
11.69723 0 TD
(5)Tj
0.55589 0 TD
(6)Tj
0.81989 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(k)Tj
0.49989 0 TD
(s)Tj
0.49989 0 TD
(:)Tj
5.51677 0 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(4)Tj
0.55588 0 TD
(6)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81987 0 TD
<D0>Tj
0.55588 0 TD
(4)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(7)Tj
0.81987 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81987 0 TD
(=)Tj
0.84787 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(8)Tj
0.81987 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76387 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
/F20 1 Tf
-57.63304 -1.2 TD
0 Tc
<B2>Tj
/F1 1 Tf
0.53383 0 TD
-0.0151 Tc
(4)Tj
0.54086 0 TD
(0)Tj
0.54086 0 TD
(0)Tj
0.78983 0 TD
(m)Tj
0.81786 0 TD
(g)Tj
0.54086 0 TD
(/)Tj
0.26286 0 TD
(d)Tj
0.54086 0 TD
(L)Tj
0.78983 0 TD
(o)Tj
0.54086 0 TD
(r)Tj
0.56683 0 TD
(t)Tj
0.26286 0 TD
(r)Tj
0.31786 0 TD
(e)Tj
0.54086 0 TD
(a)Tj
0.54086 0 TD
(t)Tj
0.26286 0 TD
(e)Tj
0.54086 0 TD
(d)Tj
0.78983 0 TD
(w)Tj
0.70686 0 TD
(i)Tj
0.20686 0 TD
(t)Tj
0.26286 0 TD
(h)Tj
/F20 1 Tf
0.78996 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.53383 0 TD
-0.0151 Tc
(2)Tj
0.78989 0 TD
(d)Tj
0.54089 0 TD
(r)Tj
0.31789 0 TD
(u)Tj
0.54089 0 TD
(g)Tj
0.54089 0 TD
(s)Tj
0.73389 0 TD
(t)Tj
0.26289 0 TD
(o)Tj
0.78989 0 TD
(a)Tj
0.54089 0 TD
(c)Tj
0.48489 0 TD
(h)Tj
0.54089 0 TD
(i)Tj
0.20689 0 TD
(e)Tj
0.54089 0 TD
(v)Tj
0.48489 0 TD
(e)Tj
11.3764 0 TD
-0.0001 Tc
(7)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(4)Tj
0.55587 0 TD
(6)Tj
0.81984 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
(6)Tj
0.55587 0 TD
(2)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(1)Tj
2.79271 0 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(6)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-58.18808 -1.2 TD
(T)Tj
0.61086 0 TD
(G)Tj
1.04183 0 TD
(<)Tj
0.58386 0 TD
(2)Tj
0.55586 0 TD
(0)Tj
0.55586 0 TD
(0)Tj
0.81983 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(d)Tj
0.55586 0 TD
(L)Tj
24.50905 0 TD
(1)Tj
0.55587 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(9)Tj
0.55587 0 TD
(2)Tj
0.81985 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81985 0 TD
(=)Tj
0.84785 0 TD
(7)Tj
0.55587 0 TD
(0)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(0)Tj
2.57052 0 TD
0 Tc
(T)Tj
0.485 0 TD
-0.0151 Tc
(o)Tj
0.54088 0 TD
(t)Tj
0.26288 0 TD
(a)Tj
0.54088 0 TD
(l)Tj
0.45586 0 TD
(c)Tj
0.48488 0 TD
(h)Tj
0.54088 0 TD
(o)Tj
0.54088 0 TD
(l)Tj
0.20688 0 TD
(e)Tj
0.54088 0 TD
(s)Tj
0.48488 0 TD
(t)Tj
0.26288 0 TD
(e)Tj
0.54088 0 TD
(r)Tj
0.31788 0 TD
(o)Tj
0.54088 0 TD
(l)Tj
0.45586 0 TD
(c)Tj
0.48488 0 TD
(h)Tj
0.54088 0 TD
(a)Tj
0.54088 0 TD
(n)Tj
0.54088 0 TD
(g)Tj
0.54088 0 TD
(e)Tj
0.78986 0 TD
(\()Tj
0.31788 0 TD
(%)Tj
0.87388 0 TD
(\))Tj
0.31788 0 TD
(,)Tj
0.51186 0 TD
(m)Tj
0.81788 0 TD
(e)Tj
0.54088 0 TD
(a)Tj
0.54088 0 TD
(n)Tj
0.54088 0 TD
(:)Tj
-55.72899 -1.2 TD
-0.0001 Tc
(M)Tj
0.83288 0 TD
(e)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(a)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(i)Tj
0.22188 0 TD
(c)Tj
0.76388 0 TD
(d)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(s)Tj
0.49988 0 TD
(o)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(d)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(s)Tj
0.76388 0 TD
(w)Tj
0.72188 0 TD
(i)Tj
0.22188 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
/F20 1 Tf
0.82001 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.47485 0 TD
-0.0001 Tc
(1)Tj
0.81986 0 TD
(o)Tj
0.55588 0 TD
(f)Tj
0.54186 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.55588 0 TD
(e)Tj
0.81986 0 TD
(f)Tj
0.27788 0 TD
(o)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(l)Tj
0.22188 0 TD
(o)Tj
0.55588 0 TD
(w)Tj
0.72188 0 TD
(i)Tj
0.22188 0 TD
(n)Tj
0.55588 0 TD
(g)Tj
0.55588 0 TD
(:)Tj
12.00613 0 TD
(P)Tj
0.66691 0 TD
(l)Tj
0.22191 0 TD
(a)Tj
0.55591 0 TD
(c)Tj
0.49991 0 TD
(e)Tj
0.55591 0 TD
(b)Tj
0.55591 0 TD
(o)Tj
0.81992 0 TD
(=)Tj
0.84792 0 TD
(2)Tj
0.55591 0 TD
(1)Tj
0.55591 0 TD
(.)Tj
0.27791 0 TD
(0)Tj
4.11204 0 TD
-0.0151 Tc
(7)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(5)Tj
0.54088 0 TD
(/)Tj
0.26288 0 TD
(4)Tj
0.54088 0 TD
(6)Tj
0.78987 0 TD
(m)Tj
0.81788 0 TD
(g)Tj
0.78988 0 TD
(=)Tj
0.81788 0 TD
<D0>Tj
0.54088 0 TD
(4)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(9)Tj
0.78988 0 TD
(\()Tj
0.31788 0 TD
(p)Tj
0.78988 0 TD
(=)Tj
0.81788 0 TD
(0)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(0)Tj
0.54088 0 TD
(3)Tj
0.54088 0 TD
(4)Tj
0.54088 0 TD
(5)Tj
0.78988 0 TD
(v)Tj
0.48488 0 TD
(s)Tj
0.73388 0 TD
(p)Tj
0.54088 0 TD
(l)Tj
0.20688 0 TD
(a)Tj
0.54088 0 TD
(c)Tj
0.48488 0 TD
(e)Tj
0.54088 0 TD
(b)Tj
0.54088 0 TD
(o)Tj
0.54088 0 TD
(\))Tj
-57.88096 -1.2 TD
-0.0001 Tc
(f)Tj
0.2779 0 TD
(a)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(t)Tj
0.2779 0 TD
(i)Tj
0.2219 0 TD
(n)Tj
0.5559 0 TD
(g)Tj
0.8199 0 TD
(b)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(o)Tj
0.5559 0 TD
(d)Tj
0.8199 0 TD
(g)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(u)Tj
0.5559 0 TD
(c)Tj
0.4999 0 TD
(o)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(e)Tj
0.8199 0 TD
(l)Tj
0.2219 0 TD
(e)Tj
0.5559 0 TD
(v)Tj
0.4999 0 TD
(e)Tj
0.5559 0 TD
(l)Tj
0.4859 0 TD
(>)Tj
0.5839 0 TD
(1)Tj
0.5559 0 TD
(0)Tj
0.5559 0 TD
(0)Tj
0.8199 0 TD
(m)Tj
0.8329 0 TD
(g)Tj
0.5559 0 TD
(/)Tj
0.2779 0 TD
(d)Tj
0.5559 0 TD
(L)Tj
0.5559 0 TD
(,)Tj
23.38399 0 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(6)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(3)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-58.18808 -1.2 TD
(g)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(u)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(e)Tj
0.81987 0 TD
(l)Tj
0.22188 0 TD
(e)Tj
0.55588 0 TD
(v)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(l)Tj
0.48587 0 TD
(>)Tj
0.58388 0 TD
(1)Tj
0.55588 0 TD
(4)Tj
0.55588 0 TD
(0)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(d)Tj
0.55588 0 TD
(L)Tj
0.81987 0 TD
(a)Tj
0.55588 0 TD
(t)Tj
0.54187 0 TD
(2)Tj
0.55588 0 TD
(-)Tj
0.33288 0 TD
(h)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(u)Tj
0.55588 0 TD
(r)Tj
0.59687 0 TD
(O)Tj
0.77788 0 TD
(G)Tj
0.77788 0 TD
(T)Tj
0.61088 0 TD
(T)Tj
0.50015 0 TD
0 Tc
(,)Tj
21.62136 0 TD
-0.0001 Tc
(T)Tj
0.61086 0 TD
(G)Tj
1.04182 0 TD
(c)Tj
0.49986 0 TD
(h)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(g)Tj
0.55586 0 TD
(e)Tj
0.81982 0 TD
(\()Tj
0.33286 0 TD
(%)Tj
0.88886 0 TD
(\))Tj
0.33286 0 TD
(,)Tj
0.54182 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(:)Tj
-49.91827 -1.2 TD
(T)Tj
0.61088 0 TD
(2)Tj
0.55588 0 TD
(D)Tj
0.72188 0 TD
(M)Tj
1.09688 0 TD
(m)Tj
0.83288 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(g)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(d)Tj
0.81988 0 TD
(w)Tj
0.72188 0 TD
(i)Tj
0.22188 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.81988 0 TD
(l)Tj
0.22188 0 TD
(i)Tj
0.22188 0 TD
(f)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(t)Tj
0.27789 0 TD
(y)Tj
0.49989 0 TD
(l)Tj
0.22189 0 TD
(e)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(o)Tj
0.55589 0 TD
(d)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(f)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(c)Tj
0.49989 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(s)Tj
0.76388 0 TD
(o)Tj
0.55589 0 TD
(r)Tj
20.91604 0.00001 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(4)Tj
0.55588 0 TD
(6)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(8)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(6)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-58.46596 -1.20001 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(f)Tj
0.27786 0 TD
(o)Tj
0.55586 0 TD
(r)Tj
0.33286 0 TD
(m)Tj
0.83286 0 TD
(i)Tj
0.22186 0 TD
(n)Tj
0.81982 0 TD
(m)Tj
0.83286 0 TD
(o)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(o)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(h)Tj
0.55586 0 TD
(e)Tj
0.55586 0 TD
(r)Tj
0.33286 0 TD
(a)Tj
0.55586 0 TD
(p)Tj
0.55586 0 TD
(y)Tj
0.76382 0 TD
(W)Tj
0.94386 0 TD
(C)Tj
/F20 1 Tf
0.98597 0.00001 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.47485 0.00002 TD
-0.0002 Tc
(1)Tj
0.55585 0 TD
(0)Tj
0.55585 0 TD
(2)Tj
0.8198 0 TD
(c)Tj
0.49985 0 TD
(m)Tj
1.0968 0 TD
(f)Tj
0.27785 0 TD
(o)Tj
0.55585 0 TD
(r)Tj
0.5968 0 TD
(m)Tj
0.83285 0 TD
(e)Tj
0.55585 0 TD
(n)Tj
21.06755 0.00001 TD
-0.0001 Tc
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(6)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-58.74397 -1.20003 TD
-0.0002 Tc
(o)Tj
0.55575 0 TD
(r)Tj
/F20 1 Tf
0.59686 0.00001 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54883 0.00002 TD
-0.0001 Tc
(8)Tj
0.55586 0 TD
(8)Tj
0.81982 0 TD
(c)Tj
0.49986 0 TD
(m)Tj
1.09682 0 TD
(f)Tj
0.27786 0 TD
(o)Tj
0.55586 0 TD
(r)Tj
0.59682 0 TD
(w)Tj
0.72186 0 TD
(o)Tj
0.55586 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(n)Tj
31.35492 0 TD
(F)Tj
0.61086 0 TD
(P)Tj
0.66686 0 TD
(G)Tj
1.04182 0 TD
(c)Tj
0.49986 0 TD
(h)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(g)Tj
0.55586 0 TD
(e)Tj
0.81982 0 TD
(\()Tj
0.33286 0 TD
(m)Tj
0.83286 0 TD
(m)Tj
0.83286 0 TD
(o)Tj
0.55586 0 TD
(l)Tj
0.22186 0 TD
(/)Tj
0.27786 0 TD
(L)Tj
0.55586 0 TD
(\))Tj
0.33286 0 TD
(,)Tj
0.54182 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(:)Tj
-12.34779 -1.20002 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(4)Tj
0.55588 0 TD
(6)Tj
0.81987 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(4)Tj
0.55588 0 TD
(7)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-18.39618 -1.2 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(7)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-18.61831 -1.2 TD
-0.0151 Tc
(F)Tj
0.59588 0 TD
(a)Tj
0.54088 0 TD
(s)Tj
0.48488 0 TD
(t)Tj
0.26288 0 TD
(i)Tj
0.20688 0 TD
(n)Tj
0.54088 0 TD
(g)Tj
0.78987 0 TD
(i)Tj
0.20688 0 TD
(n)Tj
0.54088 0 TD
(s)Tj
0.48488 0 TD
(u)Tj
0.54088 0 TD
(l)Tj
0.20688 0 TD
(i)Tj
0.20688 0 TD
(n)Tj
0.78987 0 TD
(c)Tj
0.48488 0 TD
(h)Tj
0.54088 0 TD
(a)Tj
0.54088 0 TD
(n)Tj
0.54088 0 TD
(g)Tj
0.54088 0 TD
(e)Tj
0.78987 0 TD
(\()Tj
0.31788 0 TD
(p)Tj
0.54088 0 TD
(m)Tj
0.81788 0 TD
(o)Tj
0.54088 0 TD
(l)Tj
0.20688 0 TD
(/)Tj
0.26288 0 TD
(L)Tj
0.54088 0 TD
(\))Tj
0.31788 0 TD
(,)Tj
0.51187 0 TD
(m)Tj
0.81788 0 TD
(e)Tj
0.54088 0 TD
(a)Tj
0.54088 0 TD
(n)Tj
0.54088 0 TD
(:)Tj
-15.83604 -1.2 TD
(7)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(5)Tj
0.54088 0 TD
(/)Tj
0.26288 0 TD
(4)Tj
0.54088 0 TD
(6)Tj
0.78987 0 TD
(m)Tj
0.81788 0 TD
(g)Tj
0.78988 0 TD
(=)Tj
1.06687 0 TD
<D0>Tj
0.54088 0 TD
(2)Tj
0.54088 0 TD
(4)Tj
0.78988 0 TD
(\()Tj
0.31788 0 TD
(p)Tj
0.78988 0 TD
(=)Tj
0.81788 0 TD
(0)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(0)Tj
0.54088 0 TD
(0)Tj
0.54088 0 TD
(0)Tj
0.54088 0 TD
(4)Tj
0.78988 0 TD
(v)Tj
0.48488 0 TD
(s)Tj
0.73388 0 TD
(p)Tj
0.54088 0 TD
(l)Tj
0.20688 0 TD
(a)Tj
0.54088 0 TD
(c)Tj
0.48488 0 TD
(e)Tj
0.54088 0 TD
(b)Tj
0.54088 0 TD
(o)Tj
0.54088 0 TD
(\))Tj
-17.24141 -1.2 TD
-0.0001 Tc
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(2)Tj
0.55588 0 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(6)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
ET
Q

endstream
endobj
9 0 obj
<<
/Length 35389
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
Q
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 309 725.7904 Tm
0 0 0 1 k
-0.0188 Tc
(a)Tj
0.42523 -0.00001 TD
-0.019 Tc
0.019 Tw
(ctive comparator groups.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 413.8116 729.0904 Tm
0 0 0 1 k
-0.018 Tc
[(1)55(1,12)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 429.0452 725.7904 Tm
0 0 0 1 k
-0.0188 Tc
(L)Tj
0.5922 -0.00001 TD
-0.019 Tc
0.019 Tw
[(ike EQUIP)110(, limited hetero-)]TJ
-12.02507 -1.22857 TD
-0.018 Tc
0.018 Tw
[(geneity of the study population af)20(fects the generalizability)]TJ
T*
0 Tc
0.039 Tw
[(of findings. Additionally)65(, although the CONQUER and)]TJ
-0.0338 Tc
(S)'
0.52223 -0.00001 TD
-0.034 Tc
0.019 Tw
(EQUEL study findings showed a reduction in concomitant)Tj
-0.52223 -1.22857 TD
-0.04 Tc
0.025 Tw
(use of drugs for comorbid conditions, patients with type 2 di-)Tj
T*
-0.039 Tc
0.024 Tw
(abetes did not have advanced disease, again limiting the gen-)Tj
T*
-0.04 Tc
0.023 Tw
[(eralizability of the findings. Further)-25(more, not all CONQUER)]TJ
0 -1.22856 TD
0.025 Tw
[(subjects were eligible for enrollment in SEQUEL b)-15(e)-15(c)-15(a)-15(u)-15(s)-15(e)-15( )-15(o)-15(f)]TJ
0 -1.22857 TD
-0.012 Tc
0.012 Tw
(limitations in enrollment based on study center; only par-)Tj
T*
-0.024 Tc
0.024 Tw
(ticipants from high-enrolling centers were given the option)Tj
T*
-0.01 Tc
0.01 Tw
((36 of 93 centers in CONQUER). Since patients were al-)Tj
T*
0 Tc
0.001 Tw
(lowed an option for continuation, a bias for inclusion of)Tj
T*
-0.015 Tc
0.015 Tw
(subjects with positive treatment outcomes may have been)Tj
T*
-0.002 Tc
0.002 Tw
[(introduced. Further)-25(more, for unknown reasons, a higher)]TJ
T*
-0.001 Tc
0.001 Tw
[(percentage of subjects in the high-)-75(dose ar)-25(m were lost to)]TJ
T*
-0.006 Tc
0.006 Tw
(follow-up, resulting in an underestimation of reasons for)Tj
T*
-0.022 Tc
0.022 Tw
[(drop-)-75(out including potential adverse events or lack of ef)20(fi)-1(-)]TJ
T*
-0.008 Tc
0.007 Tw
[(cacy)65(. Finally)65(, some patients treated with metfor)-25(min were)]TJ
T*
-0.006 Tc
0.006 Tw
[(likely included in the studies; however)40(, neither study ad-)]TJ
T*
-0.02 Tc
0.02 Tw
[(dressed the impact of metfor)-25(min on additional weight loss)]TJ
T*
-0.025 Tc
0.013 Tw
(when compared with PHEN/TPM. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 309 439.7405 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
(Dosing Recommendations)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 418.6905 Tm
0 0 0 1 k
-0.004 Tc
0.004 Tw
[(FDA-approved dosage for)-25(ms for PHEN/TPM include)]TJ
-1 -1.24286 TD
-0.025 Tc
0.003 Tw
[(3.75/23 mg (low dose), 7.5/46 mg (mid dose), 1)35(1.25/69 mg)]TJ
T*
0 Tc
0.05 Tw
((three-quarter dose), and 15/92 mg (high dose), but the)Tj
T*
-0.019 Tc
0 Tw
(low-)Tj
1.83355 0 TD
0.018 Tw
(dose and three-quarter dose PHEN/TPM are for titra)Tj
20.16706 0 TD
0 Tc
(-)Tj
-22.00061 -1.24286 TD
-0.017 Tc
0.017 Tw
(tion purposes only)Tj
7.05164 0 TD
0 Tc
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 385.4893 369.7905 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 391.0126 366.4905 Tm
0 0 0 1 k
-0.017 Tc
0.017 Tw
(PHEN/TPM is given as a single daily)Tj
-7.81072 -1.24286 TD
-0.012 Tc
0.012 Tw
(dose in the mor)Tj
6.07157 0 TD
(ning, with or without food. T)Tj
11.27472 0 TD
-0.0123 Tc
(o)Tj
0.73766 0 Td
-0.012 Tc
(prevent in)Tj
3.91662 0 TD
0 Tc
(-)Tj
-22.00058 -1.24287 TD
-0.025 Tc
0.013 Tw
(somnia, evening doses should be avoided.)Tj
1 -1.24285 TD
-0.02 Tc
0.02 Tw
(The recommended starting dose is PHEN/TPM 3.75/23)Tj
-1 -1.24286 TD
-0.018 Tc
0.018 Tw
(mg daily for 14 days, subsequently increasing to a recom)Tj
22.0006 0 TD
0 Tc
(-)Tj
-22.0006 -1.24286 TD
-0.01 Tc
0.01 Tw
[(mended 7.5/46)-25(-mg daily dose. Dosing should not exceed)]TJ
T*
-0.011 Tc
(7.5/46 mg daily in patients with moderate or severe renal)Tj
0 -1.24285 TD
-0.015 Tc
0 Tw
(impair)Tj
2.54639 0.00001 TD
0.015 Tw
(ment (estimated CrCl <50 mL/min) or moderate or)Tj
-2.54639 -1.24286 TD
-0.025 Tc
0.013 Tw
(severe hepatic impair)Tj
8.07542 0.00001 TD
(ment \(Child-Pugh score )Tj
/F20 1 Tf
9.26545 0 Td
0 Tc
<B3>Tj
/F2 1 Tf
0.52383 0 Td
-0.025 Tc
0 Tw
(7\). )Tj
-16.86469 -1.24286 TD
-0.015 Tc
0.038 Tw
[(F)-15(o)-15(r)-15( )-15(p)-15(a)-15(t)-15(ients not achieving clinically significant weight)]TJ
-1 -1.24286 TD
-0.019 Tc
0.004 Tw
(loss of at least 3% after 12 weeks, PHEN/TPM may be in-)Tj
T*
-0.02 Tc
0.005 Tw
[(c)1(r)1(e)1(a)1(s)1(e)1(d)1( )1(t)1(o)1( )1(1)36(1.25/69 mg for 14 days, followed by 15/92 mg)]TJ
0 -1.24285 TD
-0.015 Tc
0.074 Tw
(daily if needed. If, after 12 weeks of taking PHEN/TPM)Tj
0 -1.24286 TD
-0.04 Tc
0.025 Tw
(15/92 mg daily)Tj
5.48427 0.00001 TD
-0.0397 Tc
(,)Tj
0.44519 0 Td
-0.04 Tc
(5% weight loss is not achieved, PHEN/TPM)Tj
-5.92946 -1.24286 TD
-0.038 Tc
0.023 Tw
(should be discontinued gradually by taking a dose every oth-)Tj
T*
-0.036 Tc
0.021 Tw
(er day for 1 week to minimize the possibility of precipitating)Tj
T*
-0.035 Tc
0.02 Tw
(seizures from rapid topiramate withdrawal.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 475.6218 160.9904 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 480.8821 157.6904 Tm
0 0 0 1 k
-0.035 Tc
0.02 Tw
(The mechanism)Tj
-16.36972 -1.24285 TD
-0.04 Tc
0.013 Tw
(of precipitant seizures is unclear)Tj
11.57204 0.00001 TD
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 309 116.5905 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
(Adverse Effects)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 95.7404 Tm
0 0 0 1 k
-0.001 Tc
(In general, PHEN/TPM was well tolerated in Phase 3)Tj
-1 -1.22382 TD
-0.005 Tc
0.004 Tw
(clinical trials, with the most commonly reported adverse)Tj
0 -1.22381 TD
-0.022 Tc
0 Tw
(ef)Tj
0.71275 0.00001 TD
0.022 Tw
(fects being dry mouth, dizziness, constipation, insomnia,)Tj
-0.71275 -1.22382 TD
-0.01 Tc
0.009 Tw
[(dysgeusia, and paresthesia \(T)70(able 4\).)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 460.0791 60.4904 Tm
0 0 0 1 k
-0.008 Tc
[(1)-1(2)-24(-14)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 476.5663 57.1904 Tm
0 0 0 1 k
-0.01 Tc
0.009 Tw
(Rates of discon-)Tj
-15.95869 -1.22381 TD
0 Tc
0.043 Tw
(tinuation due to adverse events were greater with high-)Tj
ET
0 0 0 0 k
308.5 740.1929 235 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8.4 0 0 8 366.993 744.7228 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Phenter)-25(mine/T)90(opiramate for the T)35(reatment of Obesity)]TJ
ET
0 0 0 0 k
157.5 15.444 386 13.08 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 269.1412 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 402.2662 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 415.4473 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 515.819 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 529 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(345)Tj
ET
0 0 0 0 k
50.5 16.524 79.5 11.669 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 50.5 21.3551 Tm
0 0 0 1 k
-0.025 Tc
(theannals.com)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 55.9657 46.5 Tm
0 0 0 1 k
-0.0001 Tc
(O)Tj
0.7779 0 TD
(B)Tj
0.6669 0 TD
(-)Tj
0.3329 0 TD
(3)Tj
0.5559 0 TD
(0)Tj
0.5559 0 TD
(3)Tj
4.3989 0 TD
(R)Tj
0.7219 0 TD
(,)Tj
0.5418 0 TD
(D)Tj
0.7219 0 TD
(B)Tj
0.66687 0 TD
(,)Tj
0.54184 0 TD
(P)Tj
0.66687 0 TD
(G)Tj
0.77787 0 TD
(,)Tj
3.27281 0 TD
(C)Tj
0.7219 0 TD
(O)Tj
0.7779 0 TD
(N)Tj
0.7219 0 TD
(Q)Tj
0.7779 0 TD
(U)Tj
0.7219 0 TD
(E)Tj
0.6669 0 TD
(R)Tj
0.98591 0 TD
(i)Tj
0.2219 0 TD
(n)Tj
0.5559 0 TD
(c)Tj
0.4999 0 TD
(l)Tj
0.2219 0 TD
(u)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(i)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(/)Tj
0.2779 0 TD
(e)Tj
0.5559 0 TD
(x)Tj
0.4999 0 TD
(c)Tj
0.4999 0 TD
(l)Tj
0.2219 0 TD
(u)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(i)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(n)Tj
0.81991 0 TD
(c)Tj
0.4999 0 TD
(r)Tj
0.3329 0 TD
(i)Tj
0.2219 0 TD
(t)Tj
0.2779 0 TD
(e)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(i)Tj
0.2219 0 TD
(a)Tj
0.5559 0 TD
(:)Tj
0.54191 0 TD
(B)Tj
0.6669 0 TD
(M)Tj
0.8329 0 TD
(I)Tj
3.0866 0 TD
(P)Tj
0.66689 0 TD
(T)Tj
0.61089 0 TD
(S)Tj
0.66689 0 TD
(.)Tj
0.54189 0 TD
(c)Tj
0.49989 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(n)Tj
0.55589 0 TD
(u)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
2.53399 0 TD
(P)Tj
0.66689 0 TD
(l)Tj
0.22189 0 TD
(a)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(e)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(o)Tj
0.55589 0 TD
(-)Tj
0.33289 0 TD
(s)Tj
0.49989 0 TD
(u)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(t)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
1.66882 0 TD
0 Tc
(W)Tj
0.92603 0 TD
-0.0001 Tc
(e)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(g)Tj
0.55588 0 TD
(h)Tj
0.55588 0 TD
(t)Tj
0.54186 0 TD
(l)Tj
0.22188 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(s)Tj
0.76387 0 TD
(c)Tj
0.49988 0 TD
(h)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(g)Tj
0.55588 0 TD
(e)Tj
0.81987 0 TD
(\()Tj
0.33288 0 TD
(%)Tj
0.88888 0 TD
(\))Tj
0.33288 0 TD
(,)Tj
0.54187 0 TD
(m)Tj
0.83288 0 TD
(e)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(:)Tj
-68.8649 -1.2 TD
(E)Tj
0.6669 0 TD
(x)Tj
0.4999 0 TD
(t)Tj
0.2779 0 TD
(e)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(i)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(n)Tj
3.4538 0 TD
-0.0002 Tc
(\()Tj
0.3328 0 TD
(3)Tj
0.8197 0 TD
(a)Tj
0.5558 0 TD
(r)Tj
0.33281 0 TD
(m)Tj
0.83281 0 TD
(\))Tj
0.3328 0 TD
(,)Tj
0.54172 0 TD
(M)Tj
0.8328 0 TD
(C)Tj
/F20 1 Tf
3.33055 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54883 0 TD
-0.0001 Tc
(2)Tj
0.55586 0 TD
(7)Tj
0.81982 0 TD
(k)Tj
0.49986 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 62.2157 194.9332 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 64.9657 199.6923 Tm
0 0 0 1 k
-0.0001 Tc
(a)Tj
0.55585 0 TD
(n)Tj
0.55585 0 TD
(d)Tj
/F20 1 Tf
0.81996 0 TD
0 Tc
<B2>Tj
/F1 1 Tf
0.54883 0 TD
-0.0001 Tc
(4)Tj
0.55586 0 TD
(5)Tj
0.81982 0 TD
(k)Tj
0.49986 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 62.2157 244.8629 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 64.9657 249.622 Tm
0 0 0 1 k
-0.0001 Tc
(a)Tj
0.55585 0 TD
(n)Tj
0.55585 0 TD
(d)Tj
/F20 1 Tf
0.81996 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54882 0 TD
-0.0001 Tc
(2)Tj
0.81983 0 TD
(w)Tj
0.72186 0 TD
(e)Tj
0.55586 0 TD
(i)Tj
0.22186 0 TD
(g)Tj
0.55586 0 TD
(h)Tj
0.55586 0 TD
(t)Tj
0.27786 0 TD
(-)Tj
4.52747 0 TD
(r)Tj
0.33287 0 TD
(a)Tj
0.55587 0 TD
(n)Tj
0.55587 0 TD
(d)Tj
0.55587 0 TD
(o)Tj
0.55587 0 TD
(m)Tj
0.83287 0 TD
(l)Tj
0.22187 0 TD
(y)Tj
5.18865 0 TD
(w)Tj
0.7219 0 TD
(e)Tj
0.5559 0 TD
(i)Tj
0.2219 0 TD
(g)Tj
0.5559 0 TD
(h)Tj
0.5559 0 TD
(t)Tj
0.54191 0 TD
(l)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(s)Tj
0.4999 0 TD
(,)Tj
0.54191 0 TD
(w)Tj
0.7219 0 TD
(e)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(k)Tj
2.41937 0 TD
(7)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(4)Tj
0.55587 0 TD
(6)Tj
0.81984 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
<D0>Tj
0.55587 0 TD
(9)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(3)Tj
-62.759 -1.2 TD
0 Tc
(T)Tj
0.574 0 TD
-0.0001 Tc
(r)Tj
0.3329 0 TD
(i)Tj
0.2219 0 TD
(a)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(,)Tj
0.5418 0 TD
(O)Tj
0.7779 0 TD
(B)Tj
0.6669 0 TD
(-)Tj
0.3329 0 TD
(3)Tj
0.5559 0 TD
(0)Tj
0.5559 0 TD
(5)Tj
1.9506 0 TD
(P)Tj
0.6669 0 TD
(h)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(s)Tj
0.49991 0 TD
(e)Tj
0.81992 0 TD
(3)Tj
4.81325 0 TD
(r)Tj
0.33288 0 TD
(e)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(d)Tj
0.81987 0 TD
(c)Tj
0.49988 0 TD
(o)Tj
0.55588 0 TD
(m)Tj
0.83288 0 TD
(o)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(b)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(d)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(t)Tj
0.27788 0 TD
(i)Tj
0.22188 0 TD
(e)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(;)Tj
0.54187 0 TD
(p)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(s)Tj
0.49988 0 TD
(.)Tj
0.54187 0 TD
(w)Tj
0.72188 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(e)Tj
0.81987 0 TD
(e)Tj
0.55588 0 TD
(x)Tj
0.49988 0 TD
(c)Tj
0.49988 0 TD
(l)Tj
0.22188 0 TD
(u)Tj
0.55588 0 TD
(d)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(d)Tj
0.81987 0 TD
(f)Tj
0.27788 0 TD
(r)Tj
0.33288 0 TD
(o)Tj
0.55588 0 TD
(m)Tj
2.61177 0 TD
(a)Tj
0.55592 0 TD
(s)Tj
0.49992 0 TD
(s)Tj
0.49992 0 TD
(i)Tj
0.22192 0 TD
(g)Tj
0.55592 0 TD
(n)Tj
0.55592 0 TD
(e)Tj
0.55592 0 TD
(d)Tj
5.35427 0 TD
-0.0002 Tc
(1)Tj
0.55583 0 TD
(0)Tj
0.55583 0 TD
(8)Tj
0.81977 0 TD
(\()Tj
0.33283 0 TD
(%)Tj
0.88883 0 TD
(\))Tj
0.33283 0 TD
(:)Tj
6.24009 0 TD
-0.0001 Tc
(1)Tj
0.55589 0 TD
(5)Tj
0.55589 0 TD
(/)Tj
0.27789 0 TD
(9)Tj
0.55589 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(f)Tj
0.27788 0 TD
(o)Tj
0.55588 0 TD
(r)Tj
0.59688 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.81988 0 TD
(d)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(s)Tj
0.76388 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-80.5155 -1.2 TD
(S)Tj
0.6669 0 TD
(E)Tj
0.6669 0 TD
(Q)Tj
0.7779 0 TD
(U)Tj
0.7219 0 TD
(E)Tj
0.6669 0 TD
(L)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 80.2157 80.6748 Tm
0 0 0 1 k
-0.0002 Tc
(1)Tj
0.5558 0 TD
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 82.9657 101.1614 Tm
0 0 0 1 k
-0.0002 Tc
(2)Tj
0.5558 0 TD
(:)Tj
0.2778 0 TD
(1)Tj
0.5558 0 TD
(:)Tj
0.2778 0 TD
(2)Tj
6.74443 0 TD
-0.0001 Tc
(e)Tj
0.55588 0 TD
(x)Tj
0.49988 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(i)Tj
0.22188 0 TD
(o)Tj
0.55588 0 TD
(n)Tj
0.81987 0 TD
(i)Tj
0.22188 0 TD
(f)Tj
0.54187 0 TD
(B)Tj
0.66688 0 TD
(M)Tj
0.83288 0 TD
(I)Tj
/F20 1 Tf
0.54201 0 TD
0 Tc
<B2>Tj
/F1 1 Tf
0.54883 0 TD
-0.0001 Tc
(2)Tj
0.55586 0 TD
(2)Tj
0.81982 0 TD
(k)Tj
0.49986 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 80.2157 250.0466 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 82.9657 252.8262 Tm
0 0 0 1 k
-0.0001 Tc
(,)Tj
0.54186 0 TD
(i)Tj
0.22188 0 TD
(f)Tj
0.54186 0 TD
(s)Tj
0.49988 0 TD
(t)Tj
0.27788 0 TD
(u)Tj
0.55588 0 TD
(d)Tj
0.55588 0 TD
(y)Tj
0.76386 0 TD
(d)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(u)Tj
0.55588 0 TD
(g)Tj
0.81986 0 TD
(h)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(d)Tj
2.95456 0 TD
-0.0002 Tc
(t)Tj
0.27784 0 TD
(r)Tj
0.33284 0 TD
(e)Tj
0.55584 0 TD
(a)Tj
0.55584 0 TD
(t)Tj
0.27784 0 TD
(m)Tj
0.83284 0 TD
(e)Tj
0.55584 0 TD
(n)Tj
0.55584 0 TD
(t)Tj
0.27784 0 TD
(s)Tj
0.76379 0 TD
(f)Tj
0.27784 0 TD
(r)Tj
0.33284 0 TD
(o)Tj
0.55584 0 TD
(m)Tj
3.14686 0 TD
-0.0001 Tc
(7)Tj
0.55586 0 TD
(.)Tj
0.27786 0 TD
(5)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(4)Tj
0.55586 0 TD
(6)Tj
0.81983 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
0.81983 0 TD
(=)Tj
0.84783 0 TD
(7)Tj
0.55586 0 TD
(.)Tj
0.27786 0 TD
(5)Tj
2.34862 0 TD
(W)Tj
0.94386 0 TD
(C)Tj
0.98583 0 TD
(c)Tj
0.49986 0 TD
(h)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(g)Tj
0.55586 0 TD
(e)Tj
0.81983 0 TD
(\()Tj
0.33286 0 TD
(c)Tj
0.49986 0 TD
(m)Tj
0.83286 0 TD
(\))Tj
0.33286 0 TD
(,)Tj
0.54183 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(:)Tj
-65.8392 -1.2 TD
0 Tc
(W)Tj
0.926 0 TD
-0.0001 Tc
(e)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(k)Tj
0.4999 0 TD
(s)Tj
0.7639 0 TD
(5)Tj
0.5559 0 TD
(6)Tj
0.5559 0 TD
(-)Tj
2.8748 0 TD
(a)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(l)Tj
0.2219 0 TD
(o)Tj
0.5559 0 TD
(c)Tj
0.49989 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
0.81988 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(o)Tj
2.0364 0 TD
(b)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(n)Tj
0.81989 0 TD
(d)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(s)Tj
0.49989 0 TD
(c)Tj
0.49989 0 TD
(o)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(i)Tj
0.22189 0 TD
(n)Tj
0.55589 0 TD
(u)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
0.81989 0 TD
(f)Tj
0.27789 0 TD
(o)Tj
0.55589 0 TD
(r)Tj
0.59689 0 TD
(>)Tj
0.58389 0 TD
(4)Tj
0.81988 0 TD
(w)Tj
0.72189 0 TD
(e)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(k)Tj
0.49989 0 TD
(s)Tj
0.76389 0 TD
(a)Tj
0.55589 0 TD
(f)Tj
0.27789 0 TD
(t)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(r)Tj
6.13621 0 TD
(C)Tj
0.72189 0 TD
(O)Tj
0.77789 0 TD
(N)Tj
0.72189 0 TD
(Q)Tj
0.77789 0 TD
(U)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(R)Tj
4.91138 0 TD
(1)Tj
0.55587 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(9)Tj
0.55587 0 TD
(2)Tj
0.81984 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
(8)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(7)Tj
3.12643 0 TD
(7)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(5)Tj
0.55587 0 TD
(/)Tj
0.27787 0 TD
(4)Tj
0.55587 0 TD
(6)Tj
0.81984 0 TD
(m)Tj
0.83287 0 TD
(g)Tj
0.81984 0 TD
(=)Tj
0.84784 0 TD
<D0>Tj
0.55587 0 TD
(9)Tj
0.55587 0 TD
(.)Tj
0.27787 0 TD
(8)Tj
-62.759 -1.2 TD
(1)Tj
0.5559 0 TD
(0)Tj
0.5559 0 TD
(8)Tj
14.08828 0 TD
(C)Tj
0.72189 0 TD
(O)Tj
0.77789 0 TD
(N)Tj
0.72189 0 TD
(Q)Tj
0.77789 0 TD
(U)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(R)Tj
0.98589 0 TD
(s)Tj
0.49989 0 TD
(t)Tj
0.27789 0 TD
(u)Tj
0.55589 0 TD
(d)Tj
0.55589 0 TD
(y)Tj
0.76389 0 TD
(e)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(d)Tj
0.55589 0 TD
(,)Tj
0.54189 0 TD
(a)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(d)Tj
0.81989 0 TD
(i)Tj
0.22189 0 TD
(f)Tj
0.54189 0 TD
(t)Tj
0.27789 0 TD
(h)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(y)Tj
0.76389 0 TD
(h)Tj
0.55589 0 TD
(a)Tj
0.55589 0 TD
(d)Tj
5.40188 0 TD
(P)Tj
0.66689 0 TD
(l)Tj
0.22189 0 TD
(a)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(e)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(o)Tj
0.81988 0 TD
(\()Tj
0.33289 0 TD
(n)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(2)Tj
0.55589 0 TD
(2)Tj
0.55589 0 TD
(7)Tj
0.55589 0 TD
(\))Tj
1.25522 0 TD
(P)Tj
0.66688 0 TD
(t)Tj
0.27788 0 TD
(s)Tj
0.49988 0 TD
(.)Tj
0.54186 0 TD
(w)Tj
0.72188 0 TD
(i)Tj
0.22188 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
/F20 1 Tf
0.82 0 TD
0 Tc
<B3>Tj
/F1 1 Tf
0.54883 0 TD
-0.0002 Tc
(5)Tj
0.55583 0 TD
(%)Tj
5.09323 0 TD
-0.0001 Tc
(1)Tj
0.55589 0 TD
(5)Tj
0.55589 0 TD
(/)Tj
0.27789 0 TD
(9)Tj
0.55589 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83289 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(6)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(<)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.81988 0 TD
(f)Tj
0.27788 0 TD
(o)Tj
0.55588 0 TD
(r)Tj
0.59688 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.81988 0 TD
(d)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(s)Tj
0.76388 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-80.5155 -1.2 TD
(N)Tj
0.9859 0 TD
(=)Tj
0.8479 0 TD
(6)Tj
0.5559 0 TD
(7)Tj
0.5559 0 TD
(6)Tj
12.25449 0 TD
(p)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(t)Tj
0.27788 0 TD
(i)Tj
0.22188 0 TD
(c)Tj
0.49988 0 TD
(i)Tj
0.22188 0 TD
(p)Tj
0.55588 0 TD
(a)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(d)Tj
0.81987 0 TD
(i)Tj
0.22188 0 TD
(n)Tj
0.81987 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.59687 0 TD
(f)Tj
0.27788 0 TD
(o)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(m)Tj
0.83288 0 TD
(a)Tj
0.55588 0 TD
(l)Tj
0.48587 0 TD
(w)Tj
0.72188 0 TD
(e)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(g)Tj
0.55588 0 TD
(h)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(-)Tj
0.33288 0 TD
(l)Tj
0.22188 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(s)Tj
3.93144 0 TD
(P)Tj
0.66689 0 TD
(H)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(N)Tj
0.72189 0 TD
(/)Tj
0.27789 0 TD
(T)Tj
0.61089 0 TD
(P)Tj
0.66689 0 TD
(M)Tj
1.09689 0 TD
(C)Tj
0.72189 0 TD
(R)Tj
3.14767 0 TD
(w)Tj
0.72188 0 TD
(e)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(g)Tj
0.55588 0 TD
(h)Tj
0.55588 0 TD
(t)Tj
0.54186 0 TD
(l)Tj
0.22188 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(s)Tj
0.76386 0 TD
(f)Tj
0.27788 0 TD
(r)Tj
0.33288 0 TD
(o)Tj
0.55588 0 TD
(m)Tj
2.86463 0 TD
(F)Tj
0.61086 0 TD
(P)Tj
0.66686 0 TD
(G)Tj
1.04183 0 TD
(c)Tj
0.49986 0 TD
(h)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(g)Tj
0.55586 0 TD
(e)Tj
0.81983 0 TD
(\()Tj
0.33286 0 TD
(m)Tj
0.83286 0 TD
(g)Tj
0.55586 0 TD
(/)Tj
0.27786 0 TD
(d)Tj
0.55586 0 TD
(L)Tj
0.55586 0 TD
(\))Tj
0.33286 0 TD
(,)Tj
0.54183 0 TD
(m)Tj
0.83286 0 TD
(e)Tj
0.55586 0 TD
(a)Tj
0.55586 0 TD
(n)Tj
0.55586 0 TD
(:)Tj
-52.47461 -1.2 TD
(p)Tj
0.55585 0 TD
(r)Tj
0.33285 0 TD
(o)Tj
0.55585 0 TD
(g)Tj
0.55585 0 TD
(r)Tj
0.33285 0 TD
(a)Tj
0.55585 0 TD
(m)Tj
1.09681 0 TD
(i)Tj
0.22185 0 TD
(n)Tj
0.81981 0 TD
(t)Tj
0.27785 0 TD
(h)Tj
0.55585 0 TD
(e)Tj
0.81981 0 TD
(i)Tj
0.22185 0 TD
(n)Tj
0.55585 0 TD
(t)Tj
0.27785 0 TD
(e)Tj
0.55585 0 TD
(r)Tj
0.33285 0 TD
(i)Tj
0.22185 0 TD
(m)Tj
13.25266 0 TD
-0.0002 Tc
(7)Tj
0.55585 0 TD
(.)Tj
0.27785 0 TD
(5)Tj
0.55585 0 TD
(/)Tj
0.27785 0 TD
(4)Tj
0.55585 0 TD
(6)Tj
0.81981 0 TD
(m)Tj
0.83285 0 TD
(g)Tj
4.9238 0 TD
-0.0001 Tc
(b)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(s)Tj
0.4999 0 TD
(e)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(i)Tj
0.2219 0 TD
(n)Tj
0.5559 0 TD
(e)Tj
0.81991 0 TD
(t)Tj
0.2779 0 TD
(o)Tj
0.81991 0 TD
(w)Tj
0.7219 0 TD
(e)Tj
0.5559 0 TD
(e)Tj
0.5559 0 TD
(k)Tj
2.80728 0 TD
(7)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(4)Tj
0.55588 0 TD
(6)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(1)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(8)Tj
0.55588 0 TD
(7)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-35.81017 -1.2 TD
(\()Tj
0.33285 0 TD
(n)Tj
0.81981 0 TD
(=)Tj
0.84781 0 TD
(1)Tj
0.55585 0 TD
(5)Tj
0.55585 0 TD
(3)Tj
0.55585 0 TD
(\))Tj
5.1317 0 TD
-0.0002 Tc
(1)Tj
0.55585 0 TD
(0)Tj
0.55585 0 TD
(8)Tj
0.55585 0 TD
(:)Tj
8.05848 0 TD
-0.0001 Tc
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(4)Tj
0.55588 0 TD
(8)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-36.58817 -1.2 TD
(P)Tj
0.66689 0 TD
(H)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(N)Tj
0.72189 0 TD
(/)Tj
0.27789 0 TD
(T)Tj
0.61089 0 TD
(P)Tj
0.66689 0 TD
(M)Tj
1.09689 0 TD
(C)Tj
0.72189 0 TD
(R)Tj
3.61767 0 TD
-0.0151 Tc
(7)Tj
0.54087 0 TD
(.)Tj
0.26287 0 TD
(5)Tj
0.54087 0 TD
(/)Tj
0.26287 0 TD
(4)Tj
0.54087 0 TD
(6)Tj
0.78984 0 TD
(m)Tj
0.81787 0 TD
(g)Tj
0.78984 0 TD
(=)Tj
0.81784 0 TD
(7)Tj
0.54087 0 TD
(5)Tj
0.54087 0 TD
(.)Tj
0.26287 0 TD
(2)Tj
2.0477 0 TD
(F)Tj
0.59589 0 TD
(a)Tj
0.54089 0 TD
(s)Tj
0.48489 0 TD
(t)Tj
0.26289 0 TD
(i)Tj
0.20689 0 TD
(n)Tj
0.54089 0 TD
(g)Tj
0.7899 0 TD
(i)Tj
0.2069 0 TD
(n)Tj
0.5409 0 TD
(s)Tj
0.4849 0 TD
(u)Tj
0.5409 0 TD
(l)Tj
0.2069 0 TD
(i)Tj
0.2069 0 TD
(n)Tj
0.7899 0 TD
(c)Tj
0.4849 0 TD
(h)Tj
0.5409 0 TD
(a)Tj
0.5409 0 TD
(n)Tj
0.5409 0 TD
(g)Tj
0.5409 0 TD
(e)Tj
0.7899 0 TD
(\()Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F5 1 Tf
0 7.5 -7.5 0 136.9657 541.3619 Tm
0 0 0 1 k
(m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 136.9657 547.4951 Tm
0 0 0 1 k
-0.0152 Tc
(I)Tj
0.26284 0 TD
(U)Tj
0.70684 0 TD
(/)Tj
0.26284 0 TD
(m)Tj
0.81784 0 TD
(L)Tj
0.54084 0 TD
(\))Tj
0.31784 0 TD
(,)Tj
0.51177 0 TD
(m)Tj
0.81784 0 TD
(e)Tj
0.54084 0 TD
(a)Tj
0.54084 0 TD
(n)Tj
0.54084 0 TD
(:)Tj
-34.86058 -1.2 TD
-0.0001 Tc
(1)Tj
0.55585 0 TD
(5)Tj
0.55585 0 TD
(/)Tj
0.27785 0 TD
(9)Tj
0.55585 0 TD
(2)Tj
0.81981 0 TD
(m)Tj
0.83285 0 TD
(g)Tj
5.67165 0 TD
-0.0151 Tc
(1)Tj
0.54087 0 TD
(5)Tj
0.54087 0 TD
(/)Tj
0.26287 0 TD
(9)Tj
0.54087 0 TD
(2)Tj
0.78985 0 TD
(m)Tj
0.81787 0 TD
(g)Tj
0.78985 0 TD
(=)Tj
0.81785 0 TD
(7)Tj
0.54087 0 TD
(9)Tj
0.54087 0 TD
(.)Tj
0.26287 0 TD
(3)Tj
2.81051 0 TD
(7)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(5)Tj
0.54088 0 TD
(/)Tj
0.26288 0 TD
(4)Tj
0.54088 0 TD
(6)Tj
0.78988 0 TD
(m)Tj
0.81788 0 TD
(g)Tj
0.78988 0 TD
(=)Tj
0.81788 0 TD
<D0>Tj
0.54088 0 TD
(5)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(3)Tj
0.78988 0 TD
(\()Tj
0.31788 0 TD
(p)Tj
0.78988 0 TD
(=)Tj
0.81788 0 TD
(0)Tj
0.54088 0 TD
(.)Tj
0.26288 0 TD
(0)Tj
0.54088 0 TD
(0)Tj
0.54088 0 TD
(5)Tj
0.54088 0 TD
(1)Tj
0.78988 0 TD
(v)Tj
0.48488 0 TD
(s)Tj
0.73388 0 TD
(p)Tj
0.54088 0 TD
(l)Tj
0.20688 0 TD
(a)Tj
0.54088 0 TD
(c)Tj
0.48488 0 TD
(e)Tj
0.54104 0 TD
-0.0002 Tc
(b)Tj
0.55579 0 TD
(o)Tj
0.55579 0 TD
(\))Tj
ET
0.5 w 
0 0 0 1 K
161.216 43.5 m
161.216 733.5 l
S
BT
/F1 1 Tf
0 7.5 -7.5 0 154.9657 329.9993 Tm
-0.0001 Tc
(\()Tj
0.33285 0 TD
(n)Tj
0.81981 0 TD
(=)Tj
0.84781 0 TD
(2)Tj
0.55585 0 TD
(9)Tj
0.55585 0 TD
(5)Tj
0.55585 0 TD
(\))Tj
4.6317 0 TD
(P)Tj
0.66691 0 TD
(l)Tj
0.22191 0 TD
(a)Tj
0.55591 0 TD
(c)Tj
0.49991 0 TD
(e)Tj
0.55591 0 TD
(b)Tj
0.55591 0 TD
(o)Tj
0.81992 0 TD
(=)Tj
0.84792 0 TD
(3)Tj
0.55591 0 TD
(0)Tj
0.55591 0 TD
(.)Tj
0.27791 0 TD
(0)Tj
4.11203 0 TD
(1)Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(9)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(m)Tj
0.83288 0 TD
(g)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
<D0>Tj
0.55588 0 TD
(5)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(2)Tj
0.81988 0 TD
(\()Tj
0.33288 0 TD
(p)Tj
0.81988 0 TD
(=)Tj
0.84788 0 TD
(0)Tj
0.55588 0 TD
(.)Tj
0.27788 0 TD
(0)Tj
0.55588 0 TD
(0)Tj
0.55588 0 TD
(1)Tj
0.55588 0 TD
(2)Tj
0.81988 0 TD
(v)Tj
0.49988 0 TD
(s)Tj
0.76388 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(\))Tj
-73.88808 -2.4 TD
-0.0013 Tc
(B)Tj
0.66567 0 TD
(M)Tj
0.83167 0 TD
(I)Tj
0.52677 0 TD
(=)Tj
0.83277 0 TD
(b)Tj
0.55467 0 TD
(o)Tj
0.55467 0 TD
(d)Tj
0.55467 0 TD
(y)Tj
0.74877 0 TD
(m)Tj
0.83167 0 TD
(a)Tj
0.55467 0 TD
(s)Tj
0.49867 0 TD
(s)Tj
0.74877 0 TD
(i)Tj
0.22067 0 TD
(n)Tj
0.55467 0 TD
(d)Tj
0.55467 0 TD
(e)Tj
0.55467 0 TD
(x)Tj
0.49867 0 TD
(;)Tj
0.52677 0 TD
(B)Tj
0.66567 0 TD
(P)Tj
0.91577 0 TD
(=)Tj
0.83277 0 TD
(b)Tj
0.55467 0 TD
(l)Tj
0.22067 0 TD
(o)Tj
0.55467 0 TD
(o)Tj
0.55467 0 TD
(d)Tj
0.80477 0 TD
(p)Tj
0.55467 0 TD
(r)Tj
0.33167 0 TD
(e)Tj
0.55467 0 TD
(s)Tj
0.49867 0 TD
(s)Tj
0.49867 0 TD
(u)Tj
0.55467 0 TD
(r)Tj
0.33167 0 TD
(e)Tj
0.55467 0 TD
(;)Tj
0.52677 0 TD
(C)Tj
0.72067 0 TD
(R)Tj
0.97077 0 TD
(=)Tj
0.83277 0 TD
(c)Tj
0.49867 0 TD
(o)Tj
0.55467 0 TD
(n)Tj
0.55467 0 TD
(t)Tj
0.27667 0 TD
(r)Tj
0.33167 0 TD
(o)Tj
0.55467 0 TD
(l)Tj
0.22067 0 TD
(l)Tj
0.22067 0 TD
(e)Tj
0.55467 0 TD
(d)Tj
0.80477 0 TD
(r)Tj
0.33166 0 TD
(e)Tj
0.55467 0 TD
(l)Tj
0.22066 0 TD
(e)Tj
0.55466 0 TD
(a)Tj
0.55466 0 TD
(s)Tj
0.49866 0 TD
(e)Tj
0.55466 0 TD
(;)Tj
0.52677 0 TD
(D)Tj
0.72067 0 TD
(B)Tj
0.91577 0 TD
(=)Tj
0.83277 0 TD
(d)Tj
0.55467 0 TD
(o)Tj
0.55466 0 TD
(u)Tj
0.55466 0 TD
(b)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(e)Tj
0.55466 0 TD
(-)Tj
0.33166 0 TD
(b)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(i)Tj
0.22066 0 TD
(n)Tj
0.55466 0 TD
(d)Tj
0.55466 0 TD
(;)Tj
0.52677 0 TD
(D)Tj
0.72067 0 TD
(B)Tj
0.66566 0 TD
(P)Tj
0.91577 0 TD
(=)Tj
0.83277 0 TD
(d)Tj
0.55467 0 TD
(i)Tj
0.22066 0 TD
(a)Tj
0.55466 0 TD
(s)Tj
0.49866 0 TD
(t)Tj
0.27666 0 TD
(o)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(i)Tj
0.22066 0 TD
(c)Tj
0.74877 0 TD
(b)Tj
0.55467 0 TD
(l)Tj
0.22066 0 TD
(o)Tj
0.55466 0 TD
(o)Tj
0.55466 0 TD
(d)Tj
0.80477 0 TD
(p)Tj
0.55467 0 TD
(r)Tj
0.33166 0 TD
(e)Tj
0.55466 0 TD
(s)Tj
0.49866 0 TD
(s)Tj
0.49866 0 TD
(u)Tj
0.55466 0 TD
(r)Tj
0.33166 0 TD
(e)Tj
0.55466 0 TD
(;)Tj
0.52677 0 TD
(F)Tj
0.60966 0 TD
(P)Tj
0.66567 0 TD
(G)Tj
1.02677 0 TD
(=)Tj
0.83277 0 TD
(f)Tj
0.27666 0 TD
(a)Tj
0.55467 0 TD
(s)Tj
0.49866 0 TD
(t)Tj
0.27666 0 TD
(i)Tj
0.22066 0 TD
(n)Tj
0.55466 0 TD
(g)Tj
0.80477 0 TD
(p)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(a)Tj
0.55466 0 TD
(s)Tj
0.49866 0 TD
(m)Tj
0.83166 0 TD
(a)Tj
0.80477 0 TD
(g)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(u)Tj
0.55466 0 TD
(c)Tj
0.49866 0 TD
(o)Tj
0.55466 0 TD
(s)Tj
0.49866 0 TD
(e)Tj
0.55466 0 TD
(;)Tj
0.52677 0 TD
(M)Tj
0.83166 0 TD
(C)Tj
0.97077 0 TD
(=)Tj
0.83277 0 TD
(m)Tj
0.83166 0 TD
(u)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(t)Tj
0.27666 0 TD
(i)Tj
0.22066 0 TD
(c)Tj
0.49866 0 TD
(e)Tj
0.55466 0 TD
(n)Tj
0.55466 0 TD
(t)Tj
0.27666 0 TD
(e)Tj
0.55466 0 TD
(r)Tj
0.33166 0 TD
(;)Tj
0.52677 0 TD
(O)Tj
0.77666 0 TD
(G)Tj
0.77666 0 TD
(T)Tj
0.60966 0 TD
(T)Tj
0.85977 0 TD
(=)Tj
0.83277 0 TD
(o)Tj
0.55466 0 TD
(r)Tj
0.33166 0 TD
(a)Tj
0.55466 0 TD
(l)Tj
0.47077 0 TD
(g)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(u)Tj
0.55466 0 TD
(c)Tj
0.49866 0 TD
(o)Tj
0.55466 0 TD
(s)Tj
0.49866 0 TD
(e)Tj
0.80477 0 TD
(t)Tj
0.27666 0 TD
(o)Tj
0.55466 0 TD
(l)Tj
0.22066 0 TD
(e)Tj
0.55466 0 TD
(r)Tj
0.33166 0 TD
(a)Tj
0.55466 0 TD
(n)Tj
0.55466 0 TD
(c)Tj
0.49866 0 TD
(e)Tj
0.80477 0 TD
(t)Tj
0.27666 0 TD
(e)Tj
0.55466 0 TD
(s)Tj
0.49866 0 TD
(t)Tj
0.27666 0 TD
(;)Tj
-90.92233 -1.2 TD
-0.0001 Tc
(P)Tj
0.66689 0 TD
(G)Tj
1.04188 0 TD
(=)Tj
0.84788 0 TD
(p)Tj
0.55589 0 TD
(a)Tj
0.55589 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(l)Tj
0.22189 0 TD
(e)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(-)Tj
0.33289 0 TD
(g)Tj
0.55589 0 TD
(r)Tj
0.33289 0 TD
(o)Tj
0.55589 0 TD
(u)Tj
0.55589 0 TD
(p)Tj
0.55589 0 TD
(;)Tj
0.54188 0 TD
(P)Tj
0.66689 0 TD
(H)Tj
0.72189 0 TD
(E)Tj
0.66689 0 TD
(N)Tj
0.72189 0 TD
(/)Tj
0.27789 0 TD
(T)Tj
0.61089 0 TD
(P)Tj
0.66689 0 TD
(M)Tj
1.09688 0 TD
(=)Tj
0.84788 0 TD
(p)Tj
0.55589 0 TD
(h)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(m)Tj
0.83289 0 TD
(i)Tj
0.22189 0 TD
(n)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(/)Tj
0.27789 0 TD
(t)Tj
0.27789 0 TD
(o)Tj
0.55589 0 TD
(p)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(m)Tj
0.83289 0 TD
(a)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(;)Tj
0.54188 0 TD
(R)Tj
0.98588 0 TD
(=)Tj
0.84788 0 TD
(r)Tj
0.33289 0 TD
(a)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(d)Tj
0.55589 0 TD
(o)Tj
0.55589 0 TD
(m)Tj
0.83289 0 TD
(i)Tj
0.22189 0 TD
(z)Tj
0.49989 0 TD
(e)Tj
0.55589 0 TD
(d)Tj
0.55589 0 TD
(;)Tj
0.54189 0 TD
(S)Tj
0.66689 0 TD
(B)Tj
0.66689 0 TD
(P)Tj
0.93089 0 TD
(=)Tj
0.84788 0 TD
(s)Tj
0.49989 0 TD
(y)Tj
0.49989 0 TD
(s)Tj
0.49989 0 TD
(t)Tj
0.27789 0 TD
(o)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(i)Tj
0.22189 0 TD
(c)Tj
0.76388 0 TD
(b)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(o)Tj
0.55589 0 TD
(o)Tj
0.55589 0 TD
(d)Tj
0.81989 0 TD
(p)Tj
0.55589 0 TD
(r)Tj
0.33289 0 TD
(e)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(s)Tj
0.49989 0 TD
(u)Tj
0.55589 0 TD
(r)Tj
0.33289 0 TD
(e)Tj
0.55589 0 TD
(;)Tj
0.54189 0 TD
(T)Tj
0.61089 0 TD
(G)Tj
1.04189 0 TD
(=)Tj
0.84788 0 TD
(t)Tj
0.27789 0 TD
(r)Tj
0.33289 0 TD
(i)Tj
0.22189 0 TD
(g)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(y)Tj
0.49989 0 TD
(c)Tj
0.49989 0 TD
(e)Tj
0.55589 0 TD
(r)Tj
0.33289 0 TD
(i)Tj
0.22189 0 TD
(d)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(;)Tj
0.54188 0 TD
(T)Tj
0.61089 0 TD
(2)Tj
0.55589 0 TD
(D)Tj
0.72189 0 TD
(M)Tj
1.09689 0 TD
(=)Tj
0.84788 0 TD
(t)Tj
0.27789 0 TD
(y)Tj
0.49989 0 TD
(p)Tj
0.55589 0 TD
(e)Tj
0.81988 0 TD
(2)Tj
0.81988 0 TD
(d)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(a)Tj
0.55589 0 TD
(b)Tj
0.55589 0 TD
(e)Tj
0.55589 0 TD
(t)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(s)Tj
0.76388 0 TD
(m)Tj
0.83289 0 TD
(e)Tj
0.55589 0 TD
(l)Tj
0.22189 0 TD
(l)Tj
0.22189 0 TD
(i)Tj
0.22189 0 TD
(t)Tj
0.27789 0 TD
(u)Tj
0.55589 0 TD
(s)Tj
0.49989 0 TD
(;)Tj
0.54188 0 TD
(W)Tj
0.94389 0 TD
(C)Tj
0.98588 0 TD
(=)Tj
0.84788 0 TD
(w)Tj
0.72189 0 TD
(a)Tj
0.55589 0 TD
(i)Tj
0.22189 0 TD
(s)Tj
0.49989 0 TD
(t)Tj
0.54188 0 TD
(c)Tj
0.49989 0 TD
(i)Tj
0.22189 0 TD
(r)Tj
0.33289 0 TD
(c)Tj
0.49989 0 TD
(u)Tj
0.55589 0 TD
(m)Tj
0.83289 0 TD
(f)Tj
0.27789 0 TD
(e)Tj
0.55589 0 TD
(r)Tj
0.33289 0 TD
(e)Tj
0.55589 0 TD
(n)Tj
0.55589 0 TD
(c)Tj
0.49989 0 TD
(e)Tj
0.55589 0 TD
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
0 5 -5 0 189.2157 46.5 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
0 7.5 -7.5 0 191.9657 49.2795 Tm
0 0 0 1 k
-0.0001 Tc
(S)Tj
0.6669 0 TD
(e)Tj
0.5559 0 TD
(l)Tj
0.2219 0 TD
(e)Tj
0.5559 0 TD
(c)Tj
0.4999 0 TD
(t)Tj
0.2779 0 TD
(e)Tj
0.5559 0 TD
(d)Tj
0.81991 0 TD
(s)Tj
0.4999 0 TD
(e)Tj
0.5559 0 TD
(c)Tj
0.4999 0 TD
(o)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(d)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(y)Tj
0.76391 0 TD
(o)Tj
0.5559 0 TD
(u)Tj
0.5559 0 TD
(t)Tj
0.2779 0 TD
(c)Tj
0.4999 0 TD
(o)Tj
0.5559 0 TD
(m)Tj
0.8329 0 TD
(e)Tj
0.5559 0 TD
(s)Tj
0.7639 0 TD
(t)Tj
0.2779 0 TD
(h)Tj
0.5559 0 TD
(a)Tj
0.5559 0 TD
(t)Tj
0.5419 0 TD
(w)Tj
0.7219 0 TD
(e)Tj
0.5559 0 TD
(r)Tj
0.3329 0 TD
(e)Tj
0.8199 0 TD
(s)Tj
0.4999 0 TD
(i)Tj
0.2219 0 TD
(g)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(i)Tj
0.2219 0 TD
(f)Tj
0.2779 0 TD
(i)Tj
0.2219 0 TD
(c)Tj
0.4999 0 TD
(a)Tj
0.5559 0 TD
(n)Tj
0.5559 0 TD
(t)Tj
0.2779 0 TD
(l)Tj
0.2219 0 TD
(y)Tj
0.7639 0 TD
(d)Tj
0.5559 0 TD
(i)Tj
0.2219 0 TD
(f)Tj
0.2602 0 TD
(f)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(e)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(t)Tj
0.54186 0 TD
(b)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(w)Tj
0.72188 0 TD
(e)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(n)Tj
0.81986 0 TD
(p)Tj
0.55588 0 TD
(h)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(m)Tj
0.83288 0 TD
(i)Tj
0.22188 0 TD
(n)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(t)Tj
0.27788 0 TD
(o)Tj
0.55588 0 TD
(p)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(r)Tj
0.33288 0 TD
(a)Tj
0.55588 0 TD
(m)Tj
0.83288 0 TD
(a)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.81986 0 TD
(d)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(s)Tj
0.76386 0 TD
(o)Tj
0.55588 0 TD
(r)Tj
0.59686 0 TD
(b)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(w)Tj
0.72188 0 TD
(e)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(n)Tj
0.81986 0 TD
(e)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(t)Tj
0.27788 0 TD
(h)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.59686 0 TD
(p)Tj
0.55588 0 TD
(h)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.55588 0 TD
(r)Tj
0.33288 0 TD
(m)Tj
0.83288 0 TD
(i)Tj
0.22188 0 TD
(n)Tj
0.55588 0 TD
(e)Tj
0.55588 0 TD
(/)Tj
0.27788 0 TD
(t)Tj
0.27788 0 TD
(o)Tj
0.55588 0 TD
(p)Tj
0.55588 0 TD
(i)Tj
0.22188 0 TD
(r)Tj
0.33288 0 TD
(a)Tj
0.55588 0 TD
(m)Tj
0.83288 0 TD
(a)Tj
0.55588 0 TD
(t)Tj
0.27788 0 TD
(e)Tj
0.81986 0 TD
(d)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(s)Tj
0.49988 0 TD
(e)Tj
0.81986 0 TD
(a)Tj
0.55588 0 TD
(n)Tj
0.55588 0 TD
(d)Tj
0.81986 0 TD
(p)Tj
0.55588 0 TD
(l)Tj
0.22188 0 TD
(a)Tj
0.55588 0 TD
(c)Tj
0.49988 0 TD
(e)Tj
0.55588 0 TD
(b)Tj
0.55588 0 TD
(o)Tj
0.55588 0 TD
(.)Tj
ET
Q

endstream
endobj
10 0 obj
<<
/Length 12432
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
Q
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 50.5 726.0132 Tm
0 0 0 1 k
-0.021 Tc
0.021 Tw
(dose PHEN/TPM and appear to be dose-related. The most)Tj
0 -1.22381 TD
-0.011 Tc
0.011 Tw
(common reasons for discontinuation were blurred vision,)Tj
0 -1.22382 TD
-0.025 Tc
0.013 Tw
[(headache, and irritability)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 150.2717 703.6132 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 61 687.4631 Tm
0 0 0 1 k
-0.025 Tc
0.003 Tw
(In monotherapy weight loss studies, topiramate has been)Tj
-1 -1.22381 TD
-0.012 Tc
0.012 Tw
[(associated with dose-)-75(dependent neuropsychiatric adverse)]TJ
T*
-0.011 Tc
0.011 Tw
(events, mainly memory and mood events such as depres-)Tj
T*
-0.014 Tc
0.014 Tw
[(sion. Consequently)65(, during clinical trials for PHEN/TPM,)]TJ
T*
0 Tc
0.168 Tw
(depressive symptoms were assessed using the Patient)Tj
0 -1.2238 TD
-0.018 Tc
0.018 Tw
(Health Questionnaire 9 (PHQ-9), and suicide ideation and)Tj
24.61905 9.79048 TD
-0.002 Tc
0.001 Tw
(behavior were assessed using the clinician-administered)Tj
0 -1.22381 TD
-0.025 Tc
0.008 Tw
(Columbia Suicide Severity Rating Scale (C-SSRS). Across)Tj
0 -1.22382 TD
-0.006 Tc
0.006 Tw
(all 3 trials, depressive symptoms tended to improve over)Tj
0 -1.22381 TD
-0.025 Tc
0.023 Tw
(time and no significant increase in suicide risks was identi-)Tj
T*
0 Tw
(fied.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 326.6341 677.9132 Tm
0 0 0 1 k
-0.024 Tc
[(1)-1(2)-24(-14)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 661.5131 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
(Like other carbonic anhydrase inhibitors, topiramate can)Tj
-1 -1.24762 TD
-0.019 Tc
0.019 Tw
(decrease serum concentrations of bicarbonate and potassi-)Tj
T*
0 Tc
0.009 Tw
(um, increasing the risk of hypokalemia and nephrolithi-)Tj
T*
-0.017 Tc
0 Tw
(asis.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 326.5083 625.5131 Tm
0 0 0 1 k
-0.014 Tc
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 334.9364 622.2131 Tm
0 0 0 1 k
-0.016 Tc
0.016 Tw
(In the CONQUER trial, 3 serious adverse events of)Tj
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 50.5 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(346)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 74.2499 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 87.431 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 220.5559 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 233.737 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
/F8 1 Tf
10 0 0 10 488.4582 21.6616 Tm
0 0 0 1 k
0 Tw
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8 0 0 8 50.5 744.7228 Tm
0 0 0 1 k
-0.013 Tw
[(SM)-250(Smith et al.)]TJ
ET
0 0 0 0.1 k
50.5 186.7039 492.002 11.471 re
f
50.5 162.553 492.002 11.472 re
f
50.5 139.007 492.002 11.471 re
f
50.5 115.46 492.002 11.472 re
f
50.5 90.7059 492.002 11.472 re
f
0.5 w 
0 0 0 1 K
51 258.292 m
543 258.292 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
9 0 0 9 138.6596 264.0421 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(T)74(able 4.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9 0 0 9 172.1752 264.0421 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
(Adverse Events with a Frequency of 5% or More in Any PHEN/TPM Group )Tj
ET
0.5 w 
0 0 0 1 K
180 243.792 m
288 243.792 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 219.0642 248.0421 Tm
0 0 0 1 k
(EQUIP)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 242.401 250.7922 Tm
0 0 0 1 k
(12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 338.9028 248.0421 Tm
0 0 0 1 k
(CONQUER)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 377.2304 250.7922 Tm
0 0 0 1 k
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 469.2749 248.0421 Tm
0 0 0 1 k
(SEQUEL)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 500.1116 250.7922 Tm
0 0 0 1 k
(14)Tj
ET
0.5 w 
0 0 0 1 K
307 243.792 m
414 243.792 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 183.0125 234.0421 Tm
0 0 0 1 k
[(PHEN/TPM)-3323(PHEN/TPM)-3360(PHEN/TPM)-3234(PHEN/TPM)-3234(PHEN/TPM)-3369(PHEN/TPM)]TJ
ET
0.5 w 
0 0 0 1 K
434 243.792 m
540 243.792 l
S
BT
/F6 1 Tf
7.5 0 0 7.5 183.4748 226.0422 Tm
-0.014 Tw
(CR 3.75/23)Tj
8.9058 0.00001 TD
(CR 15/92)Tj
8.38735 0.00001 TD
(CR 7.5/46)Tj
8.53892 0.00001 TD
(CR 15/92)Tj
8.26108 0.00001 TD
(CR 7.5/46)Tj
8.67408 0.00001 TD
(CR 15/92 )Tj
ET
51 213.792 m
543 213.792 l
S
BT
/F6 1 Tf
7.5 0 0 7.5 95.969 218.0421 Tm
[(Event)-9439((n = 240))-4460(\(n = 51)54(1\))-4498((n = 153))-4344((n = 295))-4344((n = 153))-4479(\(n = 295)-1(\))]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 54 202.0422 Tm
0 0 0 1 k
-0.014 Tw
(General, n (%))Tj
0.5 -1.6 TD
0 Tw
(paresthesia)Tj
18.06477 0.00001 TD
-0.014 Tw
(10 (4.2))Tj
7.4514 0.00001 TD
(96 (18.8))Tj
5.75361 0.00001 TD
(21 (13.7))Tj
7.5045 0.00001 TD
(62 (21.0))Tj
10.87816 0.00001 TD
-0.0002 Tc
(1)Tj
0.81975 0 Td
0 Tc
[((0.7))-6247(10 (3.4))]TJ
-50.4722 -1.60004 TD
[(dry mouth)-13634(16 (6.7))-4021(87 (17.0))-1767(21 (13.7))-3517(59 (20.0) )-6628(1 (0.7))-6803(4 (1.4))]TJ
0 -1.6 TD
0 Tw
(constipation)Tj
18.06477 0.00001 TD
-0.014 Tw
[(19 (7.9))-4021(72 (14.1))-1767(25 (16.3) )-3253(62 (21.0) )-6146(1)74(1 (7.2))-6247(12 (4.1))]TJ
-18.06477 -1.60001 TD
(upper respiratory tract infection)Tj
18.06477 0.00001 TD
(38 (15.8))Tj
7.4514 0.00001 TD
(63 (12.3))Tj
5.75361 0.00001 TD
(23 (15.0))Tj
7.5045 0.00001 TD
(55 (18.6) )Tj
10.32225 0.00001 TD
[(26 (17.0))-5691(45 (15.3))]TJ
-49.09655 -1.60004 TD
[(headache)-13674(25 (10.4))-3464(61 \(1)74(1.9\))-2397(8 (5.2))-4074(28 (9.5))-7447(4 (2.6))-6247(12 (4.1))]TJ
0 -1.6 TD
0 Tw
(dysgeusia)Tj
18.62068 0.00001 TD
-0.0002 Tc
(3)Tj
0.81975 0 Td
0 Tc
-0.014 Tw
[((1.3))-4021(43 (8.4))-2322(18 \(1)73(1.8\))-3592(39 (13.2))-6891(1 (0.7))-6803(3 (1.0))]TJ
-19.9404 -1.6 TD
(Psychiatric, n (%) )Tj
0.5 -1.6 TD
[(depression)-13731(8 (3.3))-4020(24 (4.7))-2323(14 (3))-4908(39 (4))-7962((3.9))-7623((8.1))]TJ
T*
[(anxiety)-15453(7 (2.9))-4021(19 (3.7))-2879(9 (2))-4907(41 (4))-7962((6.5))-7623((9.5))]TJ
-0.5 -1.6 TD
(Cognitive, n (%) )Tj
ET
0.5 w 
0 0 0 1 K
51 63.792 m
543 63.792 l
S
BT
/F1 1 Tf
7.5 0 0 7.5 57.75 70.0422 Tm
[(attention disturbance)-9354(1 (0.4))-4021(18 (3.5) )-2058(10 (2))-4908(35 (4))]TJ
-0.5 -2.4 TD
(CR = controlled release; PHEN/TPM = phentermine/topiramate.)Tj
ET
50.75 43.75 492.5 233.501 re
s
0 0 0 0.1 k
50.5 519.314 492.998 12 re
f
50.5 495.314 492.998 12 re
f
50.5 471.314 492.998 12 re
f
51 561.3 m
543 561.3 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
9 0 0 9 185.4557 567.05 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(T)74(able 3.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9 0 0 9 218.9713 567.05 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
[(Baseline Characteristics for Phase 3 Clinical T)37(rials)]TJ
ET
0.5 w 
0 0 0 1 K
51 546.7999 m
543 546.7999 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 67.0277 551.0501 Tm
0 0 0 1 k
-0.014 Tw
[(Characteristic)-8417(EQUIP (OB-302))]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 236.721 553.8001 Tm
0 0 0 1 k
-0.0002 Tc
(1)Tj
0.55582 0.00001 TD
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 313.1832 551.0501 Tm
0 0 0 1 k
-0.014 Tw
(CONQUER (OB-303))Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 384.7337 553.8001 Tm
0 0 0 1 k
-0.0002 Tc
(1)Tj
0.55582 0.00001 TD
(3)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
7.5 0 0 7.5 454.1906 551.0501 Tm
0 0 0 1 k
-0.014 Tw
(SEQUEL (OB-305))Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 518.2503 553.8001 Tm
0 0 0 1 k
-0.0002 Tc
(1)Tj
0.55582 0.00001 TD
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 54 535.0501 Tm
0 0 0 1 k
-0.014 Tw
(Age (years), mean (SD))Tj
14.11839 0.00001 TD
[(42.7 \(1)74(1.6\) )-11671(51.1 (10.4) )-15637(52 (10.3) )]TJ
-14.11839 -1.60001 TD
[(Female, %)-9355(2.8)-15292(70)-19609(66.7)]TJ
0 -1.6 TD
(Race, %)Tj
0.5 -1.6 TD
(white  )Tj
13.61839 0.00001 TD
0 Tw
[(9.9)-15292(86)-19609(85.8)]TJ
-13.61839 -1.60001 TD
-0.014 Tw
[(African American)-6021(17.7)-14736(12)-19609(12.7)]TJ
-0.5 -1.6 TD
-0.015 Tc
(BMI \(kg/m)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 87.0434 477.8001 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 89.748 475.0501 Tm
0 0 0 1 k
-0.014 Tw
[(\))15(,)15( )15(m)15(e)15(a)15(n)15( )15(\()15(r)15(a)15(n)15(g)15(e)15(\))-2701(42 (35.0-78.7))-10417(36.6 (32-41))-15289(36.1 (31.4-40.8))]TJ
-4.7664 -1.6 TD
(Other factors)Tj
14.11839 0.00001 TD
[(Personal Health Questionnaire-)-2763(Comorbidities:)-14332(Comorbidities: )]TJ
0.5 -1.2 TD
-0.0001 Tc
(9)Tj
0.81985 0 Td
0 Tc
[(score, mean 2.8)-8721(hypertension)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 331.6791 456.8001 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 334.4586 454.0501 Tm
0 0 0 1 k
-0.0001 Tc
(:)Tj
0.54182 0 Td
0 Tc
[(52.4%)-11250(hypertension)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 487.083 456.8001 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 489.8625 454.0501 Tm
0 0 0 1 k
-0.0001 Tc
(:)Tj
0.54182 0 Td
0 Tc
(50.5%)Tj
-27.35681 -1.2 TD
(hypertriglyceridemia)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 355.8289 447.8001 Tm
0 0 0 1 k
(b)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 358.8831 445.0501 Tm
0 0 0 1 k
-0.0001 Tc
(:)Tj
0.54182 0 Td
0 Tc
[(36.1%)-7993(hypertriglyceridemia)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 511.2327 447.8001 Tm
0 0 0 1 k
(b)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 514.2869 445.0501 Tm
0 0 0 1 k
-0.0001 Tc
(:)Tj
0.54182 0 Td
0 Tc
(34.1%)Tj
-30.61341 -1.2 TD
-0.014 Tw
[(impaired glucose tolerance or impaired )-3289(T2DM)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 464.5646 438.8001 Tm
0 0 0 1 k
(c)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 467.3442 436.0501 Tm
0 0 0 1 k
-0.0001 Tc
(:)Tj
0.54182 0 Td
0 Tc
(21.5%)Tj
-23.85438 -1.2 TD
-0.014 Tw
[(fasting glucose (including T2DM): 68%)-3163(metabolic syndrome: 66.8%)]TJ
-0.5 -1.2 TD
0 Tw
(T2DM)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 309.1608 420.8001 Tm
0 0 0 1 k
(c)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 311.9403 418.0501 Tm
0 0 0 1 k
-0.0001 Tc
(:)Tj
0.54182 0 Td
0 Tc
(15.8%)Tj
-3.63386 -1.2 TD
-0.014 Tw
(abdominal obesity)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 349.0761 411.8001 Tm
0 0 0 1 k
(d)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 352.1303 409.0501 Tm
0 0 0 1 k
-0.0001 Tc
(:)Tj
0.54182 0 Td
0 Tc
(98.3%)Tj
ET
0.5 w 
0 0 0 1 K
51 393.8 m
543 393.8 l
S
BT
/F20 1 Tf
7.5 0 0 7.5 285 400.0501 Tm
<B3>Tj
/F1 1 Tf
0.54882 0 Td
-0.014 Tw
(Comorbidities: 51.3%)Tj
-31.34883 -2.4 TD
(BMI = body mass index; T2DM = type 2 diabetes mellitus.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 54 374.8001 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 56.75 372.0501 Tm
0 0 0 1 k
-0.014 Tw
(Defined as systolic blood pressure 140-160 m)Tj
20.19815 0 TD
(m)Tj
1.03276 0 TD
(Hg or diastolic blood pressure 90-100 m)Tj
17.64125 0 TD
(m)Tj
1.03277 0 TD
(Hg, or controlled \(<140/90 m)Tj
12.64096 0 TD
[(m)-200(Hg\) with 2 or more anti-)]TJ
-52.54589 -1.20002 TD
(hypertensive drugs.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 54 355.8001 Tm
0 0 0 1 k
(b)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 57.0542 353.0501 Tm
0 0 0 1 k
-0.014 Tw
(Defined as fasting triglycerides greater than 200-400 mg/dL or receiving treatment with 2 or more lipid-lowering agents. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 54 345.8001 Tm
0 0 0 1 k
(c)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 56.7851 343.0501 Tm
0 0 0 1 k
0.001 Tc
0.013 Tw
(Defined as fasting blood glucoses >100 mg/dL, blood glucoses greater than 140 mg/dL 2 hours after an oral glucose tolerance test, or diagnosed)Tj
-0.37135 -1.2 TD
-0.001 Tc
-0.027 Tw
[(T2DM managed with lifestyle changes or metformin monotherapy)74(. For SEQUEL, T2DM was defined as fasti)-1(ng blood glucoses )]TJ
/F20 1 Tf
55.29507 0 Td
0 Tc
<B3>Tj
/F1 1 Tf
0.47373 0 Td
-0.001 Tc
(126 mg/dL or 2-hour)Tj
-55.7688 -1.2 TD
0 Tc
-0.014 Tw
(blood glucoses )Tj
/F20 1 Tf
6.919 0 Td
<B3>Tj
/F1 1 Tf
0.54883 0 Td
(200 mg/dL after oral-glucose-tolerance tests. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
5 0 0 5 54 317.8001 Tm
0 0 0 1 k
(d)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.5 0 0 7.5 57.0542 315.0501 Tm
0 0 0 1 k
-0.014 Tw
(Defined as waist circumference of at least 102 cm for men and at least 88 cm for women. )Tj
ET
0.5 w 
0 0 0 1 K
50.75 307.648 492.5 271.721 re
s
Q

endstream
endobj
11 0 obj
<<
/Length 14611
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
Q
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 50.5 726.0132 Tm
0 0 0 1 k
-0.012 Tc
0.012 Tw
(nephrolithiasis occurred in participants treated with high-)Tj
0 -1.24762 TD
-0.003 Tc
0.003 Tw
(dose PHEN/TPM.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 126.5644 716.2132 Tm
0 0 0 1 k
-0.001 Tc
(13)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 135.1593 712.9131 Tm
0 0 0 1 k
-0.003 Tc
0.003 Tw
[(T)70(o monitor for hypokalemia and re-)]TJ
-8.06279 -1.24763 TD
-0.0163 Tc
(d)Tj
0.48367 -0.00001 TD
-0.016 Tc
0.006 Tw
(uce the risk for nephrolithiasis, a blood chemistry profile)Tj
-0.48367 -1.24761 TD
-0.034 Tc
0.023 Tw
(should be collected at baseline before initiating PHEN/TPM)Tj
0 -1.24762 TD
-0.025 Tc
0.013 Tw
[(and periodically thereafter)55(.)]TJ
1 -1.22381 TD
-0.024 Tc
0.023 Tw
(Because the area under the curve of PHEN/TPM can be)Tj
-1 -1.22381 TD
0 Tc
0 Tw
[(increased by mild hepatic and renal impair)-25(ment, careful)]TJ
T*
-0.004 Tc
0.004 Tw
(monitoring of hepatic and renal function is warranted. If)Tj
T*
0 Tc
0.028 Tw
(PHEN/TPM is used in persons with mild or worse than)Tj
T*
-0.003 Tc
0.003 Tw
(mild hepatic or renal function, careful monitoring of ad-)Tj
T*
-0.025 Tc
0.013 Tw
(verse events is needed. )Tj
1 -1.22381 TD
-0.029 Tc
0.014 Tw
[(I)-15(n)-15( )-15(a)-15(d)-15(d)-15(i)-15(t)-15(i)-15(o)-15(n)-15( )-15(to blood chemistry profiles, regular measure-)]TJ
-1 -1.22381 TD
-0.036 Tc
0.021 Tw
(ment of resting heart rate during treatment with PHEN/TPM)Tj
T*
-0.038 Tc
0.023 Tw
(is recommended.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 116.4556 561.2631 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 121.6942 557.9631 Tm
0 0 0 1 k
-0.038 Tc
0.023 Tw
[(The phenter)-25(mine component of high-)-75(dose)]TJ
-6.7804 -1.22381 TD
-0.029 Tc
0.014 Tw
(PHEN/TPM increased resting heart rate by 1.2 beats/min in)Tj
T*
-0.02 Tc
0.005 Tw
(the EQUIP study compared with placebo (p = 0.0830) and)Tj
T*
-0.038 Tc
0.023 Tw
(by 1.7 beats/min in the CONQUER and SEQUEL studies \(p)Tj
-0.015 Tc
(<)'
0.86608 0 Td
0.082 Tw
(0.0001 vs placebo\).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 140.5538 509.863 Tm
0 0 0 1 k
-0.014 Tc
[(1)-1(2)-24(-14)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 157.5802 506.5631 Tm
0 0 0 1 k
-0.015 Tc
0.082 Tw
(The clinical significance of in)Tj
11.80244 0.00001 TD
0 Tc
(-)Tj
-22.00055 -1.22383 TD
-0.015 Tc
0.049 Tw
(creased heart rate is unknown, especially in patients with)Tj
0 -1.22381 TD
-0.04 Tc
0.013 Tw
(chronic cardiac conditions. Regardless, patients should be ed-)Tj
T*
-0.015 Tc
0.062 Tw
[(ucated to infor)-25(m health care providers if they experience)]TJ
T*
-0.04 Tc
0.013 Tw
(heart palpitations while resting. )Tj
1 -1.22381 TD
-0.03 Tc
0.02 Tw
(Other safety considerations for PHEN/TPM include mis-)Tj
-1 -1.22381 TD
-0.01 Tc
0.092 Tw
[(use, abuse, and overdose potential, given phenter)-25(mine\325)55(s)]TJ
T*
0.093 Tw
(structural similarity to amphetamine.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 204.6626 419.913 Tm
0 0 0 1 k
-0.009 Tc
(5,7)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 215.4802 416.613 Tm
0 0 0 1 k
-0.01 Tc
0.093 Tw
(PHEN/TPM is a)Tj
-15.7124 -1.22381 TD
0.046 Tw
(Schedule IV drug under the FDA Controlled Substances)Tj
T*
-0.035 Tc
0.023 Tw
(Act, meaning abuse of the drug may lead to limited physical)Tj
T*
0.013 Tw
(dependence or psychological dependence. )Tj
1 -1.22381 TD
-0.014 Tc
(PHEN/TPM is contraindicated in patients with glauco)Tj
21.00065 0 TD
0 Tc
(-)Tj
-22.00065 -1.22381 TD
-0.0042 Tc
(ma)Tj
1.46348 0 Td
-0.004 Tc
0.004 Tw
(or hyperthyroidism, as well as during pregnancy and)Tj
-1.46348 -1.22381 TD
-0.025 Tc
0.013 Tw
(during or within 14 days following monoamine oxidase in)Tj
22.00057 0 TD
0 Tc
(-)Tj
-22.00057 -1.22381 TD
-0.017 Tc
0.017 Tw
(hibitor use.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 95.8046 329.963 Tm
0 0 0 1 k
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 101.3291 326.663 Tm
0 0 0 1 k
-0.017 Tc
0.017 Tw
(Due to an increased risk for cleft lip and cleft)Tj
-4.84087 -1.22381 TD
[(palate during the first trimester of pregnancy)65(, the FDA re-)]TJ
T*
-0.025 Tc
0.002 Tw
(cently classified PHEN/TPM in pregnancy category X.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 268.4357 304.263 Tm
0 0 0 1 k
-0.023 Tc
(10)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 276.5184 300.963 Tm
0 0 0 1 k
-0.025 Tc
(In)Tj
-21.52556 -1.22382 TD
-0.034 Tc
0.024 Tw
[(each Phase 3 trial, 2 for)-25(ms of birth control were required for)]TJ
0 -1.22381 TD
-0.024 Tc
0.014 Tw
(women of childbearing age. Even with strict study require-)Tj
T*
-0.023 Tc
0.013 Tw
(ments, 15 pregnancies were reported in women exposed to)Tj
T*
-0.01 Tc
0.079 Tw
(PHEN/TPM in the EQUIP study and 2 in the SEQUEL)Tj
0 -1.22382 TD
-0.013 Tc
0 Tw
[(study)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 74.3574 240.0128 Tm
0 0 0 1 k
-0.012 Tc
[(1)-1(2)-24(-14)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 90.7313 236.7128 Tm
0 0 0 1 k
-0.013 Tc
0.013 Tw
(Of these pregnancies, there were 3 spontaneous)Tj
-3.83155 -1.22381 TD
-0.003 Tc
0.003 Tw
(abortions, 3 elective abortions, and 9 healthy live births.)Tj
T*
-0.025 Tc
0.013 Tw
[(Congenital malfor)-25(mations were not observed.)]TJ
1 -1.22381 TD
-0.0084 Tc
(A)Tj
0.96351 0 Td
-0.008 Tc
0.008 Tw
(Risk Evaluation and Mitigation Strategy (REMS) is)Tj
-1.96351 -1.22381 TD
-0.006 Tc
0.006 Tw
(in place for PHEN)Tj
7.32509 0 TD
-0.021 Tc
(/TPM to discuss appropriate contracep-)Tj
-7.32509 -1.22381 TD
(tion and pregnancy test requirements, as well as to educate)Tj
T*
-0.025 Tc
0.01 Tw
(women on immediate discontinuation and reporting should)Tj
T*
-0.04 Tc
(pregnancy occur)Tj
5.99003 0.00001 TD
0 Tc
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 115.6003 150.0629 Tm
0 0 0 1 k
(5)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 120.675 146.7629 Tm
0 0 0 1 k
-0.0401 Tc
(A)Tj
0.90227 0 Td
-0.04 Tc
0.01 Tw
(pregnancy test is required at baseline be)Tj
14.41498 0.00001 TD
0 Tc
(-)Tj
-22.00058 -1.22382 TD
-0.021 Tc
0.005 Tw
(fore starting PHEN/TPM and monthly thereafter for all fe-)Tj
0 -1.22381 TD
-0.04 Tc
0.012 Tw
(males of childbearing age, defined as those who have not had)Tj
-0.0272 Tc
(a)'
0.6517 0 Td
-0.027 Tc
0 Tw
(hysterectomy)Tj
4.9967 0 TD
-0.0272 Tc
(,)Tj
0.4577 0 Td
-0.027 Tc
0.012 Tw
(bilateral oophorectomy)Tj
8.65313 0.00001 TD
-0.0272 Tc
(,)Tj
0.45775 0 Td
-0.027 Tc
(or medically docu-)Tj
-15.217 -1.2238 TD
-0.037 Tc
0.022 Tw
(mented spontaneous ovarian failure, and have not completed)Tj
T*
-0.039 Tc
0 Tw
(menopause.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 96.3107 85.8129 Tm
0 0 0 1 k
-0.038 Tc
(9,17)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 108.3534 82.5128 Tm
0 0 0 1 k
-0.039 Tc
0.024 Tw
[(Menopause should be confir)-25(med clinically by)]TJ
-5.5098 -1.2238 TD
-0.0216 Tc
(a)Tj
0.6573 0 Td
-0.022 Tc
0.007 Tw
[(health care provider)55(. More infor)-25(mation about prescribing)]TJ
-0.6573 -1.2238 TD
-0.027 Tc
0.012 Tw
(requirements, REMS training, and PHEN/TPM prescribing)Tj
T*
-0.04 Tc
0.013 Tw
[(requirements is available at www)65(.qsymia.com/hcp/.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 309 725.5415 Tm
0 0 0 1 k
-0.025 Tc
0.011 Tw
(Formulary Considerations)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 704.5165 Tm
0 0 0 1 k
-0.029 Tc
0.014 Tw
[(T)55(o)-15( )-15(d)-15(a)-15(t)-15(e)-15(,)-15( )-15(no clinical trials have directly compared PHEN/)]TJ
-1 -1.24047 TD
-0.036 Tc
0.021 Tw
[(TPM with other weight-loss medications. Consequently)65(, any)]TJ
T*
-0.032 Tc
0.017 Tw
[(comparison of phar)-25(macotherapy-induced weight loss across)]TJ
0 -1.24048 TD
-0.04 Tc
0.006 Tw
[(trials has inherent limitations, most notably dif)20(ferences in trial)]TJ
0 -1.24047 TD
0.012 Tw
[(design, length, and patient populations. W)40(ith these limitations)]TJ
0 -1.24048 TD
-0.015 Tc
(in mind, some general comparisons can be made between)Tj
0 -1.24047 TD
-0.04 Tc
0.013 Tw
(PHEN/TPM and other weight-loss agents. )Tj
1 -1.24048 TD
-0.006 Tc
0.006 Tw
[(When compared with other long-ter)-25(m weight-loss op-)]TJ
-1 -1.24047 TD
-0.014 Tc
0.013 Tw
(tions, PHEN/TPM has generally resulted in similar or su-)Tj
T*
-0.025 Tc
0.02 Tw
[(perior weight reductions after 1 year of therapy)65(. Specifical-)]TJ
0 -1.24048 TD
0 Tc
0.031 Tw
[(ly)65(, orlistat 120 mg 3 times daily for 1 year resulted in a)]TJ
0 -1.24047 TD
-0.009 Tc
0.008 Tw
(9.6% weight loss compared with 5.6% with placebo \(p <)Tj
T*
0 Tc
0.012 Tw
(0.001\), for a placebo-subtracted weight loss of 4%. The)Tj
T*
-0.04 Tc
0 Tw
[(p)-15(r)-15(o)-15(p)-15(o)-15(r)-15(t)-15(i)-15(o)-15(n)-15( )-15(o)-15(f)-15( )-15(p)-15(a)-15(t)-15(i)-15(e)-15(n)-15(ts achieving 5% or more weight loss was)]TJ
T*
-0.015 Tc
0.159 Tw
(also greater with orlistat (73%) compared with placebo)Tj
T*
-0.028 Tc
0.012 Tw
((45%; p < 0.001).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 378.9391 512.4416 Tm
0 0 0 1 k
-0.025 Tc
(18)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 387.0773 509.1416 Tm
0 0 0 1 k
-0.028 Tc
0.012 Tw
(Lorcaserin 10 mg twice daily for 1 year)Tj
-7.43593 -1.24047 TD
-0.021 Tc
0.006 Tw
[(resulted in 5.8% \(\261)15(7.8%\) weight loss compared with 2.2%)]TJ
0 -1.24048 TD
-0.023 Tc
0.008 Tw
[<28B1>15(3.9%\) with placebo \(p < 0.001\), for a placebo-subtracted)]TJ
T*
-0.034 Tc
0.019 Tw
(weight loss of approximately 3.6%, on average. The propor)Tj
22.00069 0 TD
0 Tc
(-)Tj
-22.00069 -1.24048 TD
-0.023 Tc
0.008 Tw
(tion of patients achieving 5% or more weight loss with lor)Tj
22.00073 0 TD
0 Tc
(-)Tj
-22.00073 -1.24048 TD
-0.015 Tc
0.039 Tw
(caserin and placebo was 48% and 20%, respectively \(p <)Tj
0 -1.24047 TD
-0.028 Tc
0 Tw
(0.001\).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 336.6725 434.2916 Tm
0 0 0 1 k
-0.026 Tc
(19)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 344.8018 430.9916 Tm
0 0 0 1 k
-0.028 Tc
0.013 Tw
(In comparison with orlistat and lorcaserin, the per-)Tj
-3.40969 -1.24048 TD
-0.017 Tc
0.001 Tw
(cent placebo-subtracted weight loss achieved with PHEN/)Tj
T*
-0.023 Tc
0.008 Tw
(TPM may be modestly superior after 1 year of treatment at)Tj
T*
-0.028 Tc
0.013 Tw
[(approximately 9% for high-)-75(dose and approximately 7% for)]TJ
0 -1.24047 TD
-0.015 Tc
0 Tw
(mid-)Tj
1.90338 0 TD
0.026 Tw
(dose. Notably)Tj
5.32015 0.00001 TD
-0.0151 Tc
(,)Tj
0.49594 0 Td
-0.015 Tc
(baseline weight was generally similar)Tj
-7.71947 -1.24048 TD
0.097 Tw
(among these trials \(mean baseline weight approximately)Tj
0 -1.24047 TD
0 Tw
(100)Tj
1.52995 0 TD
0.032 Tw
(-103 kg\), except for the EQUIP study \(mean baseline)Tj
-1.52995 -1.24047 TD
-0.03 Tc
0.015 Tw
(weight approximately 1)Tj
8.83618 0.00001 TD
(15 kg\). Further)Tj
5.63355 0 TD
(more, across Phase 3)Tj
-14.46973 -1.24049 TD
-0.023 Tc
0.008 Tw
(clinical trials, the percentages of participants who achieved)Tj
0 -1.24047 TD
-0.027 Tc
0.012 Tw
(5% or more weight loss with PHEN/TPM were 69%, 62%,)Tj
T*
-0.024 Tc
0.009 Tw
(and 27.6% for high-)Tj
7.70327 0 TD
[(dose, mid-)-75(dose, and low-)-75(dose, respec-)]TJ
-7.70327 -1.24048 TD
-0.04 Tc
0 Tw
[(tively)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 331.9126 291.0167 Tm
0 0 0 1 k
-0.038 Tc
(12)Tj
0.9449 0.00001 TD
-0.039 Tc
(-14)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 347.1946 287.7166 Tm
0 0 0 1 k
-0.04 Tc
0.012 Tw
(PHEN/TPM may also be associated with fewer ad-)Tj
-3.63758 -1.24047 TD
0.013 Tw
(verse ef)Tj
2.80846 0.00001 TD
(fects compared with lorcaserin.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 457.6223 277.9917 Tm
0 0 0 1 k
-0.039 Tc
(19,20)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 261.6666 Tm
0 0 0 1 k
-0.024 Tc
0.024 Tw
(The average wholesale price \(A)Tj
12.01746 0 TD
(WP\) per unit for PHEN/)Tj
-13.01746 -1.24046 TD
-0.025 Tc
0.017 Tw
[(TPM varies from $4.80 for 3.75/23)-25(-mg capsules and $7.35)]TJ
0 -1.24048 TD
-0.02 Tc
0.02 Tw
(for 15/92-mg capsules.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 401.2613 238.9167 Tm
0 0 0 1 k
-0.018 Tc
(21)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 409.6437 235.6167 Tm
0 0 0 1 k
-0.02 Tc
0.02 Tw
(By comparison, Adipex-P \(phen-)Tj
-9.58511 -1.24048 TD
-0.001 Tc
0 Tw
[(ter)-25(mine\) A)80(WP per unit is approximately $2.00 to $2.50,)]TJ
0 -1.24047 TD
-0.021 Tc
0.021 Tw
(and the A)Tj
3.65768 0.00001 TD
(WP per unit of regular)Tj
8.59088 0.00001 TD
-0.022 Tc
(-release topiramate at dos)Tj
9.75203 0.00001 TD
0 Tc
(-)Tj
-22.00059 -1.2405 TD
-0.015 Tc
0.015 Tw
[(es of 25)-25(-100 mg varies between approximately $2.00 and)]TJ
0 -1.24047 TD
-0.004 Tc
0.004 Tw
($7.00, depending on package size. PHEN/TPM contains)Tj
0 -1.24048 TD
0 Tc
0.127 Tw
(extended-release topiramate, which is not available as)Tj
0 -1.24047 TD
0 Tw
(monotherapy)Tj
5.21093 0.00001 TD
-0.0001 Tc
(.)Tj
0.54453 0 Td
0 Tc
0.045 Tw
(The A)Tj
2.49133 0.00001 TD
(WP per unit of orlistat is $5.40 for)Tj
-8.24679 -1.24049 TD
-0.002 Tc
0 Tw
(120)Tj
1.56866 0.00001 TD
0.002 Tw
(-mg capsules and A)Tj
7.80202 0.00001 TD
(WP infor)Tj
3.70333 0.00001 TD
(mation for lorcaserin is)Tj
-13.074 -1.24049 TD
-0.025 Tc
0.013 Tw
(currently unavailable. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 309 103.3918 Tm
0 0 0 1 k
-0.025 Tc
(Summary)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 319.5 82.4418 Tm
0 0 0 1 k
-0.025 Tc
0.008 Tw
(PHEN/TPM should be avoided or carefully initiated and)Tj
-1 -1.23333 TD
-0.02 Tc
0.02 Tw
(monitored in patient populations excluded in clinical trials)Tj
T*
-0.009 Tc
0.009 Tw
(until further postmarketing safety data become available.)Tj
0 -1.23334 TD
-0.01 Tc
0.01 Tw
[(Further)-25(more, caution should be exercised when prescrib-)]TJ
ET
0 0 0 0 k
308.5 740.1929 235 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8.4 0 0 8 366.993 744.7228 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Phenter)-25(mine/T)90(opiramate for the T)35(reatment of Obesity)]TJ
ET
0 0 0 0 k
157.5 15.444 386 13.08 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 269.1412 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 402.2662 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 415.4473 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 515.819 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 529 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(347)Tj
ET
0 0 0 0 k
50.5 16.524 79.5 11.669 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 50.5 21.3551 Tm
0 0 0 1 k
-0.025 Tc
(theannals.com)Tj
ET
Q

endstream
endobj
12 0 obj
<<
/Length 16372
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
Q
/GS1 gs
q
BT
/F2 1 Tf
10.5 0 0 10.5 50.5 726.0132 Tm
0 0 0 1 k
-0.023 Tc
0.023 Tw
(ing PHEN/TPM for the elderly or for patients with mild to)Tj
0 -1.23333 TD
-0.025 Tc
0.004 Tw
[(moderate hepatic or renal impair)-25(ment. PHEN/TPM has not)]TJ
T*
0.015 Tw
(been studied in patients on insulin or sulfonylureas. Conse-)Tj
0 -1.23334 TD
0.022 Tw
[(quently)65(, as patients lose weight, antidiabetic and antihyper-)]TJ
0 -1.23333 TD
0.002 Tw
(tensive regimens may need to be adjusted to prevent poten-)Tj
T*
0.013 Tw
(tial hypoglycemia or hypotension.)Tj
1 -1.21905 TD
0 Tc
0.135 Tw
[(Future studies evaluating the ef)20(ficacy and safety of)]TJ
-1 -1.21905 TD
0.021 Tw
(PHEN/TPM in the elderly and in men, as well as in pa-)Tj
0 -1.21904 TD
-0.025 Tc
0.011 Tw
(tients with significant depression, cardiac, or cerebrovascu-)Tj
0 -1.21905 TD
0 Tc
0.146 Tw
(lar disease are needed. Head-to-head trials comparing)Tj
T*
0.171 Tw
[(long-ter)-25(m phar)-25(macologic interventions \(ie, lorcaserin,)]TJ
0 -1.21904 TD
-0.001 Tc
0.001 Tw
[(PHEN/TPM, orlistat\) and sur)20(gical interventions \(eg, lap)]TJ
0 -1.21905 TD
-0.025 Tc
0.013 Tw
[(banding, bariatric sur)20(gery\) may further guide practitioners.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8.5 0 0 8.5 50.5 547.7632 Tm
0 0 0 1 k
-0.016 Tc
-0.012 Tw
(Steven M Smith)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 113.7215 547.7632 Tm
0 0 0 1 k
-0.016 Tc
-0.012 Tw
[(PharmD MPH, Assistant Professor)55(, Department of)]TJ
-7.90269 -1.1125 TD
-0.006 Tc
-0.022 Tw
[(Clinical Pharmacy)74(, School of Pharmacy)74(, University of Colorado, Au)-1(-)]TJ
T*
0 Tc
0 Tw
(rora)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8.5 0 0 8.5 50.5 519.0632 Tm
0 0 0 1 k
0.009 Tc
0.005 Tw
(Melissa Meyer)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 111.516 519.0632 Tm
0 0 0 1 k
0.009 Tc
0.005 Tw
(PharmD, Pharmacy Practice Resident, Exempla)Tj
-7.627 -1.1125 TD
0 Tc
-0.014 Tw
[(Saint Joseph Hospital, Denver)55(, CO)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8.5 0 0 8.5 50.5 499.2632 Tm
0 0 0 1 k
-0.007 Tc
-0.021 Tw
[(Katy E T)55(rinkley)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 112.2505 499.2632 Tm
0 0 0 1 k
-0.007 Tc
-0.021 Tw
[(PharmD, Assistant Professor)55(, Department of Clin-)]TJ
-7.71881 -1.1125 TD
0 Tc
-0.014 Tw
(ical Pharmacy)Tj
6.18996 0 TD
-0.0001 Tc
(,)Tj
0.5419 0 Td
0 Tc
(School of Pharmacy)Tj
8.84441 0 TD
-0.0001 Tc
(,)Tj
0.54188 0 Td
0 Tc
(University of Colorado )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8.5 0 0 8.5 50.5 479.4632 Tm
0 0 0 1 k
(Correspondence:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 122.9669 479.4632 Tm
0 0 0 1 k
-0.014 Tw
[(Dr)55(. T)36(rinkley)74(, katy)74(.trinkley@ucdenver)55(.edu)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8.5 0 0 8.5 50.5 468.5632 Tm
0 0 0 1 k
-0.031 Tc
-0.007 Tw
(Reprints/Online Access:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 144.562 468.5632 Tm
0 0 0 1 k
-0.031 Tc
[(www)55(.theannals.com/cgi/reprint/aph.1R501)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
8.5 0 0 8.5 50.5 453.6632 Tm
0 0 0 1 k
-0.014 Tw
(Conflict of interest:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 130.2657 453.6632 Tm
0 0 0 1 k
-0.014 Tw
(Authors reported none)Tj
-9.97071 -1.8625 TD
-0.01 Tc
-0.018 Tw
[<A9>-250(1967-2013 Harvey Whitney Books Co. All rights reserved. No part)]TJ
0 -1.1125 TD
0.003 Tc
0.011 Tw
(of this document may be reproduced or transmitted in any form or)Tj
T*
0.009 Tc
0.005 Tw
(by any means without prior written permission of Harvey Whitney)Tj
T*
-0.017 Tc
-0.011 Tw
(Books Co. For reprints of any article appearing in )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F5 1 Tf
8 0 0 8 218.9647 412.0632 Tm
0 0 0 1 k
-0.017 Tc
-0.011 Tw
(The Annals)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 258.008 412.0632 Tm
0 0 0 1 k
-0.0167 Tc
(,)Tj
0.51144 0 Td
-0.017 Tc
(please)Tj
-26.44994 -1.1125 TD
0 Tc
-0.014 Tw
(contact 415sales@hwbooks.com)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
10.5 0 0 10.5 50.5 375.1632 Tm
0 0 0 1 k
-0.025 Tc
(References )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 54.3757 357.3632 Tm
0 0 0 1 k
-0.016 Tc
0.016 Tw
[(1.)-484(Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and)]TJ
1.20304 -1.225 TD
-0.004 Tc
0.004 Tw
[(trends in the distribution of body mass index among US adults, 1999)-25(-)]TJ
T*
-0.025 Tc
0.013 Tw
[(2010. JAMA 2012;307:491)50(-7. )]TJ
-1.20805 -1.35 TD
-0.021 Tc
0.021 Tw
[(2.)-479(Centers for Disease Control and Prevention. Obesity and overweight for)]TJ
1.20805 -1.225 TD
-0.024 Tc
0.024 Tw
[(professionals: childhood data. www)65(.cdc.gov/obesity/data/childhood.html)]TJ
T*
-0.025 Tc
0.013 Tw
((accessed 2012 Jul 21). )Tj
-1.20477 -1.35 TD
-0.017 Tc
0.017 Tw
[(3.)-483(National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines)]TJ
1.20477 -1.22499 TD
-0.025 Tc
0.011 Tw
(on the identification, evaluation, and treatment of overweight and obesity)Tj
0 -1.225 TD
-0.021 Tc
0.021 Tw
[(in adults, 1998. www)65(.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf \(ac-)]TJ
T*
-0.025 Tc
0.013 Tw
(cessed 2012 Aug 20\).)Tj
-1.2125 -1.35 TD
0.019 Tw
[(4.)-475(Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in)]TJ
1.2125 -1.225 TD
0.013 Tw
[(obesity among US adults, 1999)-25(-)-25(2008. JAMA 2010;303:235)-24(-)-125(41.)]TJ
-1.19594 -1.35 TD
-0.009 Tc
0.008 Tw
[(5)-1(.)-493(Qnexa New Drug Application. Department of Health and Human Ser-)]TJ
1.19594 -1.225 TD
-0.023 Tc
0.023 Tw
[(vices: 2010. www)65(.fda.gov/downloads/AdvisoryCommittees/Committees)]TJ
T*
-0.005 Tc
0 Tw
(MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory)Tj
T*
-0.025 Tc
0.013 Tw
(Committee/UCM292317.pdf (accessed 2012 Jul 10). )Tj
-1.20531 -1.35001 TD
-0.018 Tc
0 Tw
(6.)Tj
1.19655 0.00001 TD
0.018 Tw
(Food and Drug Administration. FDA drug safety communication: com)Tj
27.30121 0.00001 TD
0 Tc
(-)Tj
-27.29245 -1.22501 TD
0.023 Tw
(pleted safety review of Xenical/Alli (orlistat) and severe liver injury)Tj
27.375 0.00001 TD
(.)Tj
-27.375 -1.225 TD
-0.017 Tc
0 Tw
(www)Tj
2.05085 0.00001 TD
(.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfor)Tj
21.44795 0.00001 TD
(mationfor)Tj
3.79366 0.00001 TD
0 Tc
(-)Tj
-27.29246 -1.22503 TD
-0.025 Tc
0.013 Tw
(PatientsandProviders/ucm213038.htm (accessed 2012 Jul 20).)Tj
-1.19543 -1.34999 TD
-0.008 Tc
0 Tw
(7.)Tj
1.22621 0.00001 TD
0.008 Tw
(Product infor)Tj
5.2335 0.00001 TD
[(mation. Adipex-p \(phenter)-25(mine\). Sellersville, P)90(A: TEV)130(A)]TJ
-5.26429 -1.22502 TD
-0.025 Tc
0 Tw
(Phar)Tj
1.75741 0.00001 TD
0.013 Tw
(maceuticals, July 2005.)Tj
-2.9613 -1.35001 TD
-0.016 Tc
0.016 Tw
[(8.)-484(Langlois KJ, Forbes JA, Bell GW)90(, et al. A double-blind clinical evalua-)]TJ
1.20389 -1.225 TD
-0.014 Tc
0.014 Tw
[(tion of the safety and ef)20(ficacy of phenter)-25(mine hydrochloride (Fastin) in)]TJ
T*
-0.025 Tc
0.013 Tw
[(the treatment of exogenous obesity)65(. Curr Ther Res 1974;16:289)-25(-96.)]TJ
-1.2125 -1.35 TD
0.01 Tw
[(9.)-475(Product infor)-25(mation. Qsymia \(phenter)-25(mine/topiramate\). W)40(inchester)40(, KY)90(:)]TJ
1.2125 -1.225 TD
0.013 Tw
(VIVUS Inc., July 2012.)Tj
-1.6875 -1.35 TD
0.004 Tw
[(10.)-475(Product infor)-25(mation. T)70(opamax (topiramate). T)35(itusville, NJ: Janssen Phar-)]TJ
1.6875 -1.225 TD
0.013 Tw
(maceuticals, January 2009. )Tj
-1.6875 -1.35 TD
0 Tc
(1)Tj
0.4484 0 TD
-0.016 Tc
0 Tw
(1.)Tj
1.2006 0 TD
-0.017 Tc
0.016 Tw
(Ben-Menachem E, Axelsen M, Hohanson EH, Stagge A, Smith U. Pre)Tj
27.33079 0.00001 TD
0 Tc
(-)Tj
-27.2923 -1.225 TD
-0.005 Tc
0.005 Tw
(dictors of weight loss in adults with topiramate-treated epilepsy)Tj
25.08986 0.00001 TD
(.)Tj
0.49495 0 Td
0 Tw
(Obes)Tj
-25.5848 -1.225 TD
-0.025 Tc
0.013 Tw
(Res 2003;1)Tj
4.2549 0 TD
0 Tw
(1:556)Tj
2.1777 0 TD
0 Tc
(-)Tj
0.3827 0 TD
-0.025 Tc
(62. )Tj
23.80964 85.51994 TD
-0.019 Tc
0.019 Tw
[(12.)-481(Allison D, Gadde K, Garvey WT)75(, et al. Controlled release phenter)-25(mine/)]TJ
1.6875 -1.22813 TD
-0.04 Tc
0.012 Tw
(topiramate in severely obese adults: a randomized, controlled trial (EQUIP).)Tj
T*
-0.025 Tc
0.013 Tw
[(O)15(besity 201)35(1;20:330)-75(-)-125(42. )]TJ
-1.6875 -1.35313 TD
-0.009 Tc
0.009 Tw
[(13.)-491(Gadde K, Allison D, R)40(yan D, et al. Ef)20(fects of low-)-75(dose, controlled-re-)]TJ
1.6875 -1.22813 TD
-0.021 Tc
0.021 Tw
[(lease, phenter)-25(mine plus topiramate combination on weight and associat-)]TJ
T*
-0.005 Tc
0.005 Tw
(ed comorbidities in overweight and obese adults (CONQUER): a ran-)Tj
T*
-0.025 Tc
0.013 Tw
[(domized, placebo-controlled, phase 3 trial. Lancet 201)35(1;377:1341)50(-52. )]TJ
-1.6875 -1.35313 TD
-0.007 Tc
0.007 Tw
[(14.)-493(Garvey T)75(, R)40(yan D, Look M, et al. T)70(wo-year sustained weight loss and)]TJ
1.6875 -1.22813 TD
0 Tc
0.009 Tw
[(metabolic benefits with controlled release phenter)-25(mine/topiramate in)]TJ
T*
-0.003 Tc
0.003 Tw
(obese and overweight adults (SEQUEL): a randomized, placebo-con-)Tj
T*
-0.025 Tc
0.013 Tw
[(trolled, phase 3 extension study)65(. Am J Clin Nutr 2012;95:297-)-25(308. )]TJ
-1.6875 -1.35312 TD
-0.011 Tc
0.011 Tw
[(15.)-489(Brownell KD. The LEARN program for weight management. 10th ed.)]TJ
1.6875 -1.22813 TD
-0.025 Tc
0.013 Tw
[(Dallas, TX: American Health Publishing Company)65(, 2004. )]TJ
-1.6875 -1.35313 TD
-0.022 Tc
0.007 Tw
[(1)-15(6)-15(.)-508(S)-16(imons-Morton DG, Obarzanek E, Cutler JA. Obesity research\321limita)1(-)]TJ
1.6875 -1.22813 TD
-0.04 Tc
0.008 Tw
[(tions of methods, measurements, and medications. JAMA 2006;295: 826)-25(-)-25(8. )]TJ
-1.6875 -1.35313 TD
-0.034 Tc
0.023 Tw
[(1)-11(7)-11(.)-488(Product infor)-25(mation. Qsymia \(phenter)-25(mine/topiramate CR\). www)66(.qsymia.)]TJ
1.6875 -1.22813 TD
-0.025 Tc
0.013 Tw
(com/hcp/ (accessed 2012 Sept 21). )Tj
-1.6875 -1.35312 TD
-0.019 Tc
0.019 Tw
[(18.)-481(T)71(o)1(r)21(gerson JS, Hauptman J, Boldrin MN, et al. Xenical in the prevention)]TJ
1.6875 -1.22813 TD
-0.011 Tc
0.01 Tw
(of diabetes in obese subjects (XENDOS) study: a randomized study of)Tj
T*
-0.025 Tc
0.022 Tw
(orlistat as an adjunct to lifestyle changes for the prevention of type 2 dia-)Tj
T*
0.013 Tw
[(betes in obese patients. Diabetes Care 2004;27:155)-25(-)-75(61. )]TJ
-1.6875 -1.35313 TD
-0.001 Tc
0.001 Tw
[(19.)-499(Smith SR, W)80(eissman NJ, Anderson CM, et al. Multi-center)40(, placebo-)]TJ
1.6875 -1.22813 TD
0 Tc
0.061 Tw
(controlled trial of lorcaserin for weight management. N Engl J Med)Tj
T*
-0.025 Tc
0 Tw
[(2010;363:245)-25(-56. )]TJ
-1.6875 -1.35313 TD
0.025 Tw
[(20.)-475(Hurr)-25(ne KM, Berlie HD. Lorcaserin: an investigational serotonin 2C ago-)]TJ
1.6875 -1.22812 TD
0.013 Tw
[(nist for weight loss. Am J Health Syst Phar)-25(m 201)35(1;68:2029)-25(-)-24(37. )]TJ
-1.6875 -1.35313 TD
0 Tc
0.115 Tw
[(21.)-500(Micromedex Healthcare Series. Greenwood V)60(illage, CO: Thomson)]TJ
1.6875 -1.22812 TD
-0.025 Tc
0.013 Tw
(Reuters (Healthcare) Inc. (accessed 2012 Sept 25).)Tj
ET
1 w 
0 0 0 1 K
363 432.448 m
489.5 432.448 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
7.5 0 0 7.5 309 407.9478 Tm
0 0 0 1 k
-0.025 Tc
[(EXTRACT)20(O)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9 0 0 9 309 392.9478 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(Fenter)-25(mina/T)70(opiramato (Qsymia) Para el T)35(ratamiento de Obesidad)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 309 378.9478 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
(SM Smith, M Meyer)Tj
7.90496 0 TD
-0.0251 Tc
(,)Tj
0.46234 0 Td
-0.025 Tc
(KE T)Tj
2.0711 0 TD
0 Tw
(rinkley)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
8 0 0 8 309 362.9478 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Ann Phar)-25(macother)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 369.0947 362.9478 Tm
0 0 0 1 k
-0.025 Tc
[(2013;47:340)-75(-9.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 309 349.4478 Tm
0 0 0 1 k
-0.024 Tc
[(OBJETIV)21(O)-2(:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 342.55 349.4478 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(Revisar la far)-25(macolog\222a, eficacia y seguridad de)]TJ
-3.94705 -1.11764 TD
0 Tw
(fenter)Tj
2.20595 0 TD
0.012 Tw
(mina/topiramato (PHEN/TPM) en el manejo de pacientes obesos.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 309 327.4478 Tm
0 0 0 1 k
-0.024 Tc
0.013 Tw
[(FUENTES DE DA)76(T)20(O)-1(S)-1(:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 369.7143 327.4478 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Se realiz\227 una revisi\227n de la literatura mediante el)Tj
-7.14286 -1.11765 TD
[(sistema de base de datos MEDLINE \(1966)-25(-julio 2012\) utilizando los)]TJ
0 -1.11764 TD
0 Tw
(t\216r)Tj
1.00434 0.00001 TD
0.012 Tw
(minos; p\216rdida de peso, obesidad, fenter)Tj
15.22018 0 TD
(mina y topiramato,)Tj
-16.22451 -1.11766 TD
[(fenter)-25(mina, topiramato, Qnexa, Qsymia, y VI-)-100(0521. T)70(ambi\216n se estudi\227)]TJ
0 -1.11764 TD
[(la infor)-25(maci\227n sometida para solicitar la aprobaci\227n de el uso como una)]TJ
0 -1.11765 TD
[(nueva droga y la infor)-25(maci\227n de prescripci\227n del producto.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 309 267.4478 Tm
0 0 0 1 k
-0.024 Tc
0.013 Tw
[(SELECCI\356N DE ESTUDIOS Y DA)76(T)20(O)-1(S)-1(:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 413.2511 267.4478 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Se revisaron todos los estudios que)Tj
-12.26483 -1.11764 TD
(consideraron la far)Tj
7.06975 0.00001 TD
(macolog\222a, eficacia y seguridad de PHEN/TPM)Tj
-7.06975 -1.11766 TD
(enfocando en los datos de eficacia y seguridad de los estudios fase III.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 309 235.9478 Tm
0 0 0 1 k
-0.024 Tc
0.013 Tw
[(S\352NTESIS DE LOS DA)76(T)20(O)-1(S)-1(:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 381.883 235.9478 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(En tres estudios fase III \(EQUIP)110(, CONQUER, y)]TJ
-8.57447 -1.11764 TD
(SEQUEL\), el tratamiento con PHEN/TPM demostr\227 en for)Tj
22.47104 0.00001 TD
[(ma unifor)-25(me)]TJ
-22.47104 -1.11766 TD
(una p\216rdida de peso estad\222sticamente significativa comparada con el)Tj
0 -1.11764 TD
(placebo. Despu\216s de 56 semanas de tratamiento, el porciento de p\216rdida)Tj
T*
(de peso que se logr\227 con PHEN/TPM fue de 10.6%, 8.4%, y 5.1% con)Tj
0 -1.11765 TD
(las dosis de 15/92 mg, 7.5/46 mg y 3.75/23 mg, respectivamente \(p <)Tj
0 -1.11764 TD
(0.0001\). La extensi\227n del estudio, que fue de 52 semanas \(SEQUEL\),)Tj
T*
(demostr\227 que la p\216rdida de peso se mantuvo sobre 2 a\226os, y que el peso)Tj
0 -1.11765 TD
(se redujo entre 9.3% y 10.5% con las dosis de 7.5/46 mg y 15/92 mg de)Tj
0 -1.11764 TD
(PHEN/TPM (p<0.0001). Un n\234mero significativamente m\207s alto de)Tj
T*
(pacientes tratados con PHEN/TPM obtuvo una p\216rdida de peso mayor)Tj
0 -1.11765 TD
(de 5%, 10% o 15% comparado con el placebo. Se obtuvieron)Tj
0 -1.11764 TD
(reducciones significativas en la circunferencia de la cintura,)Tj
T*
(concentraciones de triglic\216ridos, y de glucosa en ayunas, las cuales se)Tj
0 -1.11765 TD
(relacionaron a PHEN/TPM. PHEN/TPM fue generalmente bien tolerado)Tj
0 -1.11764 TD
(en los estudios cl\222nicos. Las reacciones adversas que ocurrieron en >5%)Tj
T*
(de los pacientes estudiados incluyeron parestesias, mareos, boca seca,)Tj
T*
(disguesia o alteraci\227n en el sentido del gusto, insomnio, y estre\226imiento.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 309 61.9478 Tm
0 0 0 1 k
-0.024 Tc
(CONCLUSIONES:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 359.0652 61.9478 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(PHEN/TPM es un nuevo producto de combinaci\227n para)Tj
-5.89002 -1.11764 TD
(bajar de peso, que se administra una vez al d\222a, se libera en for)Tj
23.57771 0.00001 TD
0 Tw
(ma)Tj
-23.57771 -1.11765 TD
0.012 Tw
(controlada y se aprob\227 como tratamiento adjunto a dieta y ejercicio para)Tj
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 50.5 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(348)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 74.2499 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 87.431 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 220.5559 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 233.737 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
/F8 1 Tf
10 0 0 10 488.4582 21.6616 Tm
0 0 0 1 k
0 Tw
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F21 1 Tf
8 0 0 8 50.5 744.7228 Tm
0 0 0 1 k
-0.013 Tw
[(SM)-250(Smith et al.)]TJ
ET
Q

endstream
endobj
13 0 obj
<<
/Length 6963
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 36.5269 493 696.6661 re
f
308.5 740.1929 235 10 re
f
Q
/GS1 gs
q
BT
/F21 1 Tf
8.4 0 0 8 366.993 744.7228 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Phenter)-25(mine/T)90(opiramate for the T)35(reatment of Obesity)]TJ
ET
0 0 0 0 k
157.5 15.444 386 13.08 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 269.1412 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 402.2662 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 415.4473 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(2013 Mar)35(ch, V)110(olume 47    )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F7 1 Tf
5 0 0 5 515.819 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
10 0 0 10 529 21.6856 Tm
0 0 0 1 k
-0.024 Tc
(349)Tj
ET
0 0 0 0 k
50.5 16.524 79.5 11.669 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
10 0 0 10 50.5 21.3551 Tm
0 0 0 1 k
-0.025 Tc
(theannals.com)Tj
ET
0 0 0 0 k
50.5 480.378 493 252.815 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 50.5 727.3808 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(el manejo cr\227nico de peso en pacientes obesos o en sobrepeso con)Tj
0 -1.11765 TD
(comorbilidades relacionadas al peso. PHEN/TPM es moderadamente)Tj
0 -1.11764 TD
-0.0251 Tc
(e)Tj
0.41891 -0.00001 TD
-0.025 Tc
(fectivo y es una opci\227n viable para pacientes interesados en perder)Tj
-0.41891 -1.11764 TD
-0.0251 Tc
(p)Tj
0.47493 -0.00001 TD
-0.025 Tc
[(eso, aunque la infor)-25(maci\227n sobre seguridad, a lar)20(go plazo, se)]TJ
-0.47493 -1.11764 TD
0 Tw
(desconoce.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 192.8777 672.8807 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(T)35(raducido por Mirza Mart\222nez)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 50.5 660.3808 Tm
0 0 0 1 k
-0.025 Tc
(R\203SUM\203)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9 0 0 9 50.5 634.3808 Tm
0 0 0 1 k
-0.0251 Tc
(P)Tj
0.53087 0.00001 TD
-0.025 Tc
0.012 Tw
[(henter)-25(mine/T)70(opiramate (Qsymia) Pour le T)35(raitement de l\325Ob\216sit\216)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 50.5 624.3807 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(SM Smith, M Meyer)40(, KE T)35(rinkley)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
8 0 0 8 50.5 608.3808 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(Ann Phar)-25(macother)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 110.5947 608.3808 Tm
0 0 0 1 k
-0.025 Tc
[(2013;47:340)-75(-9.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 50.5 594.8808 Tm
0 0 0 1 k
-0.024 Tc
(OBJECTIF:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 83.1682 594.8808 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(Revoir la phar)-25(macologie, l\325ef)20(ficacit\216 et l\325innocuit\216 du)]TJ
-3.84332 -1.11765 TD
[(phenter)-25(mine/topiramate (PHEN/TPM) dans le traitement de l\325ob\216sit\216.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 50.5 572.8808 Tm
0 0 0 1 k
-0.024 Tc
0.013 Tw
(SOURCE DES DONN\203ES:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 120.4841 572.8808 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(La banque de donn\216es MEDLINE \(1966 \210 juillet)Tj
-8.23342 -1.11764 TD
(2012\) a \216t\216 utilis\216e en utilisant les mots cl\216s perte de poids, ob\216sit\216,)Tj
0 -1.11765 TD
[(phenter)-25(mine/topiramate, phenter)-25(mine, topiramate, Qnexa, Qsymia, et)]TJ
0 -1.11764 TD
[(VI-)-100(0521. De plus, l\325infor)-25(mation sur la demande d\325homologation du)]TJ
T*
(PHEN/TPM a \216t\216 utilis\216e dans cette \216valuation. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 50.5 522.3807 Tm
0 0 0 1 k
-0.024 Tc
0.013 Tw
(S\203LECTION DES \203TUDES ET EXTRACTION DES DONN\203ES:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 216.9329 522.3807 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(T)70(outes les \216tudes qui)]TJ
-19.58034 -1.11764 TD
(ont \216valu\216 la phar)Tj
6.74788 0.00001 TD
[(macologie, l\325ef)20(ficacit\216 et l\325innocuit\216 du PHEN/TPM)]TJ
-6.74788 -1.11765 TD
[(ont \216t\216 revues en mettant l\325accent sur l\325ef)20(ficacit\216 et l\325innocuit\216 dans les)]TJ
T*
(\216tudes de phase III. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 309 727.3808 Tm
0 0 0 1 k
-0.024 Tc
0.013 Tw
[(ANAL)91(YSE DE DONN\203ES:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 378.7746 727.3808 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
[(Dans les \216tudes de phase III \(EQUIP)110(, CONQUER)]TJ
-8.20877 -1.11765 TD
(et SEQUEL\), le traitement avec le PHEN/TPM a d\216montr\216 une perte de)Tj
0 -1.11764 TD
-0.0251 Tc
(p)Tj
0.47491 -0.00001 TD
-0.025 Tc
(oids statistiquement significative lorsque compar\216 au placebo. Apr\217s 56)Tj
-0.47491 -1.11764 TD
-0.0251 Tc
(s)Tj
0.36391 -0.00001 TD
-0.025 Tc
(emaines de traitement, le pourcentage de perte de poids observ\216 avec le)Tj
-0.36391 -1.11764 TD
(PHEN/TPM \216tait de 10.6%, 8.4% et 5.1% avec 15/92 mg, 7.5/46 mg et)Tj
T*
(3.75/23 mg respectivement (p < 0.0001). Le prolongement de l\325\216tude)Tj
T*
((SEQUEL) \210 52 semaines a d\216montr\216 que la perte de poids est)Tj
0 -1.11765 TD
(maintenue sur une p\216riode de 2 ans par rapport aux valeurs initiales avec)Tj
0 -1.11764 TD
(perte de poids de 9.3% et 10.5% avec une posologie de 7.5/46 mg et de)Tj
T*
(15/92 mg de PHEN/TPM respectivement (p < 0.0001). Lorsque)Tj
T*
(compar\216 au placebo, un nombre de significativement plus \216lev\216 de)Tj
0 -1.11765 TD
(patients trait\216s avec PHEN/TPM a atteint une perte de poids 5%, 10%,)Tj
0 -1.11764 TD
(ou 15%. Une r\216duction significative du tour de taille, des triglyc\216rides et)Tj
T*
(glyc\216mies \210 jeun a \216t\216 associ\216e \210 l\325utilisation du PHEN/TPM. Ce)Tj
0 -1.11765 TD
-0.0251 Tc
(m)Tj
0.7529 -0.00001 TD
-0.025 Tc
(\216dicament \216tait g\216n\216ralement bien tol\216r\216 dans les \216tudes cliniques. Les)Tj
-0.7529 -1.11764 TD
-0.0254 Tc
(e)Tj
0.41861 -0.00001 TD
-0.025 Tc
[(f)20(fets ind\216sirables signal\216s chez plus de 5% des patients incluaient la)]TJ
-0.41861 -1.11764 TD
(paresth\216sie, les \216tourdissements, la dysgueusie, l\325insomnie, la)Tj
0 -1.11765 TD
(constipation et la bouche s\217che.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
6 0 0 6 309 553.3808 Tm
0 0 0 1 k
-0.024 Tc
(CONCLUSIONS:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 355.2133 553.3808 Tm
0 0 0 1 k
-0.025 Tc
0.012 Tw
(Le PHEN/TPM est une pr\216paration \210 lib\216ration contr\231l\216e)Tj
-5.43686 -1.11764 TD
(administr\216 une fois par jour pour le maintien chronique de surpoids chez)Tj
0 -1.11765 TD
(les patients ob\217ses avec comorbidit\216s de l\325ob\216sit\216 et ce, en compl\216ment)Tj
0 -1.11764 TD
-0.0251 Tc
<88>Tj
0.65627 0 Td
-0.025 Tc
(la di\217te et l\325exercice. Le PHEN/TPM a une certaine ef)Tj
20.42154 0.00001 TD
(ficacit\216 et)Tj
-21.07781 -1.11764 TD
(repr\216sente une option int\216ressante chez les patients int\216ress\216s \210 perdre du)Tj
0 -1.11765 TD
[(poids m\220me si les donn\216es \210 long ter)-25(me sont manquantes.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8 0 0 8 465.8714 489.3808 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(T)35(raduit par Louise Mallet)]TJ
ET
Q

endstream
endobj
14 0 obj
<<
/Nums[0<</St 340/S/D>>]
>>
endobj
15 0 obj
<<
/Type/Encoding
/Differences[65/A 67/C 69/E 73/I 76/L 82/R/S/T]
/BaseEncoding/MacRomanEncoding
>>
endobj
16 0 obj
<<
/Subtype/Type1C
/Length 744
/Length1 744
>>
stream
  DHHPIK+GillSans   @¯ ¯¯¯¯˚6˚z˙•˙#
 ãã
 ãã   Ó   Í   ˇ∑  º |ÖCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corpration Plc.Gill Sans    " 3 5 * $ - & 4 	   ; ì ± «*Sß¸ú†v˜]„¯!wã˘/˜˛˘BF˚π˝BÔ·˜]˜∂Ê˚]Ô˚È¯¨˜˚ã˚h]†v˜º„˜jﬂÿÌ˜Yÿ˘>˝>Ì˜º¥Ω¥{˚ ÂÂ˚ ˜	\Ãz¢n∫W‡e M¥‘®¥∆ã⁄ã˜
5‘˚ãA7 Í±dKåRåmU"L]†v¯Ê„˜ëÌ¯ﬂ˘>¸Œ3˜Ä¸ÊÌ¯Ê˜Ä¸$†v˘>w◊Ì˜B˘>)˝>Ì≈ÇÂ¯úÂª˘$˘≤.DúE˚m˚1˚,˚d˚#˜˚Y˜îˆ‘§ÆŒˆY>7p>˚8˚ı˜-˜*˜˜˜0⁄”uZﬂ˚4ã„¯Êw’Ì˜@˘>)˝>¯*„˚»˚*ã„˜h„˜b„÷Ì¯b˘>¸˝>¯ „˚æ˜h˜´„˚´˜b˜µ˚TÇ„¯†„≥Ê˜`Ê¯#˘´[WõW˚9D˚˚O˜ª{ã˚!eh[?HLÆÀY˚`ƒ«w’˜‹Ÿˆ˜m˚ªâã˜ª∏¨ π√{T≈Åï˘>ó˚âî˜ñó˜€ê¸∆ã€
‰Z 

yXO	˜™˘
endstream
endobj
17 0 obj
<<
/StemV 89
/Type/FontDescriptor
/XHeight 728
/StemH 0
/CapHeight 682
/Flags 32
/Descent -230
/FontName/DHHPIK+GillSans
/Ascent 716
/FontBBox[-162 -230 1041 911]
/ItalicAngle 0
/FontFile3 16 0 R
>>
endobj
18 0 obj
<<
/Name/F0
/Type/Font
/Subtype/Type1
/BaseFont/DHHPIK+GillSans
/Encoding 15 0 R
/FirstChar 65
/Widths[667 0 708 0 500 0 0 0 250 0 0 490 0 0 0 0 0 604 458 604]
/LastChar 84
/FontDescriptor 17 0 R
>>
endobj
19 0 obj
<<
/Type/Encoding
/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater 64/at/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 89/Y 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 165/bullet 169/copyright 181/mu 208/endash]
/BaseEncoding/MacRomanEncoding
>>
endobj
20 0 obj
<<
/Subtype/Type1C
/Length 5941
/Length1 5941
>>
stream
  VGEKLX+Helvetica   @¯ ¯¯¯¯˚:˚t˙|˙7
 ãã
 ãã   Û   Ô  ê¨   Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  M  5 4 U F W O  . N J I  M T B Z S , & L " V P G Q E Y  ™         ) 8 # $ H / D C X '   !  	 1 
 % - * + 2 7 6 0 3    K [   t :  ò ( o  R O    † —.VòõˆUw±‡ıo˚HÅ≤◊
DÇ…f≈§»=µÓ		_	¶
 
O
ì
ˇ\ﬁ	[µÛK¢Yt≠Ô+páú–<e†ÙV‡`~¥€1Nyú‰NdÉ‚d†v˘‡˜ïÎ¯Á˘‡¸Ÿ6˜á˝Î˘úxﬁ˜ãŸ`Â˜nﬁºÊGË˜ÍÊCË’¯ˇ˜YÔQœ#£ˆ˚a∫Qòn¨ãΩ÷ ∫˜«Z*îÊ˜/Ä3’˚B˚2,7˚3øSÒsŸ˜&h˜
oØpãN4L_˚˚D∆ˆà0åçDïe©dGøŸi˜ ˜Kˆ€˜¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è˚*†v¯üwì¯w¯¯ü+˚(¸=âä˚¯>'˜R¸üË-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷¸˜K†v˘aw‘Ë.Ê¯äÈ/Á‰˘å˘a˚˚_¸Òâ˚a¯Ò˚˝aË¯<‘«â∆ã«Ëç˜_¸ÔÎ˜]¯‰çËä˚	ä∫;ããã¸Z˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê¸@†v¯üw˜ÌŒ„˜/¯ˇÌ3)„¸ˇ¯ü3¸ü-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È¸ãı6v‚ÛXæ–˜SìÌ‡#!–¿‡äHscÅ]”õ´ªÊ¸@†v˘awŒ„˜/˘a3˝a˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛ-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚*˚j⁄˘&wñ¯q¯|¯ü+˚!¸?â˚¯?(˜V¸¨b˚Çdãv|éëv<ÖõóàúÚõ†˜_ÿÔ˜úêñﬁ˜Ç˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿú†v˘aw÷Ï˘)˚«¯@˜æ˜µ˚˚Ô˚˜*˝aÏ˜è˜˜˜è˚¸úã·˜Ö‡˜p‡·Ï¯¸·¸E˜Ö¯‡¸˜p¯<‡¸ù˝a˚*†v¯üw˜jwŒ‡¯â˚h˜€˜\˜X˚˚v˚q¯36˝a‡˜Z‘Õ˜7˚úú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-|◊cv¯üwœ‚˜â„8ﬁÙ¯|¯ü¯3˚¥ TH2Hi≤◊˜Ô4¸%…Oˆ€¥¢—∏Ùç=-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚¸†v¯U’˜awﬂ„˜ò¯U’3Ã∂õû∞ìîäâù⁄åwÄåÇ/_f=1EA—¸U„¯U-˚Lv˜R◊¯#⁄{w≈ﬁ8„3ﬂ˜±ÂÈ¯ô˜®˜24Ù˚H^qL`â˘‘8˝lÂ„˜òçWµÆy»˜#„˜˜H1Ö˚X?0„2U–˜˜!º’ÁÍºJ˚-|◊cv¯_Ÿ˜HwÆÂ˜±„4‚:‹y¯Ü˘a˙4˚°âŒ[d°E˚7&˚5˚E‰˚˜!œªß≈≠yçD¸Ñ˜â˚TD24Uÿ˜˜∫ÀÍÊø>˚˚*†v¯üwò¯r¯˚L˜†˜E˜ì˚ ˚˚M˚˜M˚˜B˚ì˚K˚†˜˜˜Y˜˚Y¸ãı‚Û˜Sı#!‚x ﬂŒ˜‡Ãﬁ…}÷Ìÿ˜úœˆ÷˘Ç˜˚˜e˚?˜=˚g˚g˚?˚=˚e˚e˜?˚=˜g˜g˜?˜=˜e@˚B˚˚!˚>˚>˚˜!˜B˜C˜˜!˜>˜>˜˚!˚C EGM{dkM6M—Ï√À‚»≤mM†ŒÙuMø"˚3.˚˚Ë)˜È ¬ıß-†v¯Ü“˜w˜úÍ¯Ü˜7¸ÜÍ˘REp$qx˚Ä-x‘˜I⁄˜ÀŸµÂ9‚˜¶Ò4‚Ú¯ï¯˜k7˜˚6˚1+˚%˚‡2˜Ÿ¡¶ƒÆçân˚X`H)ãÍEa¥’Ñ4˚î‘I˜÷∆®≈µΩŒ®˜˜Ù%Ì#XR.6Y¡ÁÒø ﬂ‚√P0-x⁄˜…⁄˜E⁄±‰2Ú˜ß‡AÂÚ¯ô˜q˜1Ë˚@VpOdàçï˜?«ÊÒãÏÀ≥fCò‡Ü«~´i≠e≤Q¢Rã˚5ã*˚#ã˚ã˚v·˚˜7ãÍ˜ÏÒ˜1Ü0RJ94OÀÁÁƒ»‡„√P--†v¯Ì·˜Í¯û¯ˆÿ¸y5¯@1W:U˚O˚l/}#Í≠˜4¢“¡˜ ƒ˜¿⁄–ÿ˚—†v˜{Â∑˜à˜¥˜{Â˚à1-ã›¯±⁄•Ó:‚˜ØÁË¯é›¸òÀª≥∆´‘≥Ô¬„º˜˜3ﬁ˚ÿ˚3?$˚)‚˜ë∏¡Â‡ƒW=Dmk&Q/VË˚Fc5Ö˚-w€¯«⁄∞Ë˜∫Ë¯ô˜È˜}6˜˚/˚/6˚˚}˚z‚˚˜-˜-‚˜˜z.˚KX)++XÌ˜K˜OΩÍÏÏΩ+˚N-x⁄˜ú‘˜w⁄≠Á˜™ÂIÈÙ¯û˜bﬁiª8≠ç¯√†¨øŒ˜6’˚˚(FD˚3É·˜ ì≤∂„›Ω`DAYd,~Öãçz?åõìãéÙ˜¬c39MU+*`π˜á/˚6ô”C˜(˜/Ó„˜”†v˜·‚˜ΩwÿÏ*Ì¯
ÏÙ˘˘a*˚Ω¸˜Ω*˝aÏÌ˜·¯
˚·˜∫†v˘awõ˙"˙2˘a ˚¸€â˚4¯€"˚6¸€â˚¯€#˜O˝a˜:¯Áéå˜7¸ËÒúãﬁ˜êŸ˜r›‘Ï˜ÿÎMÎ¯˘˜l‡gª-±Õ≠©ª–ˆ:”˚˚Œ˝a˜ Ù˜%Î·˜¯˚˜À?Ye(˚C˜r˜CÔºgCÙ≠˚Õ7U\*˚c˜ê˜R˜≈b;”w·¯›‡∑Ó¯HÁ5ÈË˘;˜ú-˚qCH˚˚&8˜˜R˜GÁˆ˜+ÔœV*§Á˜*s!‡˚7˚a˚˚%˚x˚Ç˜˚%˜\Ë˜?˜	ı˜F§-˚n”˜◊¯!€|w≥Ê@„˜ü„7ﬂ9›‘Ä¯á∂¯t9@˘ âÃ^^§H˚4"˚0˚D‰˚˜“µ†¿´ˆ çu˚cZ˚Hg§ƒ}3"úÕZ˜˜7’›˜G˘ 7˜b˚WH/5Uÿ˜˜ªŒÁÈΩC˚”†v˘aw◊Ë¯Í˘˘a,¸◊â˚˙¯◊˚˝aË¯ÿç¯¸ÿ˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô-{ÿcv¯`Ÿ˜Gw≈„3ﬂ˜±Âz¯ô˜®˜24Û˚MZqTcâ˜ò3˝aﬁÃçˆN∏ØwŒ˜Â˜˜D1É˚W?13T“˜˜Ω◊ÊÍºI˚”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Êd†v˜Ÿ·˜p··Ï¯⁄˘·¸Ñ˝aÏ˜Ÿ˜Ù·˚Ù˜p-†v˜>◊¯]w˜ﬂ„¯ù˜>◊%¯]B˚’¸R4˜∆˚>„˜>3◊˚u˜t˜‘å-x◊˜–⁄˜*·´Â˜ΩË¯î˜x˜(Î˚Tfk^™˜V˜Ω·˚ˇW¸÷ÜµºÆù¿ãÊÃK1*LJ/;\≤Ÿ|1˚ú◊K˜˜1ÏÈ˜-¯x…ËÃJ‘˜∏”Ò»˜'‘◊ﬁ¯:Ãﬂ˘ˆ¯>˜C˚*˜˚V˚e˚:˚:˚d˚k˜:˚:˜l˜˜Œ˜ I@H8d/˚B˚˜˜C˜K˜˜˜A˜3˜˚˚$ F˚Cyäöö§ßÈ»˜cGwMlƒj†Wã˚$˚˚,5ÕAÿ∂¨òΩªçaè†v±Æ¿¢¨¥“∆±›Ëˇ˚ìy*>%A[j≥ƒÏ’Ì‘π≤`Y¸çv˘áwz˜Ã˜ª˘tI˚ä˝áŒ˚—˚Mv˙>wœË˜ø˚b<˜2P˜˜J˜D≥˜Î˜;O˚˚B]˚˚=˚V—˚Ú˚0ú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;˚—˚Nv˙>w˜@Ë˜ù˜ù˜VE˜$˜0Q⁄˚2∆˚˚J˚Dc˚+˚;«˜˜Bπ˜˜=”ã›¯Ω›‹Ì¯Ó˘5¯˜g˚˜˚J˚∑˝a˜≥˜R˜˜˜z(Ö˚A< ˚˚O¯Ω˜I˜5¿˚˚-ã·˘w◊Ï¯¨·˚ˇ˘*˝a¸†v˘awÊÏ˜P˘a*˝a˚*x›˘"wúÂ˜sÏ¯?˜V¯ü*¸•7fb>Bg≤⁄Ω1D˚ÿG˜˜÷Ÿ˜˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚e˚!˚-˚u˚v˜ ˚,˜f”√ö¨√˜6º≈)÷—÷≠Ëã˜(/o>WU1—ZO’Ra{qÜeã˚(%˜
˜A˜DÔ˜	˜+˜*Ô˚	˚Dú†v˘awü˘˘˘a˚˚^¸˜â˚b¯˜ ˜ö˝aÚ”x·˘w⁄Ï¯Î˘˜ë¯d+¸Y˚FC˚˚I”˜¯V*¸r˚1˜ &˜<˜F˜Ú˜=˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚d˚"˚-˚u˚v˜ ˚,˜f˜e˜ ˜,˜v(˚A%˚
˚(˚)%˜
˜A˜EÔ˜˜+˜*Ô˚	˚D”†v˜«ﬁ˜ä‹„Î¯Ó˘>õoöÖóâ∏Ö˜á◊y©Kß÷π§∂ã‡ã˜6–˚*ã˚ﬂ˝aÎ˜«˜ÊÆi.çé˚å}òRÇ¯ô6[a*˚v˜ä˜áﬁ∏a>˜Éçvò—˜\—°—˜]—≤—˜]—˜—˜]—Ä˘Â˜8È?◊,-??--◊?ÈÍ◊◊È˚J¯∞UˇÄ¸˝g¡ˆ¯µÍ?◊-,??,-◊?ÍÈ◊◊ÈÄ¯#˚˛T^^ST^∏¬¬∏∏¬√∏^T¸i˜˛T^^TS^∏¬√∏∏√¬∏^S-x⁄˜¢◊˜oŸ±ËEÊ˜åÊGËÍ¯ò˜`Ÿh¿;≤ÏÀ¨•¥Œ˜5’˚˚7?˚I®aÕmÚ5ck[/˚Ó4˜!˜$È„˜Ï˚˜—HV[BEWªÃÃπ¥—‹æcKÚ¢˚⁄5XZ1.Q¡‚◊«¿‡ÂƒV9Iª¯{¯´ñ€¸˜6¯˜6€¸{˚dE¸@˚eŸ˘"w˜ÌŒ„˜/¯ˇÌ3)„˝L¯Ï3¸‚UÅÅTyAáúêãöË¥¥Ê˚*ã”¯’™¯I¯h”˚’˜Õ¯’¸)A˜∂˚Œ¸F¸†v¯/ı‚ÛXæ–˜S¯/ı‡#!Û¸'Ì#!–¿‡äHscÅ]”õ´ªÊ¸ãı˜≈ı‚Û˜S¯/ı#!Û¸/ı#!˚¿ù˜Œ˜‡˜˚‚E—44EE44—E‚‚——‚ú†v˘aw˜±Ï˘˘a˚˚a˚Ï˚c˜Ï˚˜£¸A˚¥Ï˜¥I†v˜‘˜‘≤¯å¯≥˜“‘¸åB¯å˚`‘¸åB-˚Mv˜R◊dv¯üwœ„˜â‚9›∫¯|¯ü¸4˚¥ SG2Ii≤ÿ˜Ô3˝m„˜uçq¢†Ç¥”∏•Œ∑∫ç>˜xﬁ`v˜¡ﬁ˜ü‡ªÔ¯eÂ|˘S¯˚Œ8˜tà@Ågqf¸PcJm8˚09Ò˜V˜EÈ˜˜'˜ –Y&´Ë˜(o˚„˚7˚b˚˚,˚˚o˜˚)˜TˆÿÆÿ…|£.-†v˜É’ã¯¿¯¿˜É’¸¿AIª¯{¯´˜m—¸{˜d;¯˚6¸˚6;-˚Nv˜T◊¯"⁄|wÆÊ˜≠‚7ﬂ8ﬁŸ¯Ç˚c˘n8Aâ¸…a\¶G˚4"˚1˚G„˚˜!»≥üº≥ç˚ô˙é¯Y˚UF14Vÿ˜˜∫ÕÁÈæA˚u°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
21 0 obj
<<
/StemV 88
/Type/FontDescriptor
/XHeight 737
/StemH 0
/CapHeight 687
/Flags 32
/Descent -194
/FontName/VGEKLX+Helvetica
/Ascent 717
/FontBBox[-166 -224 1000 931]
/ItalicAngle 0
/FontFile3 20 0 R
>>
endobj
22 0 obj
<<
/Name/F1
/Type/Font
/Subtype/Type1
/BaseFont/VGEKLX+Helvetica
/Encoding 19 0 R
/FirstChar 32
/Widths[278 0 0 0 0 889 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 584 584 584 0 1015 667 667 722 722 667 611 778 722 278 500 667 556 833 722 778 667 778 722 667 611 722 667 944 0 667 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 350 0 0 0 737 0 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556]
/LastChar 208
/FontDescriptor 21 0 R
>>
endobj
23 0 obj
<<
/Type/Encoding
/Differences[32/space 36/dollar/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y 95/underscore 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 126/asciitilde 131/Eacute 135/aacute/agrave 142/eacute/egrave/ecircumflex 146/iacute 150/ntilde/oacute 153/ocircumflex 156/uacute 177/plusminus 208/endash/emdash/quotedblleft/quotedblright 213/quoteright]
/BaseEncoding/MacRomanEncoding
>>
endobj
24 0 obj
<<
/Subtype/Type1C
/Length 10206
/Length1 10206
>>
stream
  TCWLPE+Times-Roman   @¯ ¯¯¯¯˚<˚n˙|˙
 ãã
 ãã   ˚   ˜  ∏¨  'Ω }àç002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  ]  I F  D V S O U P C T J Z Q E N B G    M   6 4  H K  "  Y 	 # . * 
  L  W X   ) % 0 ' o $ â R  5  1 & / + 2 7   ( [ 3 -  8  _ i w   9 ú  , @ : ” ÿ œ ◊ ﬁ »  ≤ À “ Ÿ – _   p Œ —àıj∂˚]ÏGøM≈wb‹?		F		¨

å
»í˝~œXñ5ü÷SÿÛTÏh”7é¸|ì 9ÖÛiÊFékÒMƒyø.ÕÒ9¢+^Û!≈I^Ã6® 1 !Ö">"d##«$N$Ω%C˚*†v¯+¡”ﬂ˜Nﬂ¯zõXêÇó–˜[ˆa¿9R_rQ`â˜¬Öè\{òè kzåìëãè∞ìÇa¸kFÇUÜ{˜kõTç~úŒ˜Öπµ´ù±∫¶eF˚ZGÄ}Rá{˚bÅ–˜o´˜Ø§–F“˜cÒÙ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÏ˚˜-˚cŸöÆØ«∆•m7ó¸$˚bÅ”¯®§◊¯0˜(}ì`HapQã1K›˜ƒ‘ÿ≤ñÇcóëwïkö|£ã¶ûù•¡E∫<˚+!˚!˚⁄/˜ﬂ∆∫˜¿˚*Åƒ¯(w—ﬂ˜Fﬂ=ŸË¯rØôYäñ∫˜Ï˚2{ÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶Ë∑∂9çàŸßîéæô˚—†v¯`w†w÷ﬂ–˜‚¯+¨wühblsH]â‰∞ÜéJqwÑMu{éöìåï§ï{_˚éYÇÉNÅ{˜ÉõKvùƒ˜súò§ûûôòôìîíìáÉîx†ìáõ°õû•˚*†v¯)¬åw⁄‹:ﬂ˜Eﬂ‘¯xõ]}õº˜yË^ƒB[p|ID€¨ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠Ãª√õî¨ª£kJ˚eN}xZà{¸Åø¯´–ﬂ˜™Õ~ñvrzÅtãg|¶ ˜≥´&˜ñâéÖU<midpÑÜâàãÖãáåâéãø˚¬5©b…∏≤§æ¨˚*Ç¶¯4ß®‰˜ö‰¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚*Å´¯Àœﬂ˜w‰¯h˜á˜?Ë$SWlXpâ˜¡Üéa{U{[~{åïíãèÆîÅc¸úm„i⁄˜Ú˜˜!2b˚	]L5[\££˜ê∂µ¨ƒ◊ø;˚˚ôÇ°êv¯Zwí¢æ»˜:—ú˜˜ªt´M∞ Ànú|§ã©Ø≠®∂≈Æd6úõ¨á˜ÉÜáâÖÜÑåéÖúôcçs:QXDO™e·Z≈j≠xùqãn_koYEiØÚs{\˚/òîíêéîìïäàñúÅ¥§á•Ÿ ƒ”¸†v¯^w˜$◊8ﬂ˜E˘ßt¢opttop°tßß¢¢¶÷˝õËKèÅñ”˜˜ÜèWwZyVy|é©åãì¶î{_˚{CÅGà{˚*˚m¯Àwô¯`¯n¯Iô˚}ØàóÑzÑéîqB<˚q˚˜êÇûãíãñúííΩëô˚a}®ÜóÑîw˜˚ä¶PÆJ|tpG{rt|z||wuùloxzpk™r¥“µº˜*ƒ˜/¯-ñ©ôò°é˚*˚Vv˜a´¯«åw’ﬂ˜v‡Ï¯i˜à˜F‰*R_sVaâç‘‹ÖéTvää4m{åóéãó´ëÅ[¸gUÑÑMÑ{˜ÖõAå}ó…˜0m´©≤˜Ê˜˜$6f˚YAArmóûs}óÇóï˜äÏØìª™∫’º>˚˚*Åø¯ß¶·˜wﬂ¯µõÉÇäãáfÇó∏¯ÀÜéUx|á=v{åòëãêØìÇa˚0¨crïb˚.˚˚˚◊2˜¿µ†∂™çNêàŸßoÅÎ≠˚+»m^l_9Sﬁ˜˜æ◊‘¬ª\U˜†v¯-øåw·ﬂ˜Lﬂ˜Kﬁ‹˘ôõRåïª˜c˜d∆=SXpSU≈xk§SbvÇXFÜáÉÜÅÉ÷ºÉéZyåã1pyéõêåñ§ïx^˚íV}}Sâ{˜rõYyô∞˜Øéïïóï‹£®´ó™ª°iC˚mU~Sà{˜sõSå|ú»˜ê∏´™ú∫¡ûn9˚gSÑÉPÑ{˚bñvåƒ¯§∞„˜6›x¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω∏Tëùx∑™ßõ≠ß˚0ﬂsàÄÉx{yb{sfo≠π»∫µ˜±˚—†v¯7´˜_®Úﬂ7ﬁ¯˘´\ßU˚QA˚2ä:k‹˚œBÅÄBá{˜òõ:çñ÷˜œ˜´Ë˚˜∆ùß≤†îÖoük°îÑú¢ûû¢˚*}Ø¯Á∆˜—⁄g“–¯C˜lÍkπ+∑‡œπ§∞≈⁄K¬/,MX˚döá≥÷∏´ ãÃ∏^L^r_cnpwvÅWyû¡¶Üz™–ªp®XO8QICqvì†h£cÇéys}~ug∑v÷˜1˜Î˜˚*~•˘•£Î˜òÎ¯p˜ﬂ˜c˜E∆§ndò[[d~rnFPb˚˚˚≥˚—Or®≤~ªª≤ò§®—«≥˜˜+˚h`!44`ı˜h˜i∂ı‚‚∂!˚i˜Kìvò™˜óÆö´˜g§œw»◊˜r§Ã÷˜q•¿˘ó˜ö—f≥H˚˚ ˚˚;ªW’ÛÎ˜˜˚¯2eYYbyDd{í†oür{ëo˚ ˚	˚BæQÕıÔ˜˜ôâñáûÉ£óâ£∑ßí†∞çâø¿˚˝∫¿¯Ö˜£˚:˚<du•∑œÀ˜?‚≤™f^¸˜º˚:˚<cu£∏»∞ÊπΩ£°°òúëçäÑíïÅöÑ®Éëéwã}¸†vÏﬂ˜îõMå~ó√¯ÁáéHwvÖEy{åôíãó∞ìÄY¸pV{}Ná{˚*†v˜i·¯ö=åyñ∫¯ÌÇç˚G0~•ïúíúèîã¢ï}j¸m\yÄ=ä|˚*ôv¯Ë‘ü¯@¯T˘ö¸|_`%úÉ≤Ã¢õ¡ã˜m˚Z¸ËÃ”}∑¯˙ûÚÚ˜¸∂˘S˘ü˚{w÷âûr(˚¢=Å`slakTtJO\ùÆnnÆÇ∞€˜‘‘ññ⁄èü˚Æy⁄ÉïÅB˚À˚@›6˜:˜HŸ›˜P˜ôõ†Ÿè-~Ø¯¯¥—·˜~Ô¯~˜<€\ƒ˚’Q≠"º‹¿µ≤∆Â–L˚ ¶§u˜hvsÖÇÅzÑ|éê}üOwëq"?D)9≠a˜C˜>¨hNGZ\C0M¿˜Wu©˚h††çñóùØ´jÁ˜
„ÿÛ¸$õv£v√˜ †˜Xñøh≤\jrskl¢wØ`ôêéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚*˚nƒ˜&÷@‘Ê§˜k≤êßß–nﬁ˜EŸ•®›¿¯i¯≤?u~çìwù]têm*AE-L§h–gCKyvtuö|≤{æ¿FZnfgTÿ`Ô˜˜ŸÊ ]¥@é˚êTçsïãùîòûôòóòôìîúêÜ®ÁœÕ‰®áû|∞P˚Snf_›¿MaÃÌ»¶Æªƒ∏B.Û˚ﬁR?b˚ﬁ¿3M©µ£ïú≤π¨Ñéõâ§àªâ¿âà°Äãi¸˚Xv˘7w˜$Á8ﬂ˜U˘ßt¢pottop¢tß¶¢¢¶Ëå˝¯^ÜèXwXyWy|é©åãì¶î{_¸!Äjg}ÇêóÄ≥iÜéwwwywk≤t¬˜∆÷˜"¸$Ä˜—˜˜I∑™r§mlrrlm§r™©§§©”ãû˜[¥¯4wö˘G˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ß˚*ã◊¯§‘˜Â·¯n˜~êmdÜpPã˚Ñ˜=˜D‚Ê≥⁄ã⁄Ì:Ÿ&˚HK˚lüÜØÍ≤Ø”ã›ƒP6?\*95˚F˚P~¯˚*†v¯Wwú¯b¯sõhçyòn∑˚˜Xﬂ˜û¶ßõ≠åö˚3}¨áíá}~uU?~üèÖs≥x™Ñöãìãõïë´çô˚b}µäêá∞SÍ˚%˚˚9pd}Ålä{˜%õnÄêóìêóô°€˜‹˚õsãäãÄ{ÄÑrá{˚—˚1v˘Íwª‡˜ƒ˚6˚·Z˜˜l˜[∂Ò˜ÓÇõ˚@˚@˚ã˚L˚µ#Î%≤aßt≤túã∞fû˜»≥c≤˜ó±xû˜Ò˜Ü;˜¶Ä¯Â˜D≈oΩ\ßröyíZôçg Ë°≤∂⁄˜.«˚<˚¨wﬁàòA¸QA~8àw˜‚¶Ä˜%Ï“Ùß ˚˜Ã<Yb)äõ -ä˜yßèç√˜»]0¶Ä†˚»*O]˚O|ì¨˜ç˜Vå–d˚˜Éãû˘ûˆ∑¯ú˘ÔüFçyù–¯Q”ôô‘éü˚[˚o¸é˚{¯é˚Zw›Üò~D¸+&|x;Ñw˜}ü@éx•Ì¯$ç˜é¸∑ô˜ê¯Œç¸V9Ä~<Üw˚—ãû˘û˜Ò˜Ãü8é~ó÷¯O÷òóﬁéü˚∫wﬁàò@¸O@~8àw˚—˚1v˘Íw˜\‡˜±˜ä˜aÛ+Òdµo¢d¢{˜5º˚˚l˚[`%˚(î{˜@˜÷˜ã˜L˚*†v˜;À¯Qw˜∑⁄>ÿË¯k˜;À&¯Q_˚Œ¸QK˜≠˚;ÿ˜;<À˚Ñ˜Ç˜Èç˚*†v›ﬂ¯çõ`çi°dº˚.˜V®¶ÔËΩÆÃâô˚_}ìêäãè¢äîáå~åÅÉÉ{|˚˚âç¯3ÜéOxzÜ>w{åòïãíØîZ¸uUââBÄ{˜~õMç~î¥˜Iç˜˚LûrçáãÖÉÇÖy{¸ív˘FwÇ˜∫˜±˘8I˚x˝FŒ˚*ív¯ewû¯\¯o¯Gõ˚{´äöÄv|Çoy]=˚[%˜îÜòáúãíúòî¨çõ˚W{üäïÜó§s˜˚ø£NéÇòeîãíãèíù∑˜˜‘¶Œíî©ç”ív°v¯dw†˘4p˘I¯Gõ˚{™àòÅy~áu~l0˚r<˜kt…çÑãò£ôì∂èõ˚^{µäôv≠%/˚\k‚H˜CãÜõäìíüòî¨çõ˚G{¢äîÄüX˜˚Èkòëíëëî©ô˜˜ÉÂ˚∞^úãåíìååªû˜˜Óúµêíûê˚—†v˜UÀ≤˜ä˜±˜UÀ˚äK˚*}ß¯∫˜Çö≠Á˜ë‰¯h˜m˜Bﬂ˚[wÑeL™˜1ÓÍ˜;´áö˚vá˚M˚;˚˚D‰˚˜˜·Í˜2j˚ cME4SÈ˜'≤ê≠îô°ò∑ù¥ÂæC˚”ãû˜º∑˜±ûıÒ˜√Ò˘PüAè~ò”¯Q”òò’èü˚®w’áò~C˚W˚√˜W”òò’èü˚®w’áò~C¸QC~~Aáw˜®üAè~ò”˜b˜√˚bC~~Aáw”ãûx∞¯·∞xûÚÒ¯˜ú˘?˜‚˜b˚)˜˚é˚†w’áò~C¸QC~~Aáw˜Ø˜Ç˜&˜˜cl˚Ö˚U#)˚a\~î´¯ê≠îë¡˜Q˜	˚˚L”}Ø¯˛Ø≠˜¯?˜˘C˜ﬁ˜_˚˜#˚S˚T˚˚#˚_˚]˜˚#˜T˜S˜˜#˜]˚å˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R-ãû˜»µb¥˜ì≤xûÓ˜î¢¥¢œ¯µ¯úà˜#¸¶w’áò~C¸QC~~Aáw˜´ü@é{ö“˜p˜&âﬂäñÅö7¢˜|t6|Å8˚&˜q∑®êêß˜˜û~0ù˚*†v˜]ºã¯à¯à˜]º¸àZú}∑¯Ov˜M≤ß˜˘˜yú=AOp5ã˚+,˜˜K˜SÂ˜	˜(ˆ“N˚∞°Ç˜tvÉu|wåÅå{éxíbôYìaã˚Zã˚!˚#ã˚]ã˚f˜˚˜_ã˜ã˜ øæ◊˜Ú†v˜]ºã˙|˙|˜]º˛|Z˚*˚Vv˜a…¯ß£‡˜|ﬂ¯|˚kõ]çzö¥¯ÍÜêNgU™|ê_ã˚,˚˚&˚Õ4Ï¿¿§ªπçä˚NT|~AÑ{‰˜ÎkÑ~t~srÖs>W◊˜˜	¡Ÿ‹Õ™kF¸Ä˜˜ç˜‹˜˜T¯)©r§mlrrml§r™©§§™˚˝™r§mlrrlm§r™©§§©dãû¯Ì∂ü°˜gÒ˜|v¯„¯ÅÑ˜>¸ƒÑ˚>§˜°†õ˜¡¸í@~8àw˜∫ü8é~ó÷¯í¡˜†{˚°˚*~∞¯‚‡Ÿ˜˘—¯J˘?ÇëyuÉáwã˚e˚˚Ääâäàãâáçâëä˜É˜5Y˚.&O?;uÑé´^°l}êpr}~tb∑u›˜5˜ Ú˜.˜@˚ƒ˚)¶µ‡˜Xúéåíé-ãû˜°≥˜Ω±xûÓÚ$Ò˜{˜⁄¯±¯w˜$—˚3˚öw’ÉìÇD¸FCäp9âw˜¨ü<å|ö’˜Hä§¢äû⁄≈ñ°≤»≠Æ«œ˚â!S\˚ÊzÅãçt˜ôßíë≠˜ÕY-dã±eû˜»µb¥˜ì≤xûÓ˜ú¢¨¢´Ä¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•WÄw’áò~C¸QC~~Aáw¯Ø”ïvñû˘û˜ ∏¯1∑x˘T˘ü˚~wÂÑëk4˚„â¸¯u˚?w∂åñÑµ[¸M%~y8Éw˜ü>éz£¯ç∏¯J¸πú¯§Ôöü⁄ë˚ôív˘&û˜CÒ¯˘ü˚¥w⁄âô}C¸d\Äwq|Üë£Ñ≤|õqqutp_≤n∆˜ »”˜¯”ôô⁄ç”˚Fû˜Gw˘Ø≠˜¯?˜˘P˚Eù˚å=∂5˜ ˜2•Ú˜ã˜Eã˜_˚˜#˚Sã˚Tã˚˚#ã˚_ã˚¡˚‚SÆu©}•ÖπT=Õ˜_˜,íåãå≤˚¯ê˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R”ïv˘#ûõ˘;‡˘K˘ü˚`‡x∆ÜôÇm}Ñqm˚&¸˚,˜ÊmÕÅ©ãô§ñê èû˚ù‡wΩàú{±6˜ã¸∫ö˜p¯∆®’õõ∫ç˚*~ß˘ß√÷F’˜o–T◊‘¯Q˜0ÿiª˚ÊÿÓ¡ÆµŒﬁC≈#!;H0J¢iÒ4‰˚<ulG&ÿI˜	˜
ÿÕÚÿ1¯PuiCVTØEø‘ƒ∏≥ œ∂_G‰ô¸-G__IAU«›Œû±…æ™tîÑãËE£rN¸õv£v˜Û˜€˜ ˚˜h˜T¯)©r§lmrrml§r©™§§™∞ß¸øh≤\jrskl¢wØpïîéãîïêáÅäâiogVgïxŒ≠∏»ƒ”}≥˜…û˜Æ≥´˜¯Î˘W˜„û˚íxŸáïÅ@˚4iOq?˚3'˜
˜O˜KÏ˜˜%Ù–U˚µ£É˜fuuÑ{ÄsÖÄçéÄ°Ejë\˚[˚"˚&˚b˚|˜A!˜K˜˜¬ù˜\≈ôö√é˚bã©¯©¶¯¯6˜yèv*|~/ã˚˜¢¯*ö˚Ôà˚ú’ïôö»˜˚ù¸*|¯úãû˜¡§˜ÆØxûÒÒ˜}˜‹˘'üdçvóp¨˚b˜ë˜¢ƒ¿Ë˜/ ˚7˚ßw‘Üó~D¸D4ÖÑ=Éw˜®ü=íó“˜X√é˜Ç˚…N¯"Kc˚=ä˜äÏ®óíΩ˜≈]1dã≤dû˘ûÓ∞¯Ë˜Bs˚
Siz˚I0Åè∞¯n”òò’èü˚ßw’áò~C¸QpC~~Aáw¯≠˚*âw˜ó∂¯ß©Á˜ÄÔ+ÎÙ¯^¯!˜5/˜
˚˚4'˚ ˚
‘:ˆ¿ªù±π¯åàm˚%˚˚>qçw˜Öõ˜3˜<ã˜Ù+bváÇÅuod}j>\’˜˜± œ‰∏4˚;˜∫ñv˘"ûê˙1˙6˘ü˚Zw¬ÜôÇl|ÑkÇs˚˚Ë˚˜Èp–ãäãó§°ï¬ü˚üw áèá≠:≠9 ˚Ø˚%¯É†àïãò°óë¿êü˚àw…Çéá“˚SÃ˚CçÜË˚°ö˜.¯;ëyë|éÇë|°U™;±*ú[™4ôŸ˜Éñ™Ã˜H¶‘ö≥ñ©öµõóªë5óv¯†wß¯è¯´Çœ¸=˜V¯=˜Vœ¸è˚{M˚†v˜ìÀ≥¯a¯â˜•hΩeRx{lãx}ê´F¢XlîkXisMfØX£ø§†±ã™´ÇqºpøüÑ©ª©†Õπ˚b†v¯E˜ ∂˜ Ê˜ ¯2¯}´tügÅÅáãÉÇäÜêïçÆßÆ¿ØÅüHh^OQWÆd∫¨§£´˚{´tügÇÄáãÉÇäÖêåïçÆßÆ¿ØÅüHi^NQWÆd∫¨§£´˚b†v¯Õˆ©˜ Ê˜ ¯%¯›øh≤\jrskl¢wØïîéãîïêáÅäâiogVhïwŒ≠∏»ƒ˚{øh≤\jrskl¢wØïîéãîïåêÜäÅâiogVhïwŒ≠∏»ƒ5†v˜Õ˜Õ©¯ã¯©˜’Õ¸ãI¯ã˚]Õ¸ãI˚—⁄˜ ˜o¯ﬁøh≤\jrskk¢wØîñèãìîåëÜäÅâhohVgïwŒ≠∏»≈”ãû˘ûï˘H‡˘RüWêwòe¬˚S˜¶˜%˜K≈’§öÃèü˚Äw≈àñÜr|É}kd˚˚`∆CÓ~¶ã¢£öë»ü˚¡w–Ö¢w„˚˜˚5˚0˚U;)~ÅWÜw˜}‡ûVçsñå°åúò§∞∏˜˜(Í˚!´\ùgã}‡uwÉSäw5ãÕ˜mÃ˜çÃ¯©˜ØÃ˚o˜2J˚2˚oJ˜o˚5Ã˜5˜o˚ØÕ¸ãI˚*ã¶qß¯Ûßo¶ø‘Û≠˜ÿn¯\˜B€hº#√U®˜å⁄Üª^ü5ö˜^f®PüIéÃiÆK"áCN4dôg¶mßl¶x‹]˚∞-çXπrı|˚g«√|–4≠n„˜ï‘ÀÓ˚w˜}~ì~ìÄîZ±y¶ã±ã¿∂¥»í˜*¸|I^^DÉ˜õ‰X¶gR”ãû˘û˜Ò‡˘eüXzñÎ2˚|˜é˜Q˜Q««£óŒêü˚òw«áíàtrxs4:tu∫∂˚@˚0˜W‡ﬁñóŸëû˚¨xŸÖñ8¸;8Ä=Öx˜¨û=ëÄóﬁ˜D•°ı!ÿ>¿Fãt‡yÇàOâw˚*˚Ωã¯à¯à˚Ω¸àY”ãû˘û˜œÒ˘R˘ü˚owæåùÇtÅáÄÅ{˚!˚x˚)˜tÄõÖöãò°ôëƒü˚¨wØâôÑßiüt≤W•e˜˚T˚M>~Ä2âw˜∆ü2ç~ñÿ˜U˜'˜w¡ﬂ®¢¬ë¸†v¯bwÃ˜r˚Uﬂo ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú˚≥˝–˜êõKèÅñ”˜˜ÜèXyWxXx|é©åãì¶î{_˚{CÅGà{˚*Ç¶¯4ß®‰∆˜rx‰ﬂ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸#˝Ë¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚bÅ–˜o´˜Ø§–F“¿˜rGÒ√˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝Ú¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó˚*†v¯)¬åw⁄‹:ﬂ<˜›Bﬂﬁ˜ﬁ˘mf{~r~tëì{tóvñsëuãUhiI}®™ìùößïòàÑô°ÄØy¢Ö¢ã¡©©÷†¸1˝“¯xõ]}õº˜yË^ƒB[p|ID€™ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠ ª√õî¨ª£kJ˚eN}xZà{˚*Åƒ¯(w—ﬂ°˜rIﬂ=Ÿﬁ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸"˝‰¯rØôYäñ∫˜Ï˚2{ËÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶‰∑∂9çàŸßîéæô˚bñvåƒ¯§∞„§˜r6›ƒ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝t¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±5óv¯†wß¯èßÇ¯è˜{…¸è˜{G¯=˚V¸=˚Vdã±eû˜»µb¥˜ì≤xûÓ¨˜rî¢¨¢˜ ˜i ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸[˝™¿¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•V¿w’áò~C¸QC~~Aáw¯Ø˚bñvåƒ¯§∞„Y˜rÅ›√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èt¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±˚bÅ–˜o´˜Ø§–F“v˜rëÒ√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èÚ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó˚*Ç¶¯4ß˜hw®‰t˜ r‰ﬂ(˜’¯ê˚˜:K˚˚:¨˜Ú˜$¸¸ê‘¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚bÅ–˜o´˜Ø˜jw§–F“t˜ ;Ò…˜’¯ê˚˜:K˚˚:¨˜Ú˜$˚Ú¸êÈ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÂ˚˜-˚cŸöÆØ«∆•m7óu°¯Wñ˜\öíã˜öî¸}é¶
ﬂ
_˜é˘
endstream
endobj
25 0 obj
<<
/StemV 84
/Type/FontDescriptor
/XHeight 677
/StemH 0
/CapHeight 662
/Flags 34
/Descent -215
/FontName/TCWLPE+Times-Roman
/Ascent 684
/FontBBox[-168 -218 1000 899]
/ItalicAngle 0
/FontFile3 24 0 R
>>
endobj
26 0 obj
<<
/Name/F2
/Type/Font
/Subtype/Type1
/BaseFont/TCWLPE+Times-Roman
/Encoding 23 0 R
/FirstChar 32
/Widths[250 0 0 0 500 833 0 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 564 564 564 0 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 722 722 0 0 0 0 0 500 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 541 0 0 0 0 611 0 0 0 444 444 0 0 0 0 0 444 444 444 0 278 0 0 0 500 500 0 500 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 564 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 1000 444 444 0 333]
/LastChar 213
/FontDescriptor 25 0 R
>>
endobj
27 0 obj
<<
/Type/Encoding
/Differences[32/space 44/comma/hyphen 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F 73/I/J 76/L 78/N/O 82/R/S/T/U/V 88/X/Y 99/c 131/Eacute 234/Iacute 238/Oacute]
/BaseEncoding/MacRomanEncoding
>>
endobj
28 0 obj
<<
/Subtype/Type1C
/Length 3689
/Length1 3689
>>
stream
  WRDTIY+Times-Bold   @¯ ¯¯¯¯˚<˚n˙z˙:
 ãã
 ãã   ˘   ı  B∞  D }áå002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku  #            D   0 # + & 5 * 7  ' 6 / 4  % " - $ ª : ∂ 3 ≤ 9 %   < | ”CöÁE∞‹g∞0Ñ	VÀP§€B®àãÔ	P	ó	¸
p
Ÿ0§+¥˚+ã§˘+w˜O˜&¯N§1çxõ◊¯Õz˚è˚q†ƒôèô§óu\¸:wz(är¸$öv£v≤˜L‡˜sµÕ`∫O[jj[[©k∑‡ííéãìóìÇ}fkd>Sñt…∞¢û¶©¨±†æª˚+ã˜¯M˜˜Ω˜¯q˜hrEo|Ç(˚*˜3˜.ﬁ€´«ã÷˜@◊˚*DI˚Y¶ƒ•∂´ø–ºV@YwSaN^K]U˚˚s¯3˚+}˜(˚(Ω¯œ€˜≠˜&@˜®¯f˜ã‹b«:Ø∞À±û©«ﬁMø(&@Y$U†Æ«∞§¿ã«≤bMIig,mxË˜ `«P+EdZT®DqÌã7iprlS«gÈ˜9˜˜˜&˚+†v˜#˜¯Ew˜ù˜&˚$˜$Ë¯m˜#˜M¯E;dYk_xr˚˚4êë#˚2˚˜ä˚#˜&˜#Ë˚$˜˚c˜a˜ªËç˚+~ß˘ß£¯V¯n˜ﬂ˜b,˜*˚˚,˚+˚a˚ZÎ˚&˜˜Î˜&˜Z˚2˚ ˚'wN\\w»˜'˜y˜&ü»∫∫üN˚&˚+É«O˜(˜S˜‹˜¯	ÿ∏¯i˘8˚’+˚Ì˜
Å∫ÉªuŒm¥VTU^\X¯DZ„ãBgqrhV»hÂ˜4˜	˜‹fÕH≥V´eì˚î°‹˜©˚+~¶˜˛π˜Ñ•ß¯R¯n˜p˜Aﬁ˚ kxá}e≥˜*—–˜/≤•˚®j˚8˚/˚w˚BÊ˚˜"˜ÊÓ˜˚-K˚nZuyñ°Ä|¶Ç⁄Âµç®ë∫íå†ìùÃ¢Q˚6˚+†v¯Ø˜ú¯^¯o˘8¸3`˚r§Àú£†√˜b˚Z¸ØÍ˚+~™˘ßß˜˚˜˜9˜˚˜
ÿ¯j˜M„b«˚“‘‚£ºΩÃ„A√˚
˚ 6H˚A≥UÔPË"l]X5&·H˜˜Á⁄˜‘˚˜ÙaÇgjeR®Cƒ“∂±±∑¬≠]?ËÖ¸+Gi_XOe¡‡≈ï™≥∆˜C£kD˚c~Õ¯™§˜!¯AÊyùfbp|cã7R‰˜ı™ ¿´ìÄUåSåõu≤µ•§≤…Gª3˚)"˚&˚‰)˜◊ÕÆ–º˚+~•˜Ñπ˜˝¶•¯R¯l¯&˜>.˜˚˚1*˚˚’9ˆ∞£êô®]˚0DD˚(kq˜ù§˜C˜8˜v˚1¶häoÉSÜsÖxMt≈˜5˜ó®ª°ùÅxïõoñ62˚“†v˜@˜∑˜Ü˜≤˜@˜˚Ü˚˜x¨˘¨Æ˘V˘y˜„˜d˚'˜(˚b˚b˚'˚(˚d˚b˜(˚(˜a˜a˜(˜(˜b˚Eå˚hO˚˚˚	P˜˜h˜_À˜˜˜Ã˚˚_õã§r´˜ °˜Æ©r§Ú˜3˜L˜?Æ¯˝˜NÂH ˚£ç˜∞≤∞ÿÚ/ƒ˚;˚«rŒàüzX¸yXÅ@Çr˜’˜?˜”˜˛˚[˜Ÿ˚ lp˚à˜tÆöô±—¨`/ß˚›&cZ8`yù∂˜ç©ÙºX˚˚+,¨˘]§é˜"›˜5¯p˘§˚Ûr‹â†}U¸¿Myr_qvòù£¶îã´≤iÆddmj`D’SÍ˜#‘‘˜&¯H‘õõ”çõã™l§˜ƒ¨˜≠¨r§Ú˜5˜6•˜§∑˘˜dp˚QBZ˚Kwòµ˜á˜
Ñ©nô˚•˜Áqz˚kn˚à˜}¥óíœ˜#ƒ`˚†§˜\¸“ˇr–Öù|Y¸wW~ÄAÇr¯€õã§¯ˇ´¨¶˜U˜6˜T¶˘¯oà˜]¸Íá˚]®°˜±≠˜î¸£BÄ6Ñr˜¯§7ê}ò’¯£˜Äæoû˚˚öã§˘§˜˜4¯§BétúΩ¯x¿¢ù‘å§˚Òr“â°zV¸xZuzDár“çv˘2§õ˘?˘O˘§˚hr´à¡åa{àÅz]˚˚‹˚˜–pÃàîãõßòë‘è§˚„rΩÇóÅ°X˜î¸Ï¶˜v¯ﬂ£…óñ¡ï˚“ìv¯yw›˜<˜é¯πf±]\ee]\±e∫π∞±∫˚—∫f±]\ee\]±e∫π∞±πcã§˜ƒ¨˜≠¨r§Ú˜5˜.§˜£ﬁ¯Ÿ¯o˜]¸…r–áù}W¸zY}CÉr˜˚§2éuô¿˜~ıà¨iô˚	§˜Êrx˚	jk&â˜~˛≤óì«˜#∆\˚ù“xº˘§Ì˜2˜’∑˘O˘§˚pr€ÉùyB˚ƒ˚*TG˚(]…˜˜·÷úõ€å§˚ÂrÕÜõyF˚·/ù\ø`aºœv‡◊€©∂≤Ø≥üœ·˜”∆ôõÀî“évù§˘§Ú∂¯B∑¯˘N˘§˚kr’ÑûvD˚√â˚Ó¯?˚fr£áô∫S¸oT|}CÅr˜v§>ïxüœ¯%ç¯¯Q¸≤¶¯·ƒòôÃî,x≠v˘:´Æ®w˜˜Ö˜
Ï¯î˜SŸa—G≠˚'÷9µw†ãº»∂≤ Á—I˚≠ß˜mmoÉÖÖxgg≠1˚7<˚1ºO˜PÕlÁ_†rãTHY_?Ù$Bÿ˜on˚å®Ï¢êîïõ≠±iÌ˜(Ô‡˜¸$“ã§rÆ¯Û≠r§Î˜6˜ï˜A‹˘D˜Î˜e˚˜˚}˚√rÃÖú}\¸Å^vzNár˜Œ˜p˜ ˜˜f¸˚A{˚VH)˚a|ö∂¯ä∞òïª˜“˚˚]“ã§˜@≤¯Zwî˘9˘B£]èÅóW˜˚s¯¢n˚p¸∏e.ÇYr˜_§Oètó§öò±´Ÿ˜sßQûRt~ÉÅ|àÄàéãYÜrû˜Ä˚VË˜áõã™l§˘§Û˜6˘˜xn˚*KO\˚Dxó∏¯lÿôó‚ç§˚rŒáù|X¸yXÇÉ?r¯’“y∫˘	≠áwº˜E˚E˘`§Ù˘A˜m§;4Ig;ã˚IÒ˜a˜k»ˆ˜Á€E˚«§Ù˜~pk~}yËoBΩã#˚V˚)˚0˚`˚d˜%˚"˜j˜ŒÆ˜Ó˜xv˘ÑvÆ˘V˘y˜„˚b˚(˚(˚a˚a˚(˜(˜b˜d˜'˜(˜b˜b˜'˚(˚d˚Eå˜_J˜˚˚K˚˚_˚h∆˚˜	˜«˜˜hz¯±vÅ~mx˚#4T˜˜0õùûïüã§üws“ã§˘§˜©˜6˘L˘§˚nsœáöÉnw~jq`˚˚M˚˜}t∏âéãó£öêÕ£˚·r≤á†{ûi˜K˚‡˚&BÅÅ9Är˜Ó§:îÄó”˜L˜Q˜Àö§ûï≠é˚ö†v˘Mvü˜Ò¯˚Ò§“è°úº¯x¿uúDç§˜ÒrBätyV¸xY¢z‘àx˘ËvÇ~lx˚"4T˜˜0õùûïüã§üws“ã§¯˛¨r§˜˜5˜K˜>¯˘]§tçÇèÇò˚]˜≤˜∞∂πﬂ˜
,»˚O˚”r‘áô{D¸NBÉÇ<Är˜Â§@ï}ö–˜V•˜c˚ÕY¯à˚dj˚$ä˜î¯´öï∫ﬁ±^)õ†v˘Mv¯X˜˘˜dd˚d¸€§’îòñø¯wΩyöFë§¯“˚\r˜vR∂˚#GÑb˚}˜é´®ú˜•˚Áq}˜m®˚
í˚áaü~À˜‘º˜≈˚˘1vÅ~mx˚#4T˜˜0õùûïüã§üws“ã§˘§õ˘<˘L§[çq∫t∞˚I˜Ø˜9˜uéúÌö§˚årÃÜíÑrráÅ˚˚(*˜+ÄùÜñãïüóëœè§˚Ìr∞àñÇ™^˜Z˚∏˚B˚qrkt~TÄr˜ç§Pëuñå§å¢£∑Õ‚≤ΩÒ˚6ôuíxãvÅáEÖrxû¯aó˜_õ˜pî˜üì¸ué§
§å
_˜é˘
endstream
endobj
29 0 obj
<<
/StemV 25
/Type/FontDescriptor
/XHeight 921
/StemH 0
/CapHeight 676
/Flags 262178
/Descent -203
/FontName/WRDTIY+Times-Bold
/Ascent 912
/FontBBox[-168 -218 998 934]
/ItalicAngle 0
/FontFile3 28 0 R
>>
endobj
30 0 obj
<<
/Name/F3
/Type/Font
/Subtype/Type1
/BaseFont/WRDTIY+Times-Bold
/Encoding 27 0 R
/FirstChar 32
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 332 0 0 499 499 499 499 499 499 499 499 499 499 332 0 0 0 0 0 0 721 666 721 721 666 610 0 0 388 499 0 666 0 721 776 0 0 721 555 666 721 721 0 721 721 0 0 0 0 0 0 0 0 0 443 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 666 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 388 0 0 0 776]
/LastChar 238
/FontDescriptor 29 0 R
>>
endobj
31 0 obj
<<
/Type/Encoding
/Differences[32/space 47/slash 65/A 68/D 78/N/O/P 84/T 97/a/b 101/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v/w 121/y]
/BaseEncoding/MacRomanEncoding
>>
endobj
32 0 obj
<<
/Subtype/Type1C
/Length 2263
/Length1 2263
>>
stream
  KESWJP+GillSans-Bold   A¯ ¯¯¯¯˚E˚zè˙5
 ãã
 ãã       ;±  ± }ãîCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans    1 I F O U S N J  5 P Q B  G 0 C T Z / X % V H " W M    E Ö ◊Xò@Xz¡äç‘)Å‘ 1l±Ò∫¸!:¸ë†v˜¶˜˜2˜ﬁ˜>˜M˜Cﬁ˘>˝>˜>˜¶˜˜1œ˜ÎËE˜˚0˚˚«Á¨vQXoo=<H†v¯ ı˜hw…˜%˜@˜%˜c˘>˚%˝>˜%˜∫º≠®†≠∏©kF˚õ˜%˜∫˜6æ7R\sVaâ)Ç·˜◊·∞˜*˜_˜¯í˜#ZG^zQ0Sª›Ü˜ﬂ˜<í˚Í˚˚"&'˚!˚$Ù-˜6Ø‚ã»ﬁ˚‘˜{Àë∞∞ƒ√±eLëH†v¯	„3Ï«˜%˜A˜%ÿ˜a¯a˚%¸a˜%∏˜Ωƒ±¶ûØ¥™pJ˚≠˜%˜π˜+¥CP^uV]˚àÇˆ˜úÓŸ˜%¯¯a˚<˜%y˚U˚loÕ˚Z˚ﬁ_Î∏±ì†æÙwdoÑm^q®∏˜R˜<˚^†v˜‚˜ÇwÀ˜%∞˜e¯a˚%¸a˜%˜[–‡´≠Ω¿¢§Ås±≥˜a™rñnãS[^+`â˜»†v¯	ÏÇw ˜%˜[˜%˜[˜%º˜d¯a˚%¸a˜%‹˜…µÆ±°±∂∏r@˚•˜%˜ªæ¨≤¶µ¿´fI˚¢˜%˜ºÙ@–"FVnFOÕkU´;npÜÄpºqqzrt¸†v¯awÂ˜4¬˜4˚,˜%Ë˜d¯a˚%¸a˜%0B˘G_gg__Øg∑∑ØØ∑∑gØ_¸óv˘Pwã˜§Ç˜?˘P$–†v¯¡˜˜ß˜>˘H˘>˝,˚˜ã¸¡˜>¯¡˜ãSÇ·˜«·∞˜/˜f˜/¯¡˜z˜E˚& ˚˚˚9˚1˚%˜,˜+Ò˜1√˜K˚/è&gSGTXÆ˜Û∂º ‘™O1H˚ev˜qÏ˜õv∞È-Úƒ˜%˜[˜'ˆ˜^¯a˚%˝G˜%˜ëw≠∑¥˜ÂÏ˜(Ó˜-Ò˚Yb|ib0ßØ¢î™–≥X35_UDnqî†n˚Ç·˜ºÏ¨˜'˜˜%¯ß˜siÄâÅ|Çî¢˜f<≤˚BHxfO˚
∫πÕ©≈ üi`à˚UO:u˚Q¬T’Ωπô±√fï¢|ª≤ƒù£≥˚t⁄usn~pqv°¶π¥ü·™¸˚†v˜˛Ó˜˜Çw‹˜%Ë˜v¯a®»Æü∏õñäÜ±ÿ˜	Ëéueëo˚	6D˚tI(Õ˚˛˜%˜˛ÕÓ˜uÇ˜"¯4˜"∫˜C¯C˜C˘–˜È˜8˚˜N˚ï˚ï˚˚M˚9˚B˜!˚D˜é˜â˜%˜C˜C˚C˚58˚˚5ﬁ˜˜·ﬁ˜˜·8˚HÇÏ3„˜±Ï˜hw≈˜%˜Y˜'º˜_˘>˚%|˝>˜%ºÆn≥∂|π˜‰Ó˜"˜!/Ï˚^oÉp]-£≠°ìß«¿b).`VGnqó¶l˚sÇÏ˜ûvæ·∞˜Í˜¯¯H£[`ïQ˚>R6˚+˜yóãHvp~`T\ûü\%Äü“t’˜œ¡Î˜.˚yçãæ´¨èû®…d ˚ ˚\v˘>wå¯ê¯ë¯a˚,#˚Å*˜Å˚/˜H¸˚˚º˜.˜V†v˘>wÿ˜>˜Ú˜>˘ì˘>˚>¸5¸ ¯5˚0˝>˜>¯I¯¸I˜#˜óv¯jwä˘£¯˜Ü˜˚è–˜c¯j˚(*˚í%˜í3$˚í*˜í˚(˜d¸jœ˜,ã˜¯D˜÷˜>˜·˜C÷˘>˝>˜Æ˜§˜˜$˜X˜O˚˜/˚ç˚˚˜˜5 (˚	'X˚˚?˚HÇÏ3„¯	w«˜%˜A˜%x¯˜%¯a˚&∏˚∫^|ci_eh¢Ã˜±˚%˚ª˚ŸSÊ≈∏°¿π˚ ˚z·˜ˇ a¿ ˇ GaHˇ I·Hˇ õ˝pÏ5·ß˜˚˜1˜˜˜%˜ÚÄ¯¶¯a˚¶˚:c˚RÒ@6—[∆ÇâpÖR~Zj§y™ÇâÙ@%qvYdNøB˜V˜)Íªˆ¢ÑØm©Ò@?ÿ˚D]¿¡˜[››ÚÄ§§úÆ¥¶Ñ°{ßÕÍÄ˚ÌB∫Ø∞ªΩ¨fa[fc]]e±∏Ù@˜\¸lcpK>aûÆ≠µ†œ”¥yj˜†v˜˜˜ù˜7ãwé˘õÿ¯o˘>˚Y˚ß˝>˜Hæ˜˜≈√˚˜K˚µ˜í˚fËÔ˜ù˚ óv¯jwç¯é˜kÇ‹˜h¯j˚.(˚í)˜í˚/¸†v˘>w ˜%˜d˘>˚%˝>˜%Çî˘>î˚zî˜äó˜Ÿí¸∆îÓ
å
yXO	˜™˘
endstream
endobj
33 0 obj
<<
/StemV 145
/Type/FontDescriptor
/XHeight 728
/StemH 0
/CapHeight 682
/Flags 262176
/Descent -221
/FontName/KESWJP+GillSans-Bold
/Ascent 716
/FontBBox[-177 -230 1167 929]
/ItalicAngle 0
/FontFile3 32 0 R
>>
endobj
34 0 obj
<<
/Name/F4
/Type/Font
/Subtype/Type1
/BaseFont/KESWJP+GillSans-Bold
/Encoding 31 0 R
/FirstChar 32
/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 281 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 781 0 0 802 0 0 0 0 0 0 0 0 0 844 875 656 0 0 0 719 0 0 0 0 0 0 0 0 0 0 0 0 531 583 0 0 552 302 542 583 271 0 0 271 958 583 594 583 0 448 427 406 583 510 781 0 510]
/LastChar 121
/FontDescriptor 33 0 R
>>
endobj
35 0 obj
<<
/Type/Encoding
/Differences[32/space 46/period 65/A 80/P 84/T 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t]
/BaseEncoding/MacRomanEncoding
>>
endobj
36 0 obj
<<
/Subtype/Type1C
/Length 1388
/Length1 1388
>>
stream
  OBASVO+Helvetica-Oblique   E¯ ¯¯¯¯˚:˚t˙|˙7
 ã
 o
 ãã      ¸  !¨  K Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    5 I F  " O B M T 1 S N D P U      Y ∂ π Û5¡÷PíÀ*|√Ùd†v˘‡˜ïÎ¯Á˘‡¸Ÿ6˜á˝Î˘-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è¸ú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü¸@†v˘awŒ„˜/˘a3˝a˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥¸ãı‚Û˜Sı#!u°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
37 0 obj
<<
/StemV 88
/Type/FontDescriptor
/XHeight 737
/StemH 0
/CapHeight 687
/Flags 32
/Descent -194
/FontName/OBASVO+Helvetica-Oblique
/Ascent 717
/FontBBox[-214 -224 1198 931]
/ItalicAngle 0
/FontFile3 36 0 R
>>
endobj
38 0 obj
<<
/Name/F5
/Type/Font
/Subtype/Type1
/BaseFont/OBASVO+Helvetica-Oblique
/Encoding 35 0 R
/FirstChar 32
/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 611 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278]
/LastChar 116
/FontDescriptor 37 0 R
>>
endobj
39 0 obj
<<
/Type/Encoding
/Differences[32/space 40/parenleft/parenright 45/hyphen/period/slash/zero/one/two/three/four/five/six/seven 57/nine/colon 61/equal 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p 114/r/s/t/u/v 120/x/y]
/BaseEncoding/MacRomanEncoding
>>
endobj
40 0 obj
<<
/Subtype/Type1C
/Length 5027
/Length1 5027
>>
stream
  SMCHOO+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      á≤  | Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  ?  0 # + & $ 5 * 7  % " 4 6 3 : - /  9 ) 1 I B S N D P M H Z L J O F U T  8 . C    Q Y   E (  V G  W  2    	  
 ' , A   T Œ2Ñ¶ΩÁUêS∏‰ˇ.Ká±ˆ=Ωs¡òﬂ<ÑÊ	"	å	è	˙
:
ö
»
›RΩıB\æ$y¿¯tüÎRäÈ_§Ã=o˜x˜¯ä˜∑˘F˘r˜˙˜m˚˜6˚v˚u˚˚4˚o˚n˜	˚3˜x˜t˜˜4˜m˚*å˚0A,˚˚AÍ˜0˜/÷Î˜˜÷+˚/”ã˜˜U˜˜0˜◊˜$˜Æ˜#˚˜)Ù˘0˜m‡m∫:±¯ Æ§¥Œ˜5”˚˚˝a˜≈ﬁ»ïû≠Ùœ±¥—€¯˚:˜¡XdmG˚C˜0˜?◊ÆtWÙú˚∫KafC˚M˜U˜Sœ≥iQ-y˜¯˙w°˜˜A˜*¯w˜d¯ë˚*¸ë?snNKs±Ú¶˚l˚OÃD˜A˜'◊ÿ˜)úã˜˜O˜˜+˜◊˜'˘ ˜¸!˜O˜˜˚˜+¯˜¸¢˝a”x˜¯É˜∑˘˘?˜â˚)*n_f6˚HÁ˜,˜4ÕÊ˜
ﬁµi1ß˜(˜-~˚˚A˚]˚˚'˚|˚|˜˚$˜^˜;ˆÊ˜A∞d†v¯„˜˜z˜+¯Ë¯„˜¸⁄˚˜l¸„˜+¯„¸†v˘awÀ˜*˜j˘a˚*˝aú†v˘awû˘˘˘a˚/˚0¸≥âä˚.¯¥˚4˜Ü˝a˜#˚—ã˜%˜r˜%Á˜*˜Ü¯˜%˚*˚%˜*¸˜%˚*˚%”ã˜¯i˜◊˜'˜»˜,˘?¯˜n'˜˚S˚–˝a˜À˜J˜˜%˜{˚,˚(M0'˚&¯i˜$˜¿@˚/”†v˜'˜¯Qwü˘;˘O˚ë˘a˚A˚ë˝a˜1Ω˜'˜ùπ˚'3˜§˚LÁ˜∞çúw˜˜I˜$˜'˜6˜≤˜"˚˜˜•˜#˚˜%’˘	˜lÚS√˚¨ˆ˚C∑Sôv†ã¥¿º¨◊Ê∫hBï˜#˜$Ñ ‚˚;˚A&8˚"˚*ıo˜nŸÿyÓt™vã^NYl&,Z∞ŸÉ˚"çCôd±aøSÂk˜ã˜@ã˜Áã˜$”x˜¯ˆw”¯÷˘˜é¯g˚,¸m/[^*;[¬Â¯e˚-¸p˚7ı*˜F˜TÒË˜D”†v˜Æ˜˜T˜◊˜(˜∏˜(˘9ûsîÑù¿˜HÄ©:Ø’©Øƒﬂ˜3⁄˚˚ˇå˝a˜'˜Æ˜/Óöy˚
çåFéoòZè¯ÜIgn:˚C˜T˜OŒ±hMú†v˘awö˘˘˘a˚=˚!˚À˚*˜À˚D˜å¸S˚¢˜+˜°dã˜¯ﬂw◊¯é¯⁄˜˚¯¯ﬂ˚*˝a”†v˘aw–˜ ˜ƒ˜ ˘!˘a˚ ¸àâ˚±¯à˚1˝a˜ ¯îç˜∏¸î¸çv˘àwj˜Î˜ ˘u˚	˚v˝à˜ú†v˘awô˘˘˚|¯	˜m˜Ï˚@˚˚z˚˜z˚F˜o˚Ú˚|¸˜B˜%˜â˜˚â”†v˜’˜˜§w“¯◊˘˘a˚*˚§˚´˜§˚*˝a˜*˜’˜´˚’ú†v˜ó˜˜h˜¯q˜)˘¯Ä˜4·˚˚‹˝a˜*˜ó˜@˜ÁÈ˜˚)âCfg@˚˜h˜
ÌÆo?d†v¯@˜˜>wÃ˜˚˜ ˜]˜Ù¯µ¯˜C—˚CVnUoà˜ë˚˝aÏ˜ ˜≈ﬂ≥≤’∆ßjC˚◊-}ÔJv˜z‹˜˜®˜˜Q˜|¯°†uíÇ£ø˜¥Î;≈˚˚0FU˚Ä˜Ωèß£¿ ®x`t|}iÜ˚x${XRã*¸.ÀMÎ”≤ù∆…|åqçÅîp¸z˜SRS[K`q§≤ª°û“ò–òàä©ú˚ô†v¯(˜"|wÀ˜˚˜ ¯¯%˜"éÜãÅJgp<_âÊ˚¸ßË˜ ˜®ﬂ∑∑ﬂñîäâü˜É†v¯?˜
˚	˜
|wÀ˜ ˚ ˜˜E˜˜>˜ Î˘Ã¯˜C–˚O`qPfÁŒ_jûCF^pJgâ˜ÿ˚¸ßÎ˜ ˜◊–®Øƒ…¢n:˚“˜˜“Î”´∞…Ω•m@˚÷-}˜˜€˜
≠˜$˜`˜!¯ü˜V˚!KjnSHg¡˜ı≥≈’∫©pPò˜!˜É+‘˚˚71$˚O˚?Â(˜/˜Âÿ˜ùd}˜	˜Ÿ˜
≠˜#˜ï˜#¯’˜û˜?!˜˚9˚:!˚˚?˚AÛ ˜<˜;Û˜ ˜@˚# _S76_√ˆÙ∏ƒﬂﬁ∏R"¸†v˘aw–˜ ˜e˘a˚ ˝ad˚mı˜ ˜
˜…˜|w≥˜#˜z˜˚˜⁄¯º®¯ä˚<â¸ÀmX©D˚4!˚<˚?‚#˜!–¥£ƒ´éáL4hh>Ktò¥Å˚,#óﬁS˜'˜èí˜.Á˚˜Ñ*eR:G`«ÈÍ∂«Œ◊∑J1-˚i˜˘wï¯£¯≠¯ß˚'˚ ¸â˚¯˚/˜X¸æ{K{|UãÖàãçs˚äßûäõ˜	ûû˜_—-†v¯ßw˜bw–˜ ¯∆˚T˜Ÿ˜N˜b˚?˚D˚]¯˚ ˝a˜ ˜<∆«˜˚x¸†v¯ßwﬁ˜–˜ ˜e¯Ê˜˚ ˚˜ ¸Ê¯ß˚ ¸ßd†v¯?˜|wÃ˜˚˜ ˜]˜Ù¯¥¯˜Dœ˚C_rH`âÙÿ˚¸ßÏ˜ ˜ƒÿµπ—«®iE˚◊-}˜˜Ê˜˜¢˜#˚#˜ ˜p˜#Ù¯¢˜x§˜P2Ù˚5˚4.%˚D˚IÁ&˜9˜⁄¬˜Ø˚#cyny\ÏAdµ‰ÑÙ˜pÊ˚m⁄ò´¨  Øf@ï˚—Öı˜ﬂÔ›˜ ˜»àıâ|Ñä^Ñë±˜≥·Ô5˜%˚ ˚%C'”˚’7≥kÚùûôåç´-}ı˜ı©˜#˚˜˚˜˜a˜ ‘¯ö˜9˜d˚·?ãÍ©´ù¿«®uZë˜˜Ñ;≈˚-˚;D ˚X˜› ã3ggxVÃ=h¢¬à‰˚#˚çÎE˜0˜#Ê–˜¸˜∫†v˘aw˜∑œ¨Ÿç⁄¨‘˙4˘a˚+b˚Cb˚Bg˚Dâh˜UçÉB˜Ë˚3N˚æîøZ˚´âh˜Sêt7˜˘˚3˜_˝a˜ ±˜N∂˜N©˜Pç™˚O≥˚P¥˚M˜#˜K†v˘aw–˜ ¯4˜˘ê˘a˚l˚¸…à˚¯…˚o˝a˜ ¯Ïç˜¸Ï˜(˜¯Ïç¸Ïd}˜;v¯=˜˜>w»˜ ˚ ˜˜É˜#z¯’˜•˜72˜˚E]rQeâ˜ë˚ ˝a˜ŒéˆSÆªr–˜·˜˜D˚#Å*]JE@[…ÏÙ∑«◊÷∑O%-†v¯}Ó˜w˜Å˜!˚˜Ë¯˘Z˚8Td w(–˜<¸}¸ã˜%À˜*˜j˜%˚*˚%-x˜˜˜˜é˜©˜˜d˜$˚˜Ù¯ù˜Ì˜ä9˜˚<˚(.-˚*˚ ·-˜ÀØõ∏Øçàá˚cHBã[p¢∫Ñ˚˚ú‹H˜˜8È˜˜{¯˚$˜?c[LId∏Ÿﬂ¥∂«œ≤];d˚Nv˜U˜˜Ÿ˜{w…˜˚˜!˜{˜#Í¯’˜§˜82˜˚AcsF^â˙ÿ˚˝vÊ˜!˜¶çå≠Rπr–ã˜·˜˜D˚#Ç)^KEÍ?\∆È˜¥∆Ÿ÷∑O$-†v¯ßwö¯†¯Ø˚H˜¢˜B˜ô˚94˚.1˜.˚>˜B˚ô˚H˚¢˜<Á˜4Á˚4-x˜¯é˜´˜$˜_˜$¯ü˜Ó˜å=˜˚<˚;=˚˚å˚éÿ˚˜<˜=ÿ˜˜é˚$å˚RqK?@qÀ˜R˜P•À÷◊•K˚P˚—†v˜k˜¶˜™˜≈˜k˜˚™˚d}˜;v¯<˜˜?w≠˜$˜|˜˚˜z¯∏˘a¸˚˚ìâ ^d†D˚5˚ ˚;˚@‰˚˜œæ¶¡ÆçzH˙é˜ò&^Q=E^ ÏÛµ∆÷⁄µR ˜x˜4v˜û˜˜u˜¯◊˜x˘[¯˚Ω˚˜9¯˚ oQY*˚AÁ˜0˜4ŸÏ˜◊∆_B°˜(˜)x˚Ê˚C˚i˚˚(˚z˚v˜˚+˜YÌÃ´Ÿ»xô0-ã˜¯h˜
´˜˜]˜ ¯í˜˚»®ƒ˜œ ≈¿ª®¬ã⁄ã˜(„˚'ã˚'ã<6Ü˚9˜Óè•¨“«≥bL4Gk˚4˚*jSÑ˚d}˜
8v¯ßwÕ˜ ˜[˜˚˜Ù¯≥¯ß¯˚˚«B`\IOm¨Ã˜›˚ ˚Ò˚ÕC˜÷æß»ØÙç@˚—†v¯EÌ‹˜·˜ ˜—¯EÌ0†øëìµ≤˜çhÄãq#XZ%_?)◊¸E˜ ¯E-x˜˜mÔ˜O˜¶˜˚˜˜M˜ ˚˜$Í¯ò˜g‹d∆G£çÏ»Ø¢±Œ˜0ÿ˚˚1:˚&ä˜‹é≠≠≈¬ÆhTIel:v'Ú˜â≤q<K^]NHl∞‚Ü˚˚)âÊ3˜,˜(ÔË˜-†v¯ßwò¯§¯±¯ß˚'˚¸â˚¯˚/˜T¸ß˜&-†v˜0˜¯Qw˜∆˜ ˚˜Ë¯°˜0˜<¯Q˚4˚ó¸D˚–˜´˚0˜ ˜0˚¯3ä'ä#%˚E»˜E˜∆˜x˜¯ä˜∑˘H˘t®=’º ¶·ãı˜m˚˜6˚v˚u˚˚4˚o˚n˜	˚3˜xÀŒù©¿ﬂ;B¯.N~Wvb@“>:‘FspÖlã˚AÍ˜0˜/÷Î˜˜÷+˚/-†v¯”˜˜˜%¯£¯‰ˆ¸áà˚˜Ù˚1˚L;˚L}˚c˜%è˜q˜˜c˜"˜8-x˜˜ô˜˜˜	¶˜˜`˜$¯ñ˜Ä˜0Ï˚ZgÄna•˜.˜¥˜	¸[¸˜ÜùÆ©õ∂ãÀ¥Y>:aVKQm™ŒÅ˚˚ï‚>˜ ˜*ÔÒ˜--x˜˜ë˜ËvŒ˜™˜˚˜˜f˜˙¯õ˜}˜4„˚Qi|`fäçë’ö˜Îãø†w\î˜˜	}=…˚˚A2˚
˚ë˚Öﬁ˚	˜@˜ÏÙ˜'˚á8eWNˆI^¡Ÿ÷¥πÕ»µ[E˚—†v˘qwÆ˜$˜Õ˚bd‘|®|≠_Òv˜ ã˜ã˜°˜¥ÓöÆîü∏ﬁ&˚˚0S˚*˚;˚3∆˚0˜
˚+I†v„˜˜˜≥¯ã¯≥˜»˜¸ã˚¯ã˚p˜¸ã˚˚—†v˘qw˜-˜$˜Ω˜û˜4R˜+˚˜0%≥@ônöjµ.¢˚ã˚ã˚x˚`'|gzleE˜	˜)≈˜1˜:d†v˜¡˜˜7˜◊¯ë¯›¯„˜¸ë˝a˜*˜¡˜Œ˜˚Œ˜7”†v˘aw‚˘˘e˚»¯=˜∑˜∏˚U˚•˚µ˜µ˚+˝a˜+˜á—”˜q˚œwü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
41 0 obj
<<
/StemV 140
/Type/FontDescriptor
/XHeight 737
/StemH 0
/CapHeight 717
/Flags 262176
/Descent -205
/FontName/SMCHOO+Helvetica-Bold
/Ascent 750
/FontBBox[-170 -227 1001 963]
/ItalicAngle 0
/FontFile3 40 0 R
>>
endobj
42 0 obj
<<
/Name/F6
/Type/Font
/Subtype/Type1
/BaseFont/SMCHOO+Helvetica-Bold
/Encoding 39 0 R
/FirstChar 32
/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 333 278 278 556 556 556 556 556 556 556 556 0 556 333 0 0 584 0 0 0 722 722 722 722 667 611 778 722 278 556 722 611 833 722 778 667 778 722 667 611 722 667 944 667 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 556 278 889 611 611 611 0 389 556 333 611 556 0 556 556]
/LastChar 121
/FontDescriptor 41 0 R
>>
endobj
43 0 obj
<<
/Type/Encoding
/Differences[110/a73]
/BaseEncoding/MacRomanEncoding
>>
endobj
44 0 obj
<<
/Subtype/Type1C
/Length 178
/Length1 178
>>
stream
  LOTGFE+ZapfDingbatsITC   6ã˚πœÉ
 à?ãã
 à?ãã   h   e   kë   ¨ a73    á %<¯
˙0˚π…˝Ã˘7˘Ã˝YV¯Á˙¸Á‰˙!—ç˙s˙sçç¯Õ˘
endstream
endobj
45 0 obj
<<
/StemV 0
/Type/FontDescriptor
/XHeight 0
/StemH 0
/CapHeight 1667
/Flags 4
/Descent -293
/FontName/LOTGFE+ZapfDingbatsITC
/Ascent 1667
/FontBBox[0 -143 976 814]
/ItalicAngle 0
/FontFile3 44 0 R
>>
endobj
46 0 obj
<<
/Name/F7
/Type/Font
/Subtype/Type1
/BaseFont/LOTGFE+ZapfDingbatsITC
/Encoding 43 0 R
/FirstChar 110
/Widths[761]
/LastChar 110
/FontDescriptor 45 0 R
>>
endobj
47 0 obj
<<
/Type/Encoding
/Differences[32/space 44/comma 46/period 48/zero/one/two/three/four 55/seven 65/A 77/M 80/P 84/T 86/V 97/a 99/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 121/y]
/BaseEncoding/MacRomanEncoding
>>
endobj
48 0 obj
<<
/Subtype/Type1C
/Length 3307
/Length1 3307
>>
stream
  VUKQJF+Times-Italic   C¯ ¯¯¯¯Ä˚=˚m˙Ö˙
 ãã
 ãã      ¸  ;¨    }âé002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z     .  7 V       Y ÏLO≥Eø|¡>≥ﬁ+ü ≠ZÆ		¶	‘
)
π
ˇ/O-†v¯ˇÆ∆¯—˘˘"¸ßa˚.ùá°∫ú§•ü§¨¶ë˜˚#¸•}YszFÑ{˜∂õ9ëÇè´ïë•í•˜ ¯á¡÷®rKÅäÇâxúä˚*óv©v¯Ovû¯]¯pÙó_QvwzãÉÑíïñëôçìƒ˜eïÆë©ãò≤pßfKFM˚#-âç˜
¯KÖêL}wÜBÉz§åúå§âãtuj|P˚¸ã÷±˜)õµ≤∆¡‹Õ∆ÆãõãóÄã}ãÜåãÉnW˚S}WÇapú{ßæ∑Æ⁄ª˚bÅ∏¯¢™·˜yÃ¯/¯
∏o¢T˚˚2˚9˚&3æV‡Œ’≤œ…óCQk{`ãSe∞¡ôéüí•®è˜,†Ú◊ã‚Jí7+G˚vù∑∞Êœ‘¿é†åö{t¸$d†v˜vØ¯+vX¯˚¯»õSéÉï”,¯Ãq˚µ¸âA˚}{bÉ{˜Oõ\ê~í¢òì•ó¢≈˜˜pü˚åÅåÇãÅgx~Pä{æ˜ö˚V˜(˜òç˚*óv©v¯Nvô¯`¯nÛ|òUFÅÅyãÇÖíîíê†ï±∑˜4ó∑î¥ãö∞q§e,4˚&H^âçÀ˜eáç˚tëå[Ç{æâòÜx~ÇnÖvãÉl@˚ß÷¥˜$¢√º— „±¨ØãòãïãzãÄÖlÅf`˚7{PäÉ|lõ{´π©§„À˚*Äº[ª¯°úﬁ¯pÔñ~~YSyãÑÜêìïê¶ñµÿ˜∆ÖéLÑÄ[äåÄÆoûdã˚˚1˚J˚-=ÆbŒ—≤©˜„çà{LÜqãwoò®±¨•ﬂÕ˚˜î3,˚z!drß∑ÂÈ˜q˜Æ¢qd¸ïv¥˜Ç˜´˘;ÜêQ{à9{§ç∑ärÑèñv>"¸v;à}ãziõy™¡ß¢Ò—îUCwxuãÅÜëïíéöì©˚ôìv¢v¯A£åv˜ ‘πÿ|¯¯O}}ÇÑá~|nqúãcC[aJ-˜?ã@[nkaRl≥Ïz|¸w˚4öõíëêñ|≠™xã±ﬂ…¬÷Í˚Ÿã‘¨¢ü≠Ω´g=ï|õ˚*ïv¯Yv¶ﬂ˜¶ﬁ¯h˜πËU√2˚(˚*˚0˚-/¬WÎ˜ ˜*˜<˜8´)B˚m˚[k∞¬Ó›˜p˜∂ßfP¸˚Mv¯Ô´˜x°ØÍ¯:¯˙±g¶Xaexdjibu\j#0ÉkÂ3¸9t˚lX_ãÑëïîîêãô†zösw}zsi¨q∑Â–Ï˜Mµ‘˜’˜ ë´ ˜0¶±”¬ôïÜÑäÜÅÄã|sö{°¢ùù°d†v˜≈∞˜Æ©¯âÚ¯¯äÓB¿˚˚åz´Ü±è`}áv`˚
¸={RÑÖPÄ{˜âõSíìßöéóî≠¿˜U∂Ö§â±ã˜,Û€˜	$ë˚OW˚xtçè{—˜ãë†óì®ãÊ¥g;˚ô†v˜ËÒåv∏¯¯0¯™xünX@7(^Çwäçº˜[àéWÅWÇWÇ{éûìåì†òÅy~ÖiÅh:˚π◊∂˜ ö¥Æ–∞’µ¿†ã†fã∂®úû´”óv©v¯ø\∫ó˘Fx˘RÙ}óZOxyzäÉÜêïîåêí£ƒ˜gî≠ë©ãòØsßk24˚Haâç¶„ï±ãúØt£iO?D˚8àéƒ˜[àé$vååPÄ{¿äñázÉçë{M8˚ ÷™üﬂ…„x—º¬ª®òìÇ|Éåç|Tãâ;˚∫◊≤˜,†¬ªœ∫œ¡ª¶ãóãîÇã}ãÜåéÄ^Z˚Z}Qáz~¯oö{¶π∫∞ÿ¿˚bÄØ¯5w©‡¯<˜¸Ωa´H˚%˚ ˚'˚.)øUÎ‘…Æ‘¿{îcZSk[ãSh∏“˜$Ï˜Ò£öÉ{|Çãruõ|£¶ûû•¸ñv¯+¨Ø˜ò˜º¯B;ßÚåçãçãçêàèÖÖääÄÇ\Sbib{mÄáàãÅãÇãîãÇ÷B˚ßt5åéãÇuä†y¶§£ñü¢ùõòú≥ƒ~ërlpj{}ãÅÖëñêåçèõﬂ˜“ﬂ˚*˚Mv˜Wû¯∂¯Â¯i˜…ﬂaºBL[l=TâéßÓáí˚0uéz©é≠àãpÑÜsÇj˚¸N~YÖÖ[Ü|˜bö\yî°©®ìÆ}¶òà®˜!˜0˜=˜+1ì˚(˚ ˚5'ltö°πª˜(ùπÃ§ƒºø≥°mW˚b˚Lv˘v˜‡Èc≥–¯>¯≤u£h‡v{|w–Z¡óãdP,˚/p]w˜Ö¨N˜qyãvE}ÅVzéüìåî¡§Y˚lºöGïV~{Ñ|tmxqplwwÄÖÇãwã}®pãtãz{ãuãpüy™ã∞ãº≤–‡˜	˜#˜˜Éã⁄˚*ã÷¯•‘¯‡¯W¯éÌF‘-*?Q%güÑ≤Õµß…ã“¿WDP`C%˚˚e˚tz˜˜Ω˜zírXv~Uã˚Rê˜U˜U˜
˜
©∫ãœ˚*Ñß˘ß´⁄˜»Ÿ¯Ö¯H˜*OÊ(˚.˚,˚|˚~˚Œ0Í˜1˜&˜j˜y=‚˚*T˚]J5_jjvhUjΩ‹˜Ω˜U¡Ó∆¨∑≠∑ø™\<˚*†vº˜¸¯-˘0ëâçáÑ2v{+{†çØãã£åòÄxÉãÖÖw˚¸ÇÄeÇá0}˜´ôtåKá∞íâÉ†÷˜#¯öèöçîãè˚*Ö±¯Ôµ˜Ÿ€p‚–¯e¯Ω—O¡<FKcLlöÜ¥º®ú∑ãæØfU8,I˚$zå{°‡Ù≈N˚3QCDzrñüm•eÑéwpz|rf¥v”˜1˜˜˜#ÿr¥E≠é–˜ª¨´“˜K†v˘"vy˙˘¸˘õ˚;˚·¸}àS¯}˚H{¿â†ÄrÇãåvC ¸	n%~zT{˜ZúXéwò©ñè†êû˜¯<ç…¸Æú¯¯¿ç˚¸d}Ww{HÉ{˜•õJêí´õçòî™˜¯Rõƒîî√ë¸$á˜˜¨≥sßinvxpzíù{ö}êÉrurVgïx‡º∂¡ã∆dév˘4v◊¯¯˘D˘õ˚N{øÑñÖuy|hfK˚^˚ÛáI¯Jäëãëãê´öî…íõ˚Ö{¿ÑëÉô9Á¸√û¯¯˝õ¶ôï•ç˚*Ä¿mv¯Nv™v˜‡˜∏¯o˜ }î[Nyy|ãÑÖëïóçåòºãê†Ÿ˜ºAa˚rT`HP/XUnãqãç•çìÊ¯ ∏àéQ}zà@Ä}†â≤ílÉãäÇgY˚W\ÜpãzgùxØ–ææ˜O˜çh˚Éhw¯lúy©œØ–ªÆ˚*†v˜EÕKÀå¯q∞¯r˘:c¸5¸CwG˜ôZ˚G⁄∫˜EÓöÕ,ô˜◊,˚◊˚iç˜≈˜’˚*òv¯Ô‘÷¯a¯¨˘&Öï¸
:˚òÇº≈•ô∆ã˜rçà¸¸Ï“¸$Ä˜¶˜˜∑™r§mlrrlm§r™©§§©xû¯Aô˜g¢íã˜°ç¸sé°
¢
_˜é˘
endstream
endobj
49 0 obj
<<
/StemV 23
/Type/FontDescriptor
/XHeight 677
/StemH 0
/CapHeight 654
/Flags 98
/Descent -205
/FontName/VUKQJF+Times-Italic
/Ascent 684
/FontBBox[-169 -217 1009 884]
/ItalicAngle -11
/FontFile3 48 0 R
>>
endobj
50 0 obj
<<
/Name/F8
/Type/Font
/Subtype/Type1
/BaseFont/VUKQJF+Times-Italic
/Encoding 47 0 R
/FirstChar 32
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 500 500 500 500 0 0 500 0 0 0 0 0 0 0 0 0 611 0 0 0 0 0 0 0 0 0 0 0 833 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 0 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 0 0 444]
/LastChar 121
/FontDescriptor 49 0 R
>>
endobj
51 0 obj
<<
/Type/Encoding
/Differences[32/space]
/BaseEncoding/MacRomanEncoding
>>
endobj
52 0 obj
<<
/Subtype/Type1C
/Length 301
/Length1 301
>>
stream
  CUFSBZ+Times-Italic   C¯ ¯¯¯¯Ä˚=˚m˙Ö˙
 ãã
 ãã   ˇ   ¸  ¨   }âé002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku      ¸$xû¯Aô˜g¢íã˜°ç¸sé°
¢
_˜é˘
endstream
endobj
53 0 obj
<<
/StemV 23
/Type/FontDescriptor
/XHeight 677
/StemH 0
/CapHeight 654
/Flags 98
/Descent -205
/FontName/CUFSBZ+Times-Italic
/Ascent 684
/FontBBox[-169 -217 1009 884]
/ItalicAngle -11
/FontFile3 52 0 R
>>
endobj
54 0 obj
<<
/Name/F9
/Type/Font
/Subtype/Type1
/BaseFont/CUFSBZ+Times-Italic
/Encoding 51 0 R
/FirstChar 32
/Widths[250]
/LastChar 32
/FontDescriptor 53 0 R
>>
endobj
55 0 obj
<<
/Type/Encoding
/Differences[32/space 103/gamma 173/arrowup]
/BaseEncoding/MacRomanEncoding
>>
endobj
56 0 obj
<<
/Subtype/Type1C
/Length 604
/Length1 604
>>
stream
  LWTQRK+Symbol   F¯ ¯ ¯!¯!¯)¡˚H˚∏˙÷˙Å
 ãã
 ãã      $™  = ")†ßgreaterequalgammaarrowuplessequal002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Simpele is a trademark of Stream Technologies Inc.Simpele    áàâä     1 ú ›	¸$&ã√®¯É¯†˜Ó ¸É˜xM¯E˚Z¸E˚ZN¯É˚
√¸ÉS˚É˚`v˘ŸÜw˜E˜
∞¯t¯Ç#˚˚ıÉ∂É≤á†˜abqΩFIhV(mõç´çóíõï•¶ù•ã≠ã¢uûU™5òS†˚"`˚{Oã\ãa†o™ã≥ã•øã€∞ØÜ∏~“\†v˜™»¯Œ˘%E∆b±˚+˜,˚+˚,beFP¨i±ßôóº¥ª≥òóØØ˝¨»˘¨Øgòªcºbô±o&ã√®¯É¯†˜
»¸E˜Z¯E˜Z…¸É˚xL¯É˚Ó√¸ÉSs£¯Üç˜?ò˜Åã˚véØ
¥
_˜é˘
endstream
endobj
57 0 obj
<<
/StemV 41
/Type/FontDescriptor
/XHeight 684
/StemH 0
/CapHeight 671
/Flags 4
/Descent -223
/FontName/LWTQRK+Symbol
/Ascent 921
/FontBBox[-180 -292 1090 1005]
/ItalicAngle 0
/FontFile3 56 0 R
>>
endobj
58 0 obj
<<
/Name/F19
/Type/Font
/Subtype/Type1
/BaseFont/LWTQRK+Symbol
/Encoding 55 0 R
/FirstChar 32
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 411 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 603]
/LastChar 173
/FontDescriptor 57 0 R
>>
endobj
59 0 obj
<<
/Type/Encoding
/Differences[32/space 178/lessequal/greaterequal 202/space]
/BaseEncoding/MacRomanEncoding
>>
endobj
60 0 obj
<<
/Name/F20
/Type/Font
/Subtype/Type1
/BaseFont/LWTQRK+Symbol
/Encoding 59 0 R
/FirstChar 32
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 549 549 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 250]
/LastChar 202
/FontDescriptor 57 0 R
>>
endobj
61 0 obj
<<
/Type/Encoding
/Differences[32/space 46/period/slash 77/M 79/O/P 83/S/T 97/a/b 101/e/f 104/h/i 108/l/m/n/o/p 114/r/s/t 121/y]
/BaseEncoding/MacRomanEncoding
>>
endobj
62 0 obj
<<
/Subtype/Type1C
/Length 2664
/Length1 2664
>>
stream
  JXSSBS+Times-BoldItalic   C¯ ¯¯¯¯Ä˚\˚l˙t˙-
 ãã
 ãã  	    8Ø  
D }éì002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku    1 I F O U S N J  5 P Q B  G 0 C T Z 4 . M     | ıX…hÜ°Û;º47√wÌkÂo∏ÿdã§˜πÆ˜±™s£¯e˜&Ë˜‡¯Â±ïìí¨æ™iRWyMrhmud|SÄÑãçxÇká≤úä§˜7˜ Ÿ˜
ÚDø˚"˚≤¯sœÇëào~áuÖt˚¸V}YUÅr˜∫§Qè~ì©óé¢ë°-óv©v¯bw˜Ù˜p˜π˘O.zná6Çq£≤èhÅâ}Öv˚.¸À˜¶Ïß›°∏∏Ë ”ØãôãîÖã{ãa3˚Sã8h¶r∞·¥‘…µvõeSrp}ãÉÑíìùÂ˜ã»∏n®^GT^˚4âå˚b~À˜´˜l¨ê˜#˚#˜˜>ÁÙ˜(˜j˜´æ‡∫ùîu(AM8v˜<CLegocÏ^uß¡úåîê¢Âî˜:Œ˜Ω`ØO˚'˚"˚<˚13 L‚Ÿ¬≥Ìƒ-óv©v¯bw˜wp˜Ö¯aS~YÑ.Öp†´åoqj äÜãÉlP˚h˜˜Ë‚Ω•òñÇ~i4˚[ã:b£u∏ƒº¥ÂæuòeP}{zäÉÑíï§„˜iã÷Ωp¢X6N/*Jâç¸óv¯4∂Ä˜∑˜ã¯ÁhZ>^f2dhæL˚pÇmxFãn`•r∏≈ª≥Î∆uôgStsyãÉÑíìöìØú»»˜oﬁ∂C˚ô†v˜◊˜ v¯-˜w¯cQ|âã˚ ~p∂äñÜw}V~]>˚°˜Ω˜2©Î ˆ•ãúìeãÆÆ£©∑¥u§h\`X˚JÜé˜óv©v¯‘äw¯⁄˜h˜}¯aO~~â˚q∑äïÜwÑåÑk˚ãÉkM˚q˜˜˜Ê˜≠ññíÇ|Çâ~Ü|ãG˚oi˚˜∞˜µ˜·˜πãôïÅ~b3˚Oã8Ë_¢vπ«¥≠Ï√uóeQ|z|ãÇÑíì∞„˜LãÁ∫m®YXL`˚?éú∏ê°®¯¥q§b-D˚H]àç¸óv¯√˜˜˜˜V˘@fmmff©m∞∞©©∞∞m©f®˚r/zÖä#ÅqπäóÖrÜâÑá{S˚lÄbávã|e¶q¥«√∏ÂøuôjWqoxãÉÑíìîäãîÆã»˜z™˜¸év˘SwK¯&˜Ê˘A5˚–˝S·dã§¯ıÆi≠Ω¯Î˘˘1¸∫e˚?§ÑπÏ…¥˜ë˚'¸Ø|UrzIãr˜ﬂ§CéÄë™òê®ë†˜¯éÓÜ™hì˚¶â˚*}©¯5®à˜˜`˜˜Ø¯b˚'˚˚3˚;5œKÁ˜%˜˜0˜9ËL….Én©äövaBS˚¨+iy°∑÷ø˜≠ˆÜ˚*˚`•˜:Æ¯”˜‘˜˜k¯c*{£é˚|pπäìáwÅÑnÉj˚¸>~X}Ä_äq˜å•Xå}í•ß•Ÿï∫{´õÜ°˜˜"˜J˜<Ÿb∫IZ\p;RâèÔ™£ôxlAD˚à*uzõ†¨¥˜ô¥€ß∫∏≤˚*ívç—˜ˇµv˜p˜û¯9¢äôxnIH˚å1rx¢™Ã‹˜çﬁÜ˜PØ˚ÖySâ∑Ös£b˚˚)˚R˚3=µ[Œ«∑≠Á√çåÄbâÉã}dßp≥∏Ω∂ﬁ¡vöfWxx|ãÉÜëïßë®ßÁ¸$˚—˚`˜˚™¯Ÿµ˜˜Çv˜˜	˚˜™˜Ä¯Vù“§Ï©æ≠ãóëáÉÄ{Åãw≤o†u¶©††´ªd´Q˚ @8˚:_BÉaÙ‘|NÑmáwM˚≠,v~-SÄÉêëîõìã§¥ßwûmoutn\≥k≈˜=Ω˜f¯&‹‰îµ”y≠˘´¶˜%¯
˜$¯S˘ »à±\C˚+¸˚CJe∫€˜Ì¯˜EÇå´˚l˚a˚y˚Ü˚Ó+˜˜o˜b˜x˜Ö˜&Ï˚!˚*~¨¯
–˜“˜˜¶¯¶úsd5L˚u˚vÄïüù…˜⁄Úî˜≈+{Ωí˚6vqæòÖsÄÇf{Q˚	¸0bååãÉnå“lÕ˜6˜1˜@˜F◊^ΩIcezFSâå˚ôìvå®¯1´äwπÎ¥Í\˜ﬂ¯ao{ÉÖÜ}|nv°ã^:VZ?TônŒ=≥[õmrlrsjYj∫·~qé¸u˚:•ôììëô|°§xã∑‰»¬Ÿı˚‹ã“ßü¢´∏©c<ò\¶à˚b˚a‹:˜¯ªw†wÙ˜∑˜KÀ™ò¯0µñâ˚T≤•˚ïJjWQIjÍqmÆãgntsli¶p∞„‰„˜Eı‚˜&æ˜ÕΩiûmÏnqpk˙V¬èãb]I˚ygâ~‘w˜w‰rŸK|vàJÑ-y≠˘Æáw˜˜˜¯˜≈¯@Gø}ü∑Õ±≥À‹µY˚ï¶á¯≥˜\nyÅÑu¯]l®ãA˚26!˚?˜â_ã˚!FVVC!^·Òàmåh˚s©ßóííûØ∑hÊ˜‰€˜ﬁi»˚Ì˜Éîvó§¯ˇ§n˙E˘A¯Ω˚¸\}Vu|Kár˜Ã§Rç|î´óè†ë°˜¯VôøúöΩè§˚i˚«¸päT¯p˚rrß∏íb~ásÖv˚¸	f˚É~T|r˜c§Nëwö≤ûéóú Ô¯ åÕ¸øß¯¯Ã¸óvç˜≥˜µ˘P3ymá1Çq¢≥èjw}\Ñq'˚ˇ}WÑjãzb§sµ‹º÷«≤uöiUqqyãÇÖíïóí¨ö¿¸$˜'Ç˜'Ã˜bjjcb¨j¥≥¨¨¥≥j¨cxû¯Vò˜bõöã˜úñ¸vé§
⁄å
_˜é˘
endstream
endobj
63 0 obj
<<
/StemV 79
/Type/FontDescriptor
/XHeight 685
/StemH 0
/CapHeight 669
/Flags 262242
/Descent -204
/FontName/JXSSBS+Times-BoldItalic
/Ascent 700
/FontBBox[-200 -216 992 921]
/ItalicAngle -11
/FontFile3 62 0 R
>>
endobj
64 0 obj
<<
/Name/F21
/Type/Font
/Subtype/Type1
/BaseFont/JXSSBS+Times-BoldItalic
/Encoding 61 0 R
/FirstChar 32
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 250 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 889 0 722 611 0 0 556 611 0 0 0 0 0 0 0 0 0 0 0 0 500 500 0 0 444 333 0 556 278 0 0 278 778 556 500 500 0 389 389 278 0 0 0 0 444]
/LastChar 121
/FontDescriptor 63 0 R
>>
endobj
65 0 obj
<<
/Kids[66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R]
/Type/Pages
/Count 6
/Parent 72 0 R
>>
endobj
66 0 obj
<<
/Type/Page
/Contents 4 0 R
/Parent 65 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F5 38 0 R
/F1 22 0 R
/F6 42 0 R
/F2 26 0 R
/F0 18 0 R
/F7 46 0 R
/F3 30 0 R
/F9 54 0 R
/F8 50 0 R
/F4 34 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
67 0 obj
<<
/Type/Page
/Contents 5 0 R
/Parent 65 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F19 58 0 R
/F6 42 0 R
/F2 26 0 R
/F7 46 0 R
/F21 64 0 R
/F3 30 0 R
/F20 60 0 R
/F8 50 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
68 0 obj
<<
/Type/Page
/Contents 6 0 R
/Parent 65 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F1 22 0 R
/F19 58 0 R
/F6 42 0 R
/F2 26 0 R
/F21 64 0 R
/F7 46 0 R
/F3 30 0 R
/F8 50 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
69 0 obj
<<
/Type/Page
/Contents 7 0 R
/Parent 65 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F6 42 0 R
/F2 26 0 R
/F7 46 0 R
/F21 64 0 R
/F3 30 0 R
/F20 60 0 R
/F8 50 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
70 0 obj
<<
/Type/Page
/Contents 8 0 R
/Parent 65 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F1 22 0 R
/F6 42 0 R
/F21 64 0 R
/F7 46 0 R
/F3 30 0 R
/F20 60 0 R
/F8 50 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
71 0 obj
<<
/Type/Page
/Contents 9 0 R
/Parent 65 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F5 38 0 R
/F1 22 0 R
/F6 42 0 R
/F2 26 0 R
/F7 46 0 R
/F21 64 0 R
/F3 30 0 R
/F20 60 0 R
/F8 50 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
73 0 obj
<<
/Kids[74 0 R 75 0 R 76 0 R 77 0 R]
/Type/Pages
/Count 4
/Parent 72 0 R
>>
endobj
74 0 obj
<<
/Type/Page
/Contents 10 0 R
/Parent 73 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F1 22 0 R
/F6 42 0 R
/F2 26 0 R
/F21 64 0 R
/F7 46 0 R
/F3 30 0 R
/F20 60 0 R
/F8 50 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
75 0 obj
<<
/Type/Page
/Contents 11 0 R
/Parent 73 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F6 42 0 R/F2 26 0 R/F7 46 0 R/F21 64 0 R/F3 30 0 R/F8 50 0 R>>/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
76 0 obj
<<
/Type/Page
/Contents 12 0 R
/Parent 73 0 R
/Resources<</ProcSet[/PDF/Text]/Font<<
/F5 38 0 R
/F1 22 0 R
/F6 42 0 R
/F2 26 0 R
/F21 64 0 R
/F7 46 0 R
/F3 30 0 R
/F8 50 0 R
>>
/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
77 0 obj
<<
/Type/Page
/Contents 13 0 R
/Parent 73 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F2 26 0 R/F3 30 0 R/F21 64 0 R/F7 46 0 R/F8 50 0 R>>/ExtGState<</GS2 3 0 R/GS1 2 0 R/GS0 1 0 R>>>>
/MediaBox[0 0 594 783]
>>
endobj
72 0 obj
<<
/Type/Pages
/Kids[65 0 R 73 0 R]
/Count 10
>>
endobj
78 0 obj
<<
/PageLabels 14 0 R
/Type/Catalog
/Pages 72 0 R
>>
endobj
79 0 obj
<<
/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)
/Producer(QuarkXPress(tm) 6.5)
/CreationDate(20130307151236)
/Title<FEFF004C00610079006F0075007400200031>
/Creator(QuarkXPress(tm) 6.5)
>>
endobj
xref
0 80
0000000000 65535 f 
0000000015 00000 n 
0000000059 00000 n 
0000000105 00000 n 
0000000152 00000 n 
0000010440 00000 n 
0000027595 00000 n 
0000041822 00000 n 
0000056225 00000 n 
0000108880 00000 n 
0000144322 00000 n 
0000156808 00000 n 
0000171473 00000 n 
0000187899 00000 n 
0000194915 00000 n 
0000194961 00000 n 
0000195077 00000 n 
0000195902 00000 n 
0000196117 00000 n 
0000196332 00000 n 
0000196727 00000 n 
0000202751 00000 n 
0000202967 00000 n 
0000203639 00000 n 
0000204212 00000 n 
0000214503 00000 n 
0000214721 00000 n 
0000215437 00000 n 
0000215695 00000 n 
0000219467 00000 n 
0000219687 00000 n 
0000220335 00000 n 
0000220516 00000 n 
0000222862 00000 n 
0000223087 00000 n 
0000223486 00000 n 
0000223646 00000 n 
0000225117 00000 n 
0000225341 00000 n 
0000225712 00000 n 
0000226024 00000 n 
0000231134 00000 n 
0000231360 00000 n 
0000231834 00000 n 
0000231924 00000 n 
0000232183 00000 n 
0000232399 00000 n 
0000232571 00000 n 
0000232798 00000 n 
0000236188 00000 n 
0000236409 00000 n 
0000236811 00000 n 
0000236902 00000 n 
0000237284 00000 n 
0000237505 00000 n 
0000237672 00000 n 
0000237785 00000 n 
0000238470 00000 n 
0000238683 00000 n 
0000239132 00000 n 
0000239260 00000 n 
0000239769 00000 n 
0000239948 00000 n 
0000242695 00000 n 
0000242923 00000 n 
0000243318 00000 n 
0000243425 00000 n 
0000243711 00000 n 
0000243978 00000 n 
0000244244 00000 n 
0000244499 00000 n 
0000244754 00000 n 
0000246119 00000 n 
0000245031 00000 n 
0000245124 00000 n 
0000245391 00000 n 
0000245627 00000 n 
0000245893 00000 n 
0000246184 00000 n 
0000246253 00000 n 
trailer
<<
/Size 80
/Root 78 0 R
/Info 79 0 R
/ID[<5526A17736BC7F550A07B2A620EB36D5><5526A17736BC7F550A07B2A620EB36D5>]
>>
startxref
246473
%%EOF
